 
  
  
Johnson & Johnson Vision Care, Inc. 
 Clinical Study Protocol  
 Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic Population 
Phase II 
 
Protocol CR-6267  Version: 2.0 Amendment 1                             Date: 22 June 2018 
 Investigational Products: JJV Investigational senofilcon A Multifocal Contact Lens and      
1-Day Acuvue
® Moist Brand Multifocal Contact Lens 
 Key Words: Presbyopia, Multifocal, etafilcon A, senofilcon A, Daily Wear, Daily Disposable, Reusable,  Dispensing, Randomized  
 Statement of Compliance to protocol, GCP and applicable regulatory guidelines: This trial will be conducted in compliance with the protocol, ISO 14155,
1 the International 
Conference on Harmonization Good Clinical Practice E6 (ICH -GCP),2 the Declaration of 
Helsinki,3 and all applicable regulatory requirements. 
 Confidentiality Statement: This document contains confidential information, which should not be copied, referred to, released or published without written approval from Johnson & Johnson Vision Care, Inc.  The information may not be disclosed to others except to the extent necessary to obtain Institutional Revie w Board/Independent Ethics Committee approval and informed consent, or 
as required by International, Federal and State Laws, as applicable. Persons to whom this information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision Care, Inc.  Any supplemental information that may be added to this document is also confidential and proprietary to Johnson & Johnson Vision Care, Inc. a nd 
must be kept in confidence in the same manner as the contents of this document.  
CR-6267, v2.0
 
Page 1 of 218
JJVC CONFIDENTIAL

 
  
  
TABLE OF CONTENTS   
PROTOCOL TITLE, NUMBER, VERSION  ........................................................................... 6  
SPONSOR NAME AND ADDR ESS ....................................................................................... 6  
MEDICAL MONITOR  ............................................................................................................. 6  
AUTHORIZED SIGNATURES  ............................................................................................... 7  
CHANGE HISTORY ................................................................................................................ 8  
SYNOPSIS  ................................................................................................................................ 9  
COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS  .................... 14  
1. INTRODUCTION AND BACKGROUND  ................................................................... 16  
1.1. Name and Descriptions of Investigational Products ................................................ 16  
1.2. Intended Use of Investigational Products................................................................. 16  
1.3. Summary of Findings from Nonclinical Studies  ...................................................... 16  
1.4. Summary of Known Risks and Benefits to Human Subjects ................................... 16  
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed 
Clinical Study ...................................................................................................................... 17 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES  ...................................... 18  
2.1. Objectives ................................................................................................................. 18  
2.2. Endpoints .................................................................................................................. 18  
2.3. Hypotheses ............................................................................................................... 18  
3. TARGETED STUDY POPULATION  ........................................................................... 19  
3.1. General Character istics ............................................................................................ 19  
3.2. Inclusion Criteria  ...................................................................................................... 19  
3.3. Exclusion Criteria  ..................................................................................................... 19  
3.4. Enrollment Strategy .................................................................................................. 20 
4. STUDY DESIGN AND RATIONALE  .......................................................................... 20  
4.1. Description of Study Design .................................................................................... 20  
4.2. Study Design Rationale ............................................................................................ 20  
4.3. Enrollment Target and Study Duration .................................................................... 21  
5. TEST ARTICLE ALLOCATION AND MASKING ..................................................... 21  
5.1. Test Article Allocation  ............................................................................................. 21  
5.2. Masking .................................................................................................................... 21  
5.3. Procedures for Maintaining and Breaking the Masking........................................... 22  
6. STUDY INTERVENTION ............................................................................................. 22  
CR-6267, v2.0
 
Page 2 of 218
JJVC CONFIDENTIAL

 
  
 6.1. Identity of Test Articles ............................................................................................ 22 
6.2 Ancillary Supplies/Products.......................................................................................... 23  
6.3. Administration of Test Articles  ................................................................................ 23  
6.4. Packaging and Labeling  ........................................................................................... 23  
6.5. Storage Conditions ................................................................................................... 24  
6.6. Collection and Storage of Samples  .......................................................................... 24  
6.7. Accountability of Test Articles  ................................................................................ 24  
7. STUDY EVALUATIONS  .............................................................................................. 25  
7.1. Time and Event Schedule ......................................................................................... 25  
7.2. Detailed Study Procedures  ....................................................................................... 29  
VISIT 1 ........................................................................................................................... 29  
VISIT 2 ........................................................................................................................... 35  
VISIT 3 ........................................................................................................................... 39  
VISIT 4 ........................................................................................................................... 44  
VISIT 5 ........................................................................................................................... 50  
VISIT 6 ........................................................................................................................... 55  
VISIT 7 ........................................................................................................................... 59  
FINAL EVALUATION  .................................................................................................. 62  
7.3. Unscheduled Visits ................................................................................................... 62  
7.4. Laboratory Procedures  ............................................................................................. 64  
8. SUBJECTS COMPLETION/WITHDRAWAL .............................................................. 64  
8.1. Completion Criteria  .................................................................................................. 64  
8.2. Withdrawal/Discontinuation from the Study  ........................................................... 64  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 65  
10. DEVIATIONS FROM THE PROTOCOL  .................................................................. 65  
11. STUDY TERMINATION ........................................................................................... 65  
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS  .............. 66  
13. ADVERSE EVENTS  ................................................................................................... 67  
13.1.  Definitions and Classifications  ............................................................................. 67  
13.2.  Assessing Adverse Events  .................................................................................... 70  
13.2.1.  Causality Assessment  .................................................................................... 70  
13.2.2.  Severity Assessment  ...................................................................................... 70  
13.3.  Documentation and Follow-Up of Adverse Events .............................................. 71  
13.4.  Reporting Adverse Events .................................................................................... 72  
CR-6267, v2.0
 
Page 3 of 218
JJVC CONFIDENTIAL

 
  
 13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 72  
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health 
Authorities ....................................................................................................................... 73 
13.4.3.  Event of Special Interest  ............................................................................... 73  
13.5.  Reporting of Pregnancy ........................................................................................ 73  
14. STATISTICAL METHODS  ........................................................................................ 74  
14.1.  General Considerations ......................................................................................... 74  
14.2.  Sample Size Justification  ...................................................................................... 74  
14.3.  Analysis Populations ............................................................................................ 74  
14.4.  Level of Statistical Significance  ........................................................................... 75  
14.5.  Primary Analysis  .................................................................................................. 75  
14.6.  Secondary Analysis  .............................................................................................. 75  
14.7.  Other Exploratory Analyses ................................................................................. 75  
14.8.  Interim Analysis  ................................................................................................... 76  
14.9.  Procedure for Handling Missing Data and Drop- Outs ......................................... 76  
14.10.  Procedure for Reporting Deviations from Statistical Plan  ................................... 76  
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING  ................................ 76  
15.1.  Electronic Case Report Form/Data Collection  ..................................................... 76  
15.2.  Subject Record  ...................................................................................................... 77  
16. DATA MANAGEMENT ............................................................................................. 77  
16.1.  Access to Source Data/Document  ........................................................................ 77  
16.2.  Confidentiality of Information.............................................................................. 77  
16.3.  Data Quality Assurance  ........................................................................................ 78  
17. MONITORING  ............................................................................................................ 78  
18. ETHICAL AND REGULATORY ASPECTS  ............................................................ 78  
18.1.  Study-Specific Design Considerations ................................................................. 78  
18.2.  Investigator Responsibility  ................................................................................... 79  
18.3.  Independent Ethics Committee or Institutional Review Board (IEC/IRB) .......... 79  
18.4.  Informed Consent ................................................................................................. 80  
18.5.  Privacy of Personal Data  ...................................................................................... 81  
19. STUDY RECORD RETENTION ................................................................................ 81  
20. FINANCIAL CONSIDERATIONS  ............................................................................ 82  
21. PUBLICATION  ........................................................................................................... 82  
22. REFERENCES  ............................................................................................................ 83  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  ..... 84  
CR-6267, v2.0
 
Page 4 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX B : PATIENT INSTRUCTION GUIDE  .......................................................... 116  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  ....................................... 117  
APPENDIX D: BINOCULAR OVER REFRACTION  ....................................................... 148  
APPENDIX E: PRESBYOPIC SYMPTOMS QUESTIONNAIRE  ..................................... 149  
APPENDIX F: OCULAR DOMINANCE ............................................................................ 150  
APPENDIX G: Test LENS FIT TING GUIDE  ..................................................................... 151  
APPENDIX H: CONTROL LENS FITTING GUIDE  ......................................................... 153  
APPENDIX I: CLINICAL TECHNICAL PROCEDURES (CTP)  ...................................... 155  
 LIMBAL AND CONJUNCTIVAL (BULBAR) REDNESS  ............................. 156 
 EXPANDE D SODIUM FLUORESCEIN CORNEAL STAINING .................. 164  
 DETE RMINATION OF NEAR ADDITION  .................................................... 169  
 NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE  ....... 177  
 LENS FITTING CHARACTERISTICS  ............................................................ 180 
 SUBJ ECT REPORTED OCULAR SYMPTOMS/PROBLEMS  ....................... 187  
 DETE RMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  ................................................................................................................... 189  
 BIOM ICROSCOPY SCALE  ............................................................................. 196  
 KERAT OMETRY PROCEDURE  ..................................................................... 202  
 DIS TANCE AND NEAR VISUAL ACUITY EVALUATION  ........................ 204  
 DIS TANCE LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE
............................................................................................................................................... 209  
 Vis ual Acuity Chart Luminance and Room Illumination Tes ting ..................... 213  
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE  ........................ 218  
 
TABLE OF CONTENTS   
Figure 1: Study Flowchart ...................................................................................................... 13  
 
TABLE OF CONTENTS   
Table 1: Test Articles  .............................................................................................................. 22  
Table 2: Ancillary Suppl ies .................................................................................................... 23  
Table 3: Time and Events ....................................................................................................... 25  
  
 
 
CR-6267, v2.0
 
Page 5 of 218
JJVC CONFIDENTIAL

 
  
 PROTOCOL TITLE, NUMBER, VERSION 
Title: Clinical Evaluation of a Reusable Multifocal Optical Design in a Presbyopic 
Population Phase II 
 
Protocol Number:  CR-6267 Version: 2.0 Amendment 1 Date: 22 June 2018 
SPONSOR NAME AND ADDRES S 
Johnson & Johnson Vision (JJV ) 
7500 Centurion Parkway  Jacksonville, FL 32256 
MEDICAL MONITOR 
Name:  Thomas R. Karkkainen, OD, MS, FAAO  
Title: Sr. Principal Research Optometrist  
Address: 7500 Centurion Parkway, Jacksonville, Florida 32256 
 
Email: TKarkkai@its.jnj.com
 
 
 
The 
Medical Monitor must be notified by the clinical institution/site by e -mail, fax, or 
telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may 
be contacted during business hours for adverse event questions. General study related 
questions should be directed towards your assigned clinical research associate.  
 The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.  
CR-6267, v2.0
 
Page 6 of 218
JJVC CONFIDENTIAL

 
  
 SYNOPSIS  
Protocol Title  Clinical Evaluation of a Reusable Multifocal Optical Design in 
a Presbyopic Population  Phase II 
Sponsor JJV, 7500 Centurion Parkwa y, Jacksonville, FL  32256  
Clinical Phase  Development phase,  Phase 2  
Trial Registration  This study will be registered on ClinicalTri als.gov. 
Test Article(s)  Investigational Product:  JJV Investigational Multifocal 
Contact Lens manufactured in senofilcon A material.  
Marketed Product:  1-Day Acuvue® Moist Brand Multifocal 
Contact Lens. 
Wear and Replacement 
Schedules  Wear Schedule:  The Test and Control lenses are used as daily 
wear (note: the Test lens will be reusable and the Control lens  
daily disposabl e).   
 
Replacement Schedule:  The Test lens  will be replaced  at the 
optimization visit.  The Control lens will be replaced after 
each day of wear as well as the optimization visit and the visit after the first week of wear in the optimized pair.    The Test  
and Control lenses will also be replaced when lost or damaged.  
Objectives  This study is an  evaluation of the visual performance , 
subjective response, lens fit and ocular physiological response of the JJV Investigational senofilcon A Multifocal Contact Lens.  The T est lens will be compared to the 1- Day Acuvue
® 
Moist Brand Multifocal Contact Lens manufactured in 
etafilcon A material  for CLUE subjective vision .  
Study Endpoints  Primary endpoint s:  CLUE vision scores   
Other observations:  logMAR visual acui ty scores, lens fit, 
summary of number of lenses needed to fit (optimize) the subject, CLUE comfort/handling scores, corneal staining, and 
ocular redness.  
Study Design  This is a single-masked, randomized -controlled , dispensing 
clinical trial.  A total of approximately 60 eligible hyperopic 
subjects will be targeted to complete the study.  The subjects 
will be fit in each  study lens and wear the lens for 2-4 days 
then undergo optimization, if applicable,  and wear the 
optimized pair for approximately 2  weeks with a follow -up at 
1 week. The primary endpoint s will be CLUE vision scores.  
Sample Size  A total of approximately 60 subjects will be targeted to 
complete.  
Study Duration  The study will last approximately 2 -4 months. 
CR-6267, v2.0
 
Page 9 of 218
JJVC CONFIDENTIAL

 
  
 Anticipated Study 
Population Healthy male and female volunteers with presbyopia will be  
invited to participate in the study .  Subjects will be adapted 
soft contact lens wearers in both eyes.  Additional information 
regarding the eligibility of the population can be found in the 
inclusion/e xclusion criteria outlined below.  
Eligibility Criteria  Potential subjects must satisfy all the following criteria to be 
enrolled in the study 
1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy o f the form.  
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.  
3. The subject must be between 40 and 70 years of age (inclusive). 
4. The subject’s distance spherical equivalent refraction 
must be in the ra nge of +1.25 D to +3.75 D in each 
eye. 
5. The subject’s refractive cylinder must be ≤0.75 D in 
each eye. 
6. The subject’s ADD power must be in the range of +0.75 D to +2.50 D. 
7. The subject must have best corrected visual acuity of 20/20
-3 or better in each eye.  
8. Subjects must own a wearable pair of spectacles if required for their distance vision. 
9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration). 
10. The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the “Presbyopic Symptoms Questionnaire”.  
 Potential subj ects who meet any of the following criteria will 
be excluded from participating in the study:  
1. Currently pregnant or lactating. 
2. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.   
3. Any active or ongoing systemic d isease, autoimmune 
disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren’s syndrome, 
xerophthalmia, acne rosacea, Stevens -Johnson 
CR-6267, v2.0
 
Page 10 of 218
JJVC CONFIDENTIAL

 
  
 syndrome, and immunosuppressi ve diseases or any 
infectious diseases (e.g. hepatitis, tuberculosis). 
4. Clinically significant (Grade 3 or 4) corneal edema, 
corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.  
5. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions. 
6. Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, 
cataract surgery, retinal surgery, etc.).  
7. A history of amblyopia, strabismus or binocular vision abnormality. 
8. Any current ocular infection or inflammation. 
9. Any current ocular abnormality that may interfere with 
contact lens wear.  
10. Use of any  of the following oral medications within 1 
week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral  
antihistamines  (e.g., Chlor-Trimeton, and Benadryl), 
systemic steroids. 
11. Use of any ocular medica tion, with the exception of 
rewetting drops. 
12. History of herpetic keratitis.  
13. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.  
14.  Employee or immediate family member of an 
employee  of clinical site  (e.g., Investigator, 
Coordinator, Technician). 
15. Any known hypersensitivity or allergic reaction to Optifree
®Replenish® multi-purpose care solution or 
Eye-Cept® rewetting drop solution.  
Disallowed 
Medications/Interventions  Use of any prescription or over -the-counter (OTC) 
medications that may affect contact lens wear.   
Measurements and 
Procedures  See Section 7.2 for the detailed procedures.   
Microbiology or Other 
Laboratory Testing  None 
CR-6267, v2.0
 
Page 11 of 218
JJVC CONFIDENTIAL

 
  
 Study Termination  The occurrence of one or more Unanticipated Adve rse Device 
Effect (UADE), or any SAE where relationship to study agent 
cannot be ruled out, will result in stopping further dispensing investigational product.  In the event of a UADE or SAE, t he 
Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal 
Investigator before any further subjects are enrolled.  
Ancillary Supplies/ Study -
Specific Materials  Eye-Cept Rewetting  drops, lens cases, glass vials, saline, 
ETDRS light cabinet, logMAR charts, and Near logMAR 
charts. Optifree®Replenish® Contact Solution.  
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)  A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the stud y Trial Master File.   
    
 
                            
CR-6267, v2.0
 
Page 12 of 218
JJVC CONFIDENTIAL

 
  
 COMMONLY USED ABBREVIATIONS AND DEFINITIONS OF TERMS  
ADD   Plus Power Required For Near Use 
ADE   Adverse Device Effect  
AE   Adverse Event/Adverse Experience  
BCC   Binocular Crossed Cylinder 
BCVA   Best Corrected Visual Acuity  
BSCVA  Best Spectacle Corrected Visual Acuity  
CFR   Code of Federal Regulations  
CLDEQ-8  Contact Lens Dry Eye Questionnaire-8 
CLUE   Contact Len s User Experience  
COAS   Complete Ophthalmic Analysis System 
COM   Clinical Operations Manager  
CRA   Clinical Research Associate  
CRF   Case Report Form  
CRO   Contract Research Organization  
CT   Center Thickness  
    
D   Diopter 
DMC   Data Monitoring Committee  
eCRF   Electronic Case Report Form  
EDC   Electronic Data Capture  
ETDRS  Early Treatment Diabetic Retinopathy Study  
FDA   Food and Drug Administration 
GCP   Good Clinical Practice  
HIPAA  Health Insurance Portability and Acc ountability Act  
HIV   Human Immunodeficiency Virus  
IB   Investigator’s Brochure  
ICF   Informed Consent Form 
ICH   International Council for Harmonization  
IDE   Investigational Device Exemption  
IEC   Independent Ethics Committee 
IRB   Institutional Review B oard 
ISO   International Organization for Standardization 
ITT   Intent- to-Treat 
JJVC   Johnson & Johnson Vision, Inc.  
LC   Limbus Center 
LogMAR   Logarithm of Minimal Angle of Resolution  
LSM   Least Square Means  
MedDRA©  Medical Dictionary for Regulatory Activities  
MOP   Manual of Procedures 
NIH   National Institutes of Health  
OD   Right Eye  
OHRP   Office for Human Research Protections  
OHSR   Office for Human Subjects Research  
OS   Left Eye 
OU   Both Eyes 
CR-6267, v2.0
 
Page 14 of 218
JJVC CONFIDENTIAL

 
  
 PD   Protocol Deviation 
PHI   Protected Health Inform ation 
PI   Principal Investigator  
PIG   Patient Instruction Guide 
PQC   Product Quality Complaint 
PRO   Patient Reported Outcome 
QA   Quality Assurance 
QC   Quality Control 
SAE   Serious Adverse Event/Serious Adverse Experience  
SAP   Statistical Analysis P lan 
SAS   Statistical Analysis System 
SD   Standard Deviation 
SOP   Standard Operating Procedure 
UADE   Unanticipated Adverse Device Effect  
USADE  Unanticipated Serious Adverse Device Effect  
VA   Visual Acuity  
                           
CR-6267, v2.0
 
Page 15 of 218
JJVC CONFIDENTIAL

 
  
 1. INTRODUCTION AND BACKGROUND  
Johnson & Johnson Vision recently launched a multifocal contact lens, 1- DAY ACUVUE® 
Moist Multifocal.  The lens is the only marketed soft multifocal lens to have its optical 
design optimized for the changes that occur in pupil size with refractive  error.  The modality 
for the lens is daily disposable.  There is a desire to evaluate the same optical design in a reusable modality.  The purpose of this study is to evaluate a multifocal optical design 
manufactured  from senofilcon -A material and compare the visual performance to the 1-DAY 
ACUVUE
® Moist Multifocal. 
1.1. Name and Descriptions of Investigational Products  
Test Lens: JJV Investigational senofilcon- A Multifocal Contact Lens -The lens has the same 
optical design, diameter, base curve and aspheric back surface design as the 1-Day Acuvue® 
Moist Brand Multifocal.  The lens is  manufactured in senofilcon- A.        
 Control Lens:  Marketed 1-Day Acuvue
® Moist Brand Multifocal Contact Lenses 
1.2. Intended Use of Investigational Products  
Both lenses are intended to correct spherical refract ive error and presbyopia.  The T est lenses 
are intended to be used as a 2-week, reusable, daily wear lens.  The lenses require use of a 
care system to clean and disinfect the lenses.  The control lenses are daily wear lenses that are disposed of at the end of each wear cycle.  No care system is required for the control lenses.  
1.3. Summary of Findings from Nonclinical Studies  
All previous pre -clinical findings were deemed satisfactory prior to proceeding with clinical 
trials on humans.   For the most comprehensive nonclinical information regarding JJV 
investigational senofilcon -A multifocal refer to the latest version of the  Investigator 
Brochure. 
1.4. Summary of Known Risks and Benefits to Human Subjects  
The Investigational multifocal contact lenses are designed as a continuous asphere providing for the correction of refractive spherical ammetropia  and presbyopia.  The material is a 
silicone hydrogel material, senofilcon -A.   
 The 1-Day Acuvue
® Moist Brand Multifocal Contact Lens is a curre ntly marketed product 
that is made of the etafilcon -A material.  The contact lenses are available as continuous 
aspheres providing for the correction of a subjects refractive  spherical ammetropia  and 
presbyopia.  The intent of the Test lens is daily wear, reusable lens that the subject wears while awake.  
This lens is not intended for extended wear.  Anticipated risks and adverse reactions with this lens are similar to other soft daily wear contact lenses used to correct presbyopia.  A listing of examples o f adverse reactions is found in the Section 13 of this protocol.  The investigator 
should follow normal clinical guidelines regarding  examination and care of subjects who  
participate in this trial. For the most comprehensive clinical information regarding the JJV 
CR-6267, v2.0
 
Page 16 of 218
JJVC CONFIDENTIAL

 
  
 Investigational senofilcon -A multifocal lens refer to the Investigator Brochure.  Additional 
details on the 1- Day Acuvue® Moist Brand Multifocal Contact Lens can be found in the 
package insert  in Appendix C . 
 
1.5. Relevant Literature References and Prio r Clinical Data Relevant to Proposed 
Clinical Study  
  The study was a dispensing 
clinical trial with primary end points of logMAR visual acuity at fit and CLUE vision scores 
at 1 week.  The stud y was a cross -over design with a marketed product  serving as the control.  
Subjects were fit in the lenses and wore them for 2 -4 then attended the first follow -up visit to 
determine if lens optimization was required.  The lenses were than worn for an additional 2 weeks with a 1-week follow-up during that period.  There were 32 subjects that completed 
the study as cohort.  The Test lens displayed good visual acuity with the mean distance and 
intermediate logMAR acuity better than 0.0 and the mean near logMAR  acuity better than 
+0.1 logMAR.  This with true of the acuity at the initial fit as well as the 1 week and 2-week 
visits in the final lens pair.  There were two non -ocular adverse events that occurred during 
the study that were not related to any of the T est lenses.  
 
which at the writing of this protocol has 
completed data collection, however does not have a completed clinical study report.  During the study there were no serious adverse events reported.     
 In addition to the above study, JJV had tested similar optical designs that have been 
manufactured in a similar material however those lenses were worn as daily disposable 
lenses.   
   
 
was a non- dispensing evaluation with a primary endpoint of logMAR visual acuity.  
There were 22 subjects that completed the trial per protocol.  In this study, the lenses provided clinically acceptable visual acuity with the mean b right high contrast binocular 
logMAR acuity of -0.016, -0.028 and 0.086 for distance, intermediate and near respectively.  
There were no ad verse events reported during the study.   
 
was a dispensing clinical trial with the primary endpoint of logMAR visual acuity.  
There were 21 subjects that completed the trial per protocol.  The lenses displayed clinically acceptable logMAR visual acuity after approximately 10 days of wear with the mean bright high contrast binocular logMAR acuity of -0.082, -0.042 and 0.054 for distance, intermediate 
and near respectively.  There were two adverse events reported during the study one that was non-ocular and not related to the test articles the other was an ocular adverse event, contact 
lens induced peripheral ulcer , that was classified as likely related to the study lens.  The event 
resolved with treatment and the subject was discontinued from the study.  For additional details refer to the Investigator Brochure for this study. 
CR-6267, v2.0
 
Page 17 of 218
JJVC CONFIDENTIAL

 
  
 2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTH ESES    
2.1. Objectives  
This study is an  evaluation of the visual performance , subjective response , lens fit and ocular 
physiological response  of the JJV Investigational senofilcon A Multifocal Contact Lens .  The 
Test lenses will be compared to the 1-Day Acuvue® Moist Brand Multifocal Contact Lens 
manufactured in etafilcon A material  for CLUE subjective vision.  
 
Primary Objective  
This study is an evaluation of how the subjective response of the JJV Investigational senofilcon A Multifocal Contact Lens compares to the 1- Day Acuvu e
® Moist Brand 
Multifocal Contact Lens manuf actured in etafilcon A material.  
2.2. Endpoints  
The study endpoints will be the subjective CLUE Vision scores.  Additional endpoints will be logMAR visual acuity at distance, intermediate and near a summary of lenses needed to fit 
(optimize) the subject, CLUE comfort/handling scores, the lens fit and ocular physiological responses.    Primary Endpoints 
• CLUE vision scores 
 Other Observation(s)  
• LogMAR visual acuity scores   
• Lens fit 
• Corneal staining 
• Ocular redness  (bulbar and limbal) 
• Summary of lenses needed to fit (optimize) the subject 
• CLUE comfort/handling scores 
• PRO individual questions 
2.3. Hypotheses  
The following primary hypothesis will be tested throughout this investigation.   
Primary Hypothesis : 
1. After 14 to 20 days of wear, the PRO CLUE vision score for the T est lenses will be 
statistically better than 32 points.  This will be recorded by the subject using the 
CLUE Follow -up Questionnaire. 
 If the primary hypothesi s is met, the following secondary hypothesi s will be tested.  
 
CR-6267, v2.0
 
Page 18 of 218
JJVC CONFIDENTIAL

 
  
 Secondary Hypothesis : 
1. After 14 to 20 days of wear, the PRO CLUE vision score for the T est lenses will be 
non-inferior to the control lens.  A non- inferiority margin of 5 CLUE points will be 
used.  This will be recorded by the subj ect using the CLUE Follow -up Questionnaire. 
3. TARGETED STUDY POPULATION  
3.1. General Characteristics  
Healthy male and female subjects who are habitual soft contact lens wearers will be 
recruited.  Subjects will be at least 40 years of age and not older than 70 y ears of age.  They 
will be hyperopic and have presbyopia .    
3.2. Inclusion Criteria  
Potential subjects must satisfy all the following criteria to be enrolled in the study:  
1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and recei ve a fully executed copy of the form. 
2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.  
3. The subject must be between 40 and 70 years of age (inclusive). 
4. The subject’s distance spherical equivalent refraction must be in the range of +1.25 D 
to +3.75 D in each eye.  
5. The subject’s refractive cylinder must be ≤0.75 D in each eye.  
6. The subject’s ADD power must be in the range of +0.75 D to +2.50 D. 
7. The subject must have distance best corrected visual acuity of 20/20
-3 or better in 
each eye. 
8. Subjects must own a wearable pair of spectacles if required for their distance vision.  
9. The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration). 
10. The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the “Presbyopic Symptoms Questionnaire”.  
3.3. Exclusion Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating in the study:  
1. Currently pregnant or lactating. 
2. Any active or ongoing ocular or s ystemic allergies that may interfere with contact 
lens wear.   
3. Any active or ongoing systemic disease, autoimmune disease, or use of medication, 
which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren’s syndrome, xerophthalmia, acne rosacea, 
CR-6267, v2.0
 
Page 19 of 218
JJVC CONFIDENTIAL

 
  
 Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious 
diseases (e.g. hepatitis, tuberculosis).  
4. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal 
staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular 
abnormalities which would contraindicate contact lens wear.  
5. Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions. 
6. Any previous, or planned, ocular or intraocular surgery ( e.g. radial keratotomy, PRK, 
LASIK, lid procedures, cataract surgery, retinal surgery, etc.).  
7. A history of amblyopia, strabismus or binocular vision abnormality. 
8. Any current ocular infection or inf lammation.  
9. Any current ocular abnormality that may interfere with contact lens wear.  
10. Use of any of the following oral medications within 1 week prior to enrollment: oral 
retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral antihistamines (e.g., Chlor-Trimeton, and Benadryl), systemic steroids.  
11. Use of any ocular medication, with the exception of rewetting drops. 
12. History of herpetic keratitis.  
13. Participation in any contact lens or lens care product clinical trial within 30 days prior 
to study enrollment.  
14.  Employee or immediate family member of an employee  of clinical site ( e.g., 
Investigator, Coordinator, Technician). 
15. Any known hypersensitivity or allergic reaction to Optifree
®Replenish® multi-
purpose care solution or Eye- Cept® rewetting drop solution. 
3.4. Enrollment Strategy  
Study subjects will be recruited from the Institution/clinical site’s subject database and/or utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.  
4. STUDY DESIGN AND RATIONALE  
4.1. Description of Study Design  
The clinical study is a randomized-contr olled, single -masked, cross-over clinical trial.  There 
are two study treatments. A total of approximately 60 eligible hyperopic subjects will be 
targeted to co mplete the study.  Each Test article will be dispensed for 3±1 days and an 
optimization visit will occur.  The final lens pair will be dispensed for 7±1 days and the fi rst 
follow-up on the final lens pair will occur.  The lenses will be dispensed for an additional 
7±1 days and the final lens  measurements will be made.  The second study lenses will then be 
fit and the above sequence repeated.   
4.2. Study Design Rationale  
The study is intended to compare two study lens types and the initial performance, in terms 
of the subjective response after a period of lens dispensing.  The lenses are dispensed to 
determine the subjective responses and the comparison is made after a total of 14-20 days of 
wear.   
CR-6267, v2.0
 
Page 20 of 218
JJVC CONFIDENTIAL

 
  
  
The cross -over study design was chosen to control for variables that may impact t he lens 
performance between subjects.  It was determined that a washout was not required as previous studies on similar populations with similar multifocal designs did not show a significant carry over effect on the primary/secondary endpoints measured in the study.      
4.3. Enrollment Target and Study Duration  
A total of approximately 70 eligible subjects will be enrolled with 60 targeted to complete 
the study.   
5. TEST ARTICLE ALLOCATION AND MASKING  
5.1. Test Article Allocation  
The study lenses will be worn in a bilateral and random fashion using a 2×2 crossover design 
with 2 lens types and 2 periods.  Using a computer -generated randomization scheme 
provided by the study biostatistician, each subject will randomly be assigned to one of two unique sequences (Test/Control or Control/Test).  Randomization will be stratified by site.  
 Permuted block randomization will be used to avoid bias in the assignment of subjects to treatment, and to enhance the validity of statistical comparisons across treatment groups. Each bloc k will contain two different lens trial sequences.  
 The order of lens wear will be based on the randomization scheme assigned to the study site.   The study site will follow the randomization scheme provided and will complete enrollment according to the randomization list and will not pre -select or assign subjects.  
5.2. Masking  
This is a single -masked study with the subjects being masked. Subjects will be unaware of 
the identity of the investigational product. Investigators and clinical site personnel involved in the data collection will not be masked as to the identity of the investigational product.  
 Under normal circumstances, the mask should not be broken until all subjects have completed the study and the database is finalized. Otherwise, the mask should be broken only if specific emergency treatment/course of action would be dictated by kno wing the treatment 
status of the subject. In such cases, the Investigator may, in an emergency, contact the medical monitor.  In the event the mask is broken, the Sponsor  must be informed as soon as 
possible. The date, time, and reason for the unmasking must be documented in the subject record. The Investigator is also advised not to reveal the study treatment assignment to the clinical site or Sponsor personnel.   Subjects who have had their treatment assignment unmasked are expected to return for all 
remaining scheduled evaluations.  Subjects who are discontinued may be replaced.  
CR-6267, v2.0
 
Page 21 of 218
JJVC CONFIDENTIAL

 
  
 
 
 
6.5. Storage Conditions 
Test articles will be maintained at ambient temperatures at the clinical site. Test articles must 
be kept under secure conditions. 
6.6. Collection and Storage of Samples 
When possible, any lens or test article associated with an Adverse Events and/or a Product 
Quality Complaint must be retained and stored in a glass vial with moderate solution pending directions from the sponsor for potential return  to JJV. 
6.7. Accountability of Test Articles  
JJV will provide the Investigator with sufficient quantities of study article and supplies to 
complete the investigation.  The Investigator is asked to retain all lens shipment documentation for the test article accountability records.   Test article must be kept in a locked storage cabinet, accessible only to those assigned by the 
Investigator for dispensing. The Investigator may delegate this activity to authorized study site personnel listed on the Site Delegation Log.  All test articles must be accounted.  This includes: 
1. What was dispensed for the subject  for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between visits  
2. What was returned to the Investigator unused 
3. The number and reason for unplanned replacements   
 The Investigator will collect all unused test articles from the subjects at the end of the 
subject’s participation. Subject returned unused test articles must be separated from the clinical study inventory of un- dispensed test articles, and must be labeled with the subject 
number and date of return.  Following final reconciliation of test articles by the monitor, the 
Investigator or monitor will return all unused test articles to the Sponsor. 
If there is a discrepancy between the shipment documents and the contents, contact the study monitor immediate ly. 
 
  Site Instructions for Test Article Receipt and Test Article 
Accountability for additional information  
CR-6267, v2.0
 
Page 24 of 218
JJVC CONFIDENTIAL

 
  
 2 near card placed at 40 cm to measure the 
Near visual acu ity 
1.26  Distance Over -
Refraction and 
Distance Visual Acuity Perform a distance over -refraction OD and OS 
using loose lenses outside of the phoropter under ambient room illumination.  The distance over -refraction may also be refined 
under binocular c
onditions.  Record the results.  
The results of the distance over- refraction may 
also be checked for the impact on near vision 
under monocular and/or binocular conditions.     
1.27  Subjective Lens Fit 
Assessment  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and 
tightness (push-up test). 
 
• The subject should not proceed to wear the 
lenses if any of the following is observed: 
• presence of limbal exposure (appearance of 
clear cornea) in any gaze 
• presence of edge lift  
• presence of unaccep table movement 
(excessive or insufficient) in all three 
movement categories (primary gaze, upgaze, and push-up). 
 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p erform a slit -lamp 
evaluation, and complete the Final Evaluation 
form.  
1.28  Modifications  If the subject reports unsatisfactory vision, or is 
unable to obtain 20/30 dista nce visual acuity  
OU with the lenses then a modification must be 
attempted. If the subject reports satisfactory 
vision with the lenses a modificat ion is not 
required, howev er at the Inve stigator’s 
discretion and bas ed upon thei r findings on the  
measured visual acuity and/or over- refraction 
the investigator may make a modification . 
Up to two attempts at modification are 
permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide allowing for at least 10 minutes of settling time between  each lens 
modification attempted.    Appendix 
G and H 
(Fitting Guides) 
CR-6267, v2.0
 
Page 32 of 218
JJVC CONFIDENTIAL

 
  
 If modifications are required steps 1.21 -1.27 
will be repeated for each modification.  
1.29  Post-Fit 
Questionnaire The subject will evaluate the vision 
characteristics, comfort characteri stics, 
handling characteristics, and visual symptoms 
of the study lenses using the PRO 
questionnaire.   
1.30  Distance and Near 
Exit Visual Acuity  Distance and near Snellen visual acuity will be 
measured for each eye with the study contact lenses in place.  
For near measures use the ETDRS 2000 Series 
Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.  
 
Note: The distance visual acuity must be at least 20/30 OU for the lenses to be 
dispensed.   
1.31  Dispensing Criteria  The lenses will be dispensed for 2 -4 days. 
• Distance Snellen acuity equal to or better 
than 20/30 OU 
• Subject must indicate that the vision is acceptable.  
• Subject must indicate that the comfort of 
the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit.  
1.32  Patient Instructions  
for Daily Disposable 
Lenses Instruct the Subject the following:  
• The lenses will be worn on a daily wear basis.  
• Only enough lenses will be dispensed to 
the subject to wear for the required number 
of days until their follow-up visit. No 
additional lenses will be dispensed. 
• A new lens will be opened and worn each 
day. 
• Instruct the subject to bring back all unworn study lenses. 
• No cleaning or disinfecting solutions will 
be used. If determined necessary by the Investigator sterile non -preserved 
rewetting drops may be dispensed to be 
used as needed for dryness.  
CR-6267, v2.0
 
Page 33 of 218
JJVC CONFIDENTIAL

 
  
 • Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every day 
during the study. 
• Subjects will be instructed to wear their 
glasses when not wearing the stud y lenses . 
• A patient instruction booklet will be provided. 
Note: In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably 
possible, a damaged lens should be returned to 
the investigatio nal site and then returned to 
the Sponsor.  If lens damage is present, 
complete the Product Quality Complaint 
Form.  The lens will be stored in labeled vial 
with sterile saline, and returned to the 
Sponsor. 
1.33  Patient Instructions  
for Daily Reusable Wear Lenses  Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis.  
• OPTI-FREE® Replenish® solution will be 
used in a rub regime to disinfect and store the lenses each night in the lens case provided.  
• If determined necessary by the I nvestigator 
sterile non -preserved rewetting drops may 
be dispensed to be used as needed for dryness. 
• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study. 
• Subjects will be instructed to wear their glasses wh en not wearing the study lenses . 
• A patient instruction booklet will be 
provided. 
Note:  In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably 
possible, a damaged lens should be returned to the investigational site and then returned to 
the Sponsor.  If lens damage is present, 
complete the Product Quality Complaint  
CR-6267, v2.0
 
Page 34 of 218
JJVC CONFIDENTIAL

 
  
 2 near card placed at 40 cm to measure the 
Near visual acuity  
2.8 Distance Over -
Refraction and 
Distance Visual Acuity Perform a distance over -refraction OD and OS 
using loose lenses outside of the phoropter under ambient room illumination.  The distance over -refraction may also be refined 
under binocular conditions.  Record the results and distance visual acuit y OD and OS.   
The results of the distance over- refraction may 
also be checked for the impact on near vision 
under monocular and/or binocular conditions.     
2.9 Determination of 
Lens Optimization  If the subject reports unsatisfactory vision, or is 
unable to obtain 20/30 dista nce visual acuity  
OU with the lenses then a modification must be 
attempted.  
If the subject reports satisfactory vision with 
the lenses a modificat ion is not requir ed, 
however at the Inve stigator’s discretion and 
based upon thei r findings on the  measured 
visual acuity and /or over- refraction the 
investigator may make a modification . 
Up to two attempts at modification are permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.   
Follow the fitting guide allowing for at least 10 minutes of settling time between each lens 
modification attempted.  Appendix 
G and H 
(Fitting Guides)  
2.10 Lens Fit Assessment:  Evaluate and grade len s centration, primary 
gaze movement, upgaze movement and tightness (push-up test). 
 
• The subject should not proceed to wear the 
lenses if any of the following is observed: 
• presence of limbal exposure (appearance of 
clear cornea) in any gaze 
• presence of edge lift  
• presence of unacceptable movement (excessive or insufficient) in all three 
movement categories (primary gaze, upgaze, and push-up). 
 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  
Remove the lenses, p erform a slit-lamp   
CR-6267, v2.0
 
Page 36 of 218
JJVC CONFIDENTIAL

 
  
 • Subject must indicate that the comfort of 
the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit. 
2.18 Patient Instructions  
for Daily Disposable 
Lenses Instruct the Subject the following:  
• The lenses will  be worn on a daily wear 
basis.  
• Only enough lenses will be dispensed to 
the subject to wear for the required number of days until their follow-up visit. No additional lenses will be dispensed. 
• A new lens will be opened and worn each day. 
• Instruct the subject to bring back all 
unworn study lenses. 
• No cleaning or disinfecting solutions will be used. If determined necessary by the 
Investigator sterile non -preserved 
rewetting drops may be dispensed to be used as needed for dryness. 
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every day during the study. 
• Subjects will be instructed to wear their 
glasses when not wearing the study lenses . 
• A patient instruction booklet will be provided. 
Note: In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably 
possible, a damaged lens should be returned to 
the investigational site and then returned to 
the Sponsor.  If lens damage is present, 
complete the Product Quality Complaint 
Form.  The lens will be stored in labeled vial 
with sterile saline, and returned to the 
Sponsor.  
2.19 Patient Instructions  
for Daily  Reusable  
Wear Lenses  Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis.  
• OPTI-FREE® Replenish® solution will be  
CR-6267, v2.0
 
Page 38 of 218
JJVC CONFIDENTIAL

 
  
 unit increme nts will be used in the grading.  
Corneal Staining Assessment  will 
be graded in 1.0 increments. 
 
If the clearance of the fluorescein needs to be expedited, preservative- free rewetting drops or 
saline may be instilled.   
3.13  Insertion of Study 
Lenses Dispense the subject new lenses if wearing the 
daily disposable lenses that match the Distance and ADD power of the lense s that were 
removed in Step 3.11 above.  
 
Subjects that are wearing the daily reusable wear lenses will reinsert the lenses that were 
temporarily stored.   
3.14  Distance and Near 
Exit Visual Acuity  Distance and near Snellen visual acuity will be 
measured for each eye with the study contact lenses in place.  
For near measures use the ETDRS 2000 Series Chart 1 or 2.  The acuity will be recorded to the nearest letter OD, OS and OU.  
  
Note: The distance visual acuity must be at least 20/30 OU for the lenses to be 
dispensed.   
3.15  Dispensing Criteria  The lenses will be dispensed for 7±1 day.  
• Distance Snellen acuity  equal to or better 
than 20/30 OU 
• Subject must indicate that the vision is 
acceptable.  
• Subject must indicate that the comfort of the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit.  
3.16  Patient Instructions  
for Daily Disposable 
Lenses Instruct the Subject the following:  
• The lenses will be worn on a daily wear basis. 
• Only enough lenses will be dispensed to 
the subject to wear for the required number 
of days until their follow-up visit. No 
additional lenses will be dispensed. 
• A new lens w ill be opened and worn each 
day.  
CR-6267, v2.0
 
Page 42 of 218
JJVC CONFIDENTIAL

 
  
 • Instruct the subject to bring back all 
unworn study lenses. 
• No cleaning or disinfecting solutions will 
be used. If determined necessary by the 
Investigator sterile non -preserved 
rewetting drops may be dispensed to be used as needed for dryness. 
• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study. 
• Subjects will be instructed to wear their glasses when not wearing the study lenses . 
  
Note:  In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably 
possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If lens damage is present, complete the Product Quality C omplaint 
Form.  The lens will be stored in labeled vial 
with sterile saline, and returned to the 
Sponsor. 
3.17  Patient Instructions  
for Daily Reusable  
Wear Lenses  Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis.  
• OPTI-FREE® Replenish® solution will be 
used in a rub regime to disinfect and store 
the lenses each night in the lens case provided.  
• If determined necessary by the Investigator 
sterile non -preserved rewetting drops may 
be dispensed to be used as needed for 
dryness. 
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every day 
during the study. 
• Subjects will be instructed to wear their 
glasses when not wearing the study lenses . 
 
Note:  In the event a lens is lost or damaged, 
the subject will ret urn to the investigator site  
CR-6267, v2.0
 
of 218
JJVC CONFIDENTIAL

 
  
 from the other worn lenses that will be shipped 
back to the Sponsor. Complete the Quality 
Product Complaint form.  
4.16  Lens Settling  Allow the study lenses to settle for a minimum 
of 10 minutes.   
4.17  Determine Visual 
Satisfaction  Determine if the subject’s vision is acceptable 
with the lenses.  Allow the subject to look 
down a hallway or out of a window for distance vision assessments, and for them to read a book, magazine or similar for near 
vision.    
4.18  Study Lens Distance 
and Near Visual Acuity Measure the distance and near visual acuity 
OD, OS and OU.  Record the results. 
For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the 
nearest letter OD, OS and OU.   
4.19  Distance Over -
Refraction and Distance Visual 
Acuity Perform a distance over -refraction OD and OS 
using loose lenses outside of the phoropter under ambient room illumination.  The distance over -refraction may also be refined 
under binocular conditions.  Record the results.  
The results of the distance over -refraction may 
also be checked for the impact on near vision 
under monocular and/or binocular conditions.     
4.20  Subjective Lens Fit 
Assessment  Evaluate overall lens fit acceptance (acceptable 
or unacceptable) based on centration, movement and other fitting characteristics.  
  An unacceptable fit is deemed by one of the following criteria:  
• limbal exposure at primary gaze or with extreme eye movement;  
• edge lift; 
• excessive movement in primary and up gaze; or  
• insufficient movement in all three of the following conditions: primary gaze, up gaze, and Josephson push up.  
If either lens is deemed unacceptable, the subject will be discontinued from the study.  Remove the lenses, p erform a slit -lamp 
evaluation, and complete the Final Evaluation 
form.  
4.21  Modifications  If the subject reports unsatisfactory vision, or is 
unable to obtain 20/30 distance visual acuity Appendix 
G (Fitting 
CR-6267, v2.0
 
Page 47 of 218
JJVC CONFIDENTIAL

 
  
 OU with the lenses then a modification must be 
attempted.  
If the subject reports satisfactory vision with 
the lenses a modificat ion is not requir ed, 
however at the Inve stigator’s discretion and 
based upon thei r findings on the  measured 
visual acuity and /or over- refraction the 
investigator may make a modification . 
Up to two attempts at modification are 
permitted if necessary, in order to achieve an 
acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.  Follow the fitting guide allowing for at least 10 minutes of settling time between each lens modification attempted.    
If modifications are required steps 4.14-4.20 
will be repeated for each modification  Guide) 
4.22  Post-Fit 
Questionnaire The subject will evaluate the vision 
characteristics, comfort characteristics, handling characteristics, and visual symptoms of the study lenses using the PRO 
questionnaire.   
4.23  Distance and Near 
Exit Visual Acuity  Distance and near Snellen visual acuity will be 
measured for each eye with the study contact lenses in place.  
For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the nearest letter OD, OS and OU.  
 
Note: The distance visual acuity must be at least 20/30 OU for the lenses to be 
dispensed.   
4.24  Dispensing Criteria  The lenses will be dispensed for 2 -4 days. 
• Distance Snellen acuity equal to or better 
than 20/30 OU 
• Subject must indicate that the vision is 
acceptable.  
• Subject must indicate that the comfort of the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit.  
4.25  Patient Instructions 
for Daily Disposable 
Lenses Instruct the Subject the following:  
• The lenses will be worn on a daily wear basis.   
CR-6267, v2.0
 
Page 48 of 218
JJVC CONFIDENTIAL

 
  
 • Only enough lenses will be dispensed to 
the subject to wear for the required number 
of days until their follow-up visit. No additional lenses will be dispensed. 
• A new lens will be opened and worn each 
day. 
• Instruct the subject to bring back all 
unworn study lenses. 
• No cleaning or disinfecting solutions will be used. If determined necessary by the 
Investigator sterile non -preserved rewetting 
drops may be dispensed to be used as needed for dryness. 
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every day 
during the study. 
• Subjects will be instructed to wear their 
glasses when not wearing the study lenses . 
• A patient instruction booklet will be provided. 
Note:  In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably 
possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If l ens damage is present, complete 
the Product Quality Complaint Form.  The lens will be stored in labeled vial with sterile 
saline, and returned to the Sponsor.  
4.26  Patient Instructions 
for Daily Reusable  
Wear Lenses  Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis.  
• OPTI-FREE® Replenish® solution will be 
used in a rub regime to disinfect and store 
the lenses each night in the lens case 
provided.  
• If determined necessary by the Investigator 
sterile non -preserved rewetting drops may 
be dispensed to be used as needed for 
dryness. 
• Subjects will be instructed to wear lenses  
CR-6267, v2.0
 
Page 49 of 218
JJVC CONFIDENTIAL

 
  
 characteristics, comfort characteristics, 
handling characteristics, and visual symptoms 
of the study lenses using the PRO 
questionnaire.   
5.5  Ocular Symptoms  Subjects will respond to a verbal open -ended 
symptoms questionnaire   
5.6  Subjective 
Acceptance  Record whether the subjects distance and near 
vision with the lenses is acceptable.   
5.7  Distance and Near 
Entrance Visual Acuity Distance and near Snellen visual acuity will be 
measured for each eye with the study contact 
lenses in place.  
For near measures use the ETDRS 2000 Series Chart 1 or 2. The acuity will be recorded to the 
nearest letter OD, OS and OU.   
5.8  Distance Over -
Refraction and Distance Visual Acuity Perform a di stance over -refraction OD and OS 
using loose lenses outside of the phoropter under ambient room illumination.  The distance over -refraction may also be refined 
under binocular conditions.  Record the results and distance visual acuity OD and OS.  The results of the distance over -refraction may also 
be checked for the impact on near vision under 
monocular and/or binocular conditions.     
5.9  Determination of 
Lens Optimization  If the subject reports unsatisfactory vision, or is 
unable to obtain 20/30 dista nce visual acuity  
OU with the lenses then a modification must be 
attempted.  
If the subject reports satisfactory vision with 
the lenses a modificat ion is not requir ed, 
however at the Inve stigator’s discretion and 
based upon thei r findings on the  measured 
visual acuity and /or over- refraction the 
investigator may make a modification . 
Up to two attempts at modification are permitted if necessary, in order to achieve an acceptable distance and near binocular performance for the subject, and to enable them to wear that particular lens type.   
Follow the fitting guide allowing for at least 10 minutes of settling time between each lens 
modification attempted.  Appendix 
G and H 
(Fitting Guides)  
5.10  Lens Fit Assessment:  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness (push-up test). 
 The subject should not proceed to wear the   
CR-6267, v2.0
 
Page 51 of 218
JJVC CONFIDENTIAL

 
  
 For near measures use the ETDRS 2000 Series 
Chart 1 or 2. The acuity will be recorded to the 
nearest letter OD, OS and OU.  
  
Note: The distance visual acuity must be at least 20/30 OU for the lenses to be 
dispensed.  
5.17  Dispensing Criteria  The lenses will be dispensed for 7±1 day.  
• Distance Snellen acuity equal to or better 
than 20/30 OU 
• Subject must indicate that the vision is 
acceptable.  
• Subject must indicate that the comfo rt of 
the lenses is acceptable.  
• Lenses must have an acceptable general 
lens fit.  
5.18  Patient Instructions 
for Daily Disposable 
Lenses Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis. 
• Only enough lenses will be dispensed to the subject to wear for the required number 
of days until their follow-up visit. No 
additional lenses will be dispensed. 
• A new lens will be opened and worn each 
day. 
• Instruct the subject to bring back all 
unworn study lenses. 
• No cleaning or disinfecting solutions will be used. If determined necessary by the Investigator sterile non -preserved 
rewetting drops may be dispensed to be used as needed for dryness. 
• Subjects will be instructed to wear lenses 
for a minimum of 6 hours a day, every day 
during the study. 
• Subjects will be instructed to wear their glasses when not wearing the study lenses . 
  
Note:  In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably  
CR-6267, v2.0
 
Page 53 of 218
JJVC CONFIDENTIAL

 
  
 possible, a damaged lens should  be returned to 
the investigational site and then returned to 
the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial 
with sterile saline, and returned to the 
Sponsor. 
5.19  Patient Instru ctions 
for Daily Reusable 
Wear Lenses  Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis.  
• OPTI-FREE® Replenish® solution will be 
used in a rub regime to disinfect and store 
the lenses each night in the lens case 
provided.  
• If determined necessary by the Investigator 
sterile non -preserved rewetting drops may 
be dispensed to be used as needed for dryness. 
• Subjects will be instructed to wear lenses for a minimum of 6 hours a day, every day during the study. 
• Subjects will be instructed to wear their 
glasses when not wearing the study lenses . 
 
Note:  In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as reasonably 
possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial 
with sterile saline, and returned to the 
Sponsor.  
5.20      Schedule  
Follow-up The subje ct will be scheduled to return for 
their follow -up appointment in 7±1 days. 
 
Note: To count the follow-up visit as a day of 
wear the Subject must have worn the study 
lenses for 6 hours prior to the visit.   
 
 
CR-6267, v2.0
 
Page 54 of 218
JJVC CONFIDENTIAL

 
  
 Contrast (1 Chart). 
Near (40 cm) High Contrast  (1 Chart) and Low 
Contrast (1 Chart).  
Distance, Dim Illuminanc e (with Distance 
goggles) 
ETDRS Char ts 3M-HC#6 
Near, Dim I lluminanc e (with Near goggles) 
Reduced Guillon-Poling charts 
High Contrast  (1 Chart at each distance)  
Intermediate (64 cm) and Ne ar (40 cm).  
Note: 
• The room illuminance must b e 
between 7.3 an d 7.9 EV. 
• Distance, HC-1 Chart l uminanc e 
Accep table E V Range 10.5-10.7. 
• Guillon-Poling, Near Chart 
Luminance  Accep table EV Range 
10.8-11.1. 
• Do not use the Mesopic filter for Dim 
luminance (Dim luminance will be 
simulated by using the goggles)  
6.9  Binocular Distance 
Over-refraction and 
Distance Visual 
Acuity Perform a binocular over -refraction and rec ord 
the OD and OS results and distance visual acuity.   
Note: No lens changes are allowed based on 
the over-refraction.    Appendix 
D 
6.10  Lens Fit Assessment:  Evaluate and grade lens centration, primary 
gaze movement, upgaze movement and tightness (push-up t est). 
 The subject should not proceed to wear the 
lenses if any of the following is observed: 
• presence of limbal exposure (appearance of 
clear cornea) in any gaze 
• presence of edge lift  
• presence of unacceptable movement (excessive or insufficient) in all three 
movement categories (primary gaze, upgaze, and push-up). 
 
If either lens is deemed unacceptable, the subject will be discontinued from the study.  
Remove the lenses, p erform a slit -lamp   
CR-6267, v2.0
 
Page 56 of 218
JJVC CONFIDENTIAL

 
  
 • Lenses must have an acceptable general 
lens fit. 
6.16  Patient Instructions 
for Daily Dispo sable 
Lenses Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis. 
• Only enough lenses will be dispensed to the subject to wear for the required number 
of days until their follow-up visit. No 
additional lenses will be dispensed. 
• A new lens will be opened and worn each 
day. 
• Instruct the subject to bring back all 
unworn stud y lenses. 
• No cleaning or disinfecting solutions will 
be used. If determined necessary by the 
Investigator sterile non -preserved 
rewetting drops may be dispensed to be 
used as needed for dryness. 
• Subjects will be instructed to wear lenses for a minimum of 6  hours a day, every day 
during the study. 
• Subjects will be instructed to wear their glasses when not wearing the study lenses . 
  
Note:  In the event a lens is lost or damaged, 
the subject will return to the investigator site 
for replacement.   As much as re asonably 
possible, a damaged lens should be returned to the investigational site and then returned to the Sponsor.  If lens damage is present, complete the Product Quality Complaint Form.  The lens will be stored in labeled vial 
with sterile salin e, and returned to the 
Sponsor.  
6.17  Patient Instructions 
for Daily Reusable 
Wear Lenses   Instruct the Subject the following:  
• The lenses will be worn on a daily wear 
basis.  
• OPTI-FREE® Replenish® solution will be 
used in a rub regime to disinfect and store 
the lenses  each night in the lens case 
provided.   
CR-6267, v2.0
 
Page 58 of 218
JJVC CONFIDENTIAL

 
  
  
For discontinued subjects, the Investigator will: 
• Complete the current visit (scheduled or unscheduled) 
• Complete the Final Evaluation, indicating the reason that the subject was 
discontinued from the study 
• Record the spherocyli ndrical refraction with best corrected distance visual acuity  
• Collect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in Section 7.2 
• Collect all un used test article(s) from the subject  
 
An additional subject may  be enrolled if a subject discontinues from the study prematurely.  
 
In cases where a subject is lost to follow -up, every possible effort must be made to contact 
the subject and determine the reason for discontinuation/withdrawal.  The measures taken to follow up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt.  
9. PRE -STUDY AND CONCOMITANT INTERVENTION/MEDICATION 
Concomitant medication s will be documented during screening and updated during the study.  
Disallowed medications and therapies are medications or therapies  that contraindicate contact 
lens wear .  See the Exclusion criteria for specific details.  
10. DEVIATIONS FROM THE PROTOCOL  
Investigator will notify study sponsor upon identification of a protocol deviation. Major 
protocol deviations must be reported to the sponsor within 24 hours after discovery of the protocol deviation.  The Investigator will report deviations per IRB/IEC requirements.  All deviations will be tracked and corrective actions implemented as appropriate.   If it becomes necessary for the Investigator to implement a deviation in order to eliminate an immediate hazard to the trial subject, the Investigator may implem ent the deviation 
immediately without notification to the sponsor. Within 24 hours after the implemented deviation, the Investigator must notify and provide the rationale to the Sponsor and, as 
required, the IEC/IRB.  
11. STUDY TERMINATION 
If more than 2 subjects in the investigational soft contact lens group develop serious expected 
(e.g., definite or probable MK) or unexpected device related adverse events, the study will be 
suspended. Upon review and consultation with IRB, DMC, and JJV  safety review committe e, 
the study may be terminated. This potential stopping rule is established based on our trial involving approximately 200 subjects wearing the investigational soft contact lens for up to 3 years with an assumed MK rate that is below 0.2% per patient -year. The rate of 0.2% per 
patient year is the established rate for extended wear lenses in adults, which was requested by the FDA as a criterion for evaluating a contact lens for pediatric use in an FDA response to a 
CR-6267, v2.0
 
Page 65 of 218
JJVC CONFIDENTIAL

 
  
 pre-IDE submission. To be conservative, 200 independent patient years were used in the 
calculation. The probability of observing 2 cases or more incidents of MK is 0.061, and 3 
cases or more incidents of MK is 0.007 (given an MK rate of 0.2% per patient year).   The occurrence of one or more Unanticipated Serious Adverse Device Effect (USADE), or any SAE where the relationship to study agent cannot be ruled out, may result in stopping further dispensing of test article.  In the event of a USADE or SAE, the Sponsor may unmask the treatment regimen for the subject(s) and will discuss this with the Investigator before any further subjects are enrolled.  The Sponsor will determine when a study will be stopped.  The Principal Investigator always has the discretion to initiate stopping the study based on patient safety or if information indicates the study’s results are compromised.  
 JJV reserves the right to terminate the study at any time for any reason.  Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined.  The study can be terminated by the Principal Investigator at the individual clinical site due to specific clinical observations, if in their opinion, after a discussion with JJV , it is determined 
that it would be unwise to continue at the clinical site.    
 JJV (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events.  If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part of the investigation presenting the risk, will be terminated, as soon as possible.  Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements. 
12. PROCEDURE FOR HANDLI NG PRODUCT QUALITY COMPLAINTS  
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety, 
effectiveness or performance of test articles after they have been released  for clinical trial 
use.    Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following are not considered product quality complaints: 
• Subject satisfaction inquiries reported via “Subjective Questionnaires” and “Patient Reported Outcomes (PRO)” 
• Clinical test articles that are stored improperly or damaged after receipt at the investigational site  
• Lens replacements that occur due to drops/fall -outs 
• Damage deemed by clinicians or clinical staff to be caused by handling by the user, and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by the subject 
CR-6267, v2.0
 
Page 66 of 218
JJVC CONFIDENTIAL

 
  
  
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In case s where the EDC system in 
use is not configured to send automatic notifications or when an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.    Upon receipt of the EDC notification, the COM /CRA will contact the study site to collect 
additional information which will include:  
• Date the complaint was received/recorded in the EDC System (Date of Sponsor Awareness)  
• Who received the complaint 
• Study number 
• Clinical site information (contact name, site ID, telephone number) 
• Lot number(s) 
• Unique Subject Identifier(s) 
• Indication of who first observed complaint (site personnel or subject) 
• OD/OS indication, along with whether  the lens was inserted  
• Any related AE number if applicable  
• Detailed complaint d escription (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.) 
• Eye Care Provider objective (slit lamp) findings if applicable  
• Confirmation of product availability for return (and tracking information, if available), or rational e if product is not available for return  
 
 
Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE).  If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow Section 13 of this 
protocol. If the AE/SAE was potentially the result of a product quality relat ed deficiency, 
these procedures also applies and will be executed in parallel.   
 In some cases, a PQC form may be generated in EDC by the site in error.  In this event, the PQC forms will be marked “Intentionally Left Blank” or “ILB”.  Justification for I LB must 
be documented. 
13. ADVERSE EVENTS  
13.1. Definitions and Classifications  
Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investigational medical device.  
Note 1 to entry: This definition includes events related to the investigational medical device 
or the comparator. 
Note 2 to entry: This definition includes events related to the procedures involved. 
CR-6267, v2.0
 
Page 67 of 218
JJVC CONFIDENTIAL

 
  
 Note 3 to entry: For users or other persons, this definition is restricted to events related to 
investigational medical devices .”1 
 
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study, but appeared or reappeared following initiation of the study  
2. Was present prior to the study, but worsened during the study. This would include any condition resulting from concomitant illnesses, reactions to conc omitant 
medications, or progression of disease states  
3. Pregnancy must be documented as an adverse event and must be reported to the clinical monitor and to the Sponsor immediately upon learning of the event 
 Serious Adverse Event (SAE) – An SAE is any untoward medical occurrence that:  
• Results in death  
• Is life threatening  
• Requires in -patient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity (e.g., a sight threatening 
event, a significant persistent or permanent change, impairment, damage, or 
disruption to the subject’s body)  
• Is a congenital anomaly/birth defect  
• Requires intervention to prevent permanent damage (the use of the test article resulting in a condition which requires medical or surgical intervention to preclude permanent impairment of the body structure or a body function).  Important medical events that may not result in death, be life -threatening, or require hospitalization may 
be considered an SAE when, based upon appropriate me dical judgment, they may 
jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in the above definition 
 Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:  
• Microbial Keratitis (MK)  
• Iritis (including cells in the anterior chamber)  
• Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater  
• Central Corneal Opacity  
• Central Corneal Neovascularization  
• Uveitis 
• Endophthalmitis 
• Hypopyon 
• Hyphemia  
• Penetration of Bowman’s Membrane 
• Persistent Epithelial Defect 
• Limbal cell Damage leading to Conjunctivalization  
 
CR-6267, v2.0
 
Page 68 of 218
JJVC CONFIDENTIAL

 
  
 Significant Adverse Events  – Those events that are usually symptomatic and warrant 
discontinuation (temporary or permanent) of the test article (excluding Serious Adverse 
Events).    Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but not limited to the following:  
• Contact Lens Induced Peripheral Ulcer (CLPU) 
• Significant Infiltrative Events (SIE)  
• Superior Epithelial Arcuate Lesions (SEALs)  
• Any Temporary Loss of > 2 Lines of BSCVA 
• Other Grade 3 or higher corneal findings, such as abrasions or edema 
• Non-contact lens related corneal events - e.g. Epidemic Keratoconjunctivit is (EKC) 
• Asymptomatic Corneal Scar  
• Any corneal event which necessitates temporary lens discontinuation > 2 weeks  
 Non-Significant Adverse Events  – Those conditions that are usually asymptomatic and 
usually do not warrant discontinuation (temporary or perma nent) of the test article.  
However, the Investigator may choose to treat as a precautionary measure.    Diagnoses and conditions that are considered Ocular Non- Significant Adverse Events 
include, but not limited to the following: 
• Non-significant Infiltrative Event (NSIE) 
• Contact Lens Papillary Conjunctivitis (CLPC)  
• Superficial Punctate Keratitis (SPK)  
• Conjunctivitis: Bacterial, Viral, Allergic  
• Blepharitis  
• Meibomianitis  
• Contact Dermatitis  
• Localized Allergic Reactions  
• Any corneal event not explicitly defined  as serious or significant adverse event, 
which necessitates temporary lens discontinuation < 2 weeks 
 
Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an 
investigational medical device.  
Note 1 to entry: This definition includes adverse events resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device.  
Note 2 to entry: This definition includes any event resulting from use error or from 
intentional misuse of the investigational medical device.”1 
 Unanticipated Adverse Device Effect (UADE) – Any serious adverse effect on health or 
safety or any life -threatening problem or deat h caused by, or associated with, the test article, 
if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan, Investigator’s Brochure or protocol, or any other 
CR-6267, v2.0
 
Page 69 of 218
JJVC CONFIDENTIAL

 
  
 unanticipated seri ous problem associated with the test article that relates to the rights, safety 
and welfare of subjects.  
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the Investigator will evaluate adverse events to 
ensure the events are categorized co rrectly.  Elements of categorization will include: 
• Seriousness/Classifications (see definition in Section 13.1) 
• Causality or Relatedness – i.e. the relationship between the test article, study 
treatment or study  procedures and the adverse event (not related; unlikely related; 
possibly related; related - see definition in Section 13.2.1) 
• Adverse Event Severity – Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild; moderate; severe for all events - see definition in 
Section 0)   
• Outcome – not recovered or not resolved; recovering or resolving ; recovered or 
resolved with sequelae; recovered or resolved ; death related to adverse event ; 
unknown 
• Actions Taken – none; temporarily discontinued; permanently discontinued; other 
13.2.1. Causality Assessment  
Causality Assessment – A determination of the relationship between an adverse event and 
the test article. The test article relationship for each adverse event should be determined by the investigator using these explanations: 
• Not Related - An adverse event that is not related to the use of the test article, study 
treatment or study procedures 
• Unlikely Rel ated – An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not likely 
• Possibly Related – An adverse event that might be  due to the use of the test article, or 
to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive.  The relationship in time is reasonable.  Therefore, the causal relationshi p cannot be excluded 
• Related – An adverse event that is listed as a possible adverse effect (device) or 
adverse reaction (drug) and cannot be reasonably explained by an alternative explanation, e.g. concomitant treatment of concomitant disease(s).  The rel ationship 
in time is very suggestive, e.g. it is confirmed by de -challenge and re- challenge  
13.2.2. Severity Assessment  
Severity Assessment – A qualitative assessment of the degree of intensity of an adverse 
event as determined by the Investigator or reported to him/her by the subject.  The assessment of severity is made irrespective of test article, study treatment or study procedure relationship or seriousness of the event and should be evaluated according to the following scale: 
• Mild – Event is noticeable to the  subject, but is easily tolerated and does not interfere 
with the subject’s daily activities  
CR-6267, v2.0
 
Page 70 of 218
JJVC CONFIDENTIAL

 
  
 • Moderate – Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject’s daily activities  
• Severe – Event is intolerable, necessi tates additional therapy or alteration of therapy 
and interferes with the subject’s daily activities  
13.3. Documentation and Follow- Up of Adverse Events  
The recording and documenting of adverse events (ocular and non- ocular) begins when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the condition deteriorates at any time during t he 
study it will be recorded and reported as an AE. Untoward medical events reported after the subject’s exit from the study will be recorded as adverse events at the discretion of the Investigator.  Upon finding an adverse event, the Principal Investigator will document the condition in the subject record and in the eCRFs. He/she will complete the Adverse Event /eCRF.   
 Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic reactions not meeting the criteria for “serious adverse events” shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship.    It is the Investigator’s responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements.  Such documentation will include the following: 
• Adverse event (diagnosis not symptom) 
• Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.)  
• Date the clinical site was notified  
• Date and time of onset  
• Date and time of resolution  
• Adverse event classi fication, severity, and relationship to test articles, as applicable 
• Treatment regimen instituted, including concomitant medications prescribed, in accordance with applicable licensing requirements  
• Any referral to another health care provider if needed  
• Outcome, ocular damage (if any)  
• Likely etiology  
• Best corrected visual acuity at the discovery of the event and upon conclusion of the event 
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF.  Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature.  If cultures are collected, the date of culture collection and laboratory utilized will be recorded.  
CR-6267, v2.0
 
Page 71 of 218
JJVC CONFIDENTIAL

 
  
  
Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed.  Adverse events characterized as intermittent require documentation of the onset and duration of each episode. Changes in the assessment of relationsh ip to the test a rticle shall also be clearly documented.  
 Subjects who present with an adverse event shall be followed by the Investigator, within licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or 
been satisfacto rily resolved.  If further treatment beyond licensure is required, the patient will 
be referred to the appropriate health care provider.  The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study.  
If a subject is discontinued from the study, it will be the responsibility of the Investigator to record the reason for discontinuation.  The Investigator will also document the adverse event appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test article, study treatment or study procedures, as of the final study visit date, should be followed to resolution of the adverse event or until referral to an appropriate health care provider, as recommended by the Investigator. Non- ocular adverse 
events that are not related to the test article, study treatment, or study procedures may be recorded as “ongoing” without further follow-up. 
13.4. Reporting Adverse Events  
The Investigator will notify the Sponsor of an adverse event by e -mail, facsimile, or 
telephone as soon as possible and no later than 24 hours from discovery for any serious 
/significant adverse events, and 2 days from discovery for any non-significant adverse event.  In addition, a wr itten report will be submitted by the Principal Investigator to the IEC/IRB 
according to their requirements (Section 13.4.2).  The report will comment whether the 
adverse event was considered to be related to th e test article, study treatment or study 
procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events  
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as poss ible by e-mail, fax, or telephone, but no later than 24 
hours following discovery of the event.  The Investigator is obligated to pursue and obtain 
information requested by the Sponsor in addition to that information reported on the eCRF. 
All subjects expe riencing a serious/significant adverse event must be followed up and all 
outcomes must be reported.  When medically necessary, the Investigator may break the randomization code to determine the identity of the treatment that the subject received.  The Sponsor and study monitor should be notified prior to unmasking the test articles.  In the event of a serious/significant adverse event, the Investigator must: 
• Notify the Sponsor immediately  
CR-6267, v2.0
 
Page 72 of 218
JJVC CONFIDENTIAL

 
  
 • Obtain and maintain in the subject’s records all pertinent medical in formation and 
medical judgment for colleagues who assisted in the treatment and follow -up of the 
subject 
• Provide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article  
• Notify the IEC/IRB as required by the IEC/IRB reporting procedure according to national regulations 
 
Unanticipated (Serious) Adverse Device Effect (UADE)  
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later than 24 hours after the Investigator first learns of the effect.  This report is in addition to the immediate notification mentioned above.  
 The Sponsor must conduct an evaluation of the UADE and must report the results of the evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after the Sponsor first receives notification of the effect.  Non-Serious Adverse Events  
All non-serious adverse e vents, including non- serious adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery. 
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Each clinical site will refer to and follow any guidelines set forth by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines set forth by their local governing Health Authorities.  The Sponsor will report applicable Adverse Events to the local health authorities according the written guidelines, including reporting timelines.  
13.4.3. Event of Special Interest  
None 
13.5. Reporting of Pregnancy 
Subjects reporting pregnancy (by self -report) during the study will be discontinued after the 
event is recorded as an Adverse Event.  Once discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes.  At the Investigator’s discretion, the study participant may be followed by the Investigator through delivery. However, this data will not be collected as part of the clinical study database.  Pregnant participants are not discontinued from contact lens or solution related studies for safety concerns, but due to general concerns relating to pregnancy and contact lens use.  Specifically, pregnant women are discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus. 
CR-6267, v2.0
 
Page 73 of 218
JJVC CONFIDENTIAL

 
  
 Intent -to-Treat (ITT) Population:  
All subjects regardless of actual treatment and subsequent withdrawal from study or 
deviation from protocol.  At least one observation should be recorded. 
14.4. Level of Statistical Significance  
All planned analysis for this study will be conducted with an overall type I error rate of 5%.  14.5. Primary Analysis  
Primary efficacy analysis : 
 
CLUE Vision : 
Overall quality of vision scores will b e analyzed using a linear mixed model adjusting for 
baseline values as fixed covariates. The model will include the experimental design factors: 
sequence of lens wear, period, lens type, time point and interaction between lens and time point as fixed effects. The covariance between residual errors from the same subject across lens wearing periods/time point will be selected based on the finite -sample corrected 
Akaike’s Information Criterion (Keselman et al. 1998)
6. Covariance structures considered 
may include: Homogenous compound symmetry (CS) and Unstructured covariance structure (UN).  The structure that returns the lowest Akaike Information Criteria Corrected (AICC) 
will be selected as the structure that best fit the data.  
 
Primary Hypothesis: 
Comparisons will be carried out using 95% confidence intervals constructed of least -square 
means (LSM) from the linear mixed models of CLUE vision scores for each study population. Statistically superiority will be conclu ded if the lower limit of the confidence 
intervals of the test lens are greater than 32 points. 
 
Secondary Hypothesis: 
Comparisons between the test lens and control lens at each time point (1 week and 2 weeks) will be carried out using 95% confidence inter vals constructed of least -square means (LSM) 
differences (Test minus Control) from the linear mixed model. The non- inferiority of the test 
lens relative to the control will be concluded if the lower confidence limit of LSM difference is above the non- inferiority margin -5. The superiority will be established if the lower 
confidence limit is above 0. 
 
In all models, the Kenward and Roger method (Kenward and Roger, 1997)
7 will be used for 
the calculation of the den ominator of degrees of freedom. 
 
14.6. Secondary Analysis 
See section 14.5. 14.7. Other Exploratory Analyses 
Not Applicable 
CR-6267, v2.0
 
Page 75 of 218
JJVC CONFIDENTIAL

 
  
 14.8. Interim Analysis  
Not Applicable 
14.9. Procedure for Handling Missing Data and Drop -Outs  
Missing or spurious values will not be imputed. The count of m issing values will be included 
in the summary tables and listings.  
 
Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. Past clinical trials don’t provide the evidence that subject dropout is systematic or not -at-
random. To evaluate the impact of missing data, sensitivity analysis will be conducted using 
multiple imputation methods if the proportion of subject dropout is greater than the 15%. The SAS/STAT procedures PROC MI and PROC MIANALYZE will be utilized w ith a 
parametric regression method used to make at least 5 imputations.  
14.10. Procedure for Reporting Deviations from Statistical Plan  
The analysis will be conducted according to that specified in above sections.  There are no known reasons for which it is planned to deviate from these analysis methods.  If for any reason a change is made, the change will be documented in the study report along with a justification for the change.  
15. DATA HANDLING AND RE CORD KEEPING/ARCHIVI NG 
15.1. Electronic Case Report Form/Data Collect ion 
The data for this study will be captured on electronic case report forms (eCRFs) using an EDC system (Bioclinica) . An authorized data originator will enter study data into the eCRFs 
using the EDC system. Data collected on equipment that is not captured  in EDC will be 
formatted to the specification of the JJV database manager and sent to JJV  for analysis.  
 External Date Sources for this study include:   
Not Applicable  The clinical data will be recorded on dedicated eCRFs specifically designed to match t he 
study procedures for each visit.  Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by the Investigator.  The sponsor or sponsor’s representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.   Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data will be transmitted from the clinical site to a secure central database as forms  are completed or updated, ensuring information accuracy, security, 
and confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy 
of the source data for the study.  
CR-6267, v2.0
 
Page 76 of 218
JJVC CONFIDENTIAL

 
  
  
The content and structure of the eCRFs are compliant with ISO14155:2011.1 
15.2. Subject Record  
At a minimum, subject record should be available for the following:  
• subject identification  
• eligibility  
• study identification  
• study discussion 
• provision of and date of informed consent 
• visit dates  
• results of safety and efficacy parameters as required  by the protocol 
• a record of all adverse events  
• follow-up of adverse events 
• medical history and concomitant medication  
• test article receipt/dispensing/return records  
• date of study completion 
• reason for early discontinuation of test article or withdrawal from the study, if applicable  
 
The subject record is the eCRF or an external record.  The author of an entry in the subject record must be identifiable.  The first point of entry is considered to be the source record.  Adverse event notes must be reviewed an d initialed by the Investigator.  
16. DATA MANAGEMENT  
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial- related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents.  Should the clinical site be contacted for an audit by an IEC/I RB or regulatory authority, JJV  must be 
contacted and notified in writing within 24 hours. 
16.2. Confidentiality of Information 
Information concerning the investigational product and patent application processes, 
scientific data or other pertinent information is confidential and remains the property of JJV .  
The Investigator may use this information for the purposes of the study only. It is understood by the Investigator that JJV  will use information deve loped in this clinical study in 
connection with the development of the investigational product and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an obligation to provide complete test results and all data developed during this study to the Sponsor. 
CR-6267, v2.0
 
Page 77 of 218
JJVC CONFIDENTIAL

 
  
 16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator.  The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are familiar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article.  Training on case report form completion will be provided to clinical site personnel before the start of the study.  The Sponsor will revi ew case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to data management.  Any data discrepancies will be resolved with the Investigator or designee, as appropriate.  
 Quality Ass urance representatives from JJV  may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials.  The clinical sites will provide direct access to  study-related source 
data/documents and reports for the purpose of  monitoring and auditing by JJV  and for 
inspection by local and regulatory authorities. 
17. MONITORING  
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator’s designated clinical site personnel.  The monitor’s responsibilities will include:  
• Ensuring that the investigation is being conducted according to the protocol, any subsequent amendments, and regulatory requirements are maintained 
• Ensuring the r ights and wellbeing of subjects are protected  
• Ensuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site personnel  
• Ensuring that protocol deviations are documented with corrective action plans, as applicable  
• Ensuring that the clinical site has sufficient test article and supplies  
• Clarifying questions regarding the study 
• Resolving study issues or problems that may arise  
• Reviewing of study records and source documentation verification in accordance with the monitoring plan 
18. ETHICAL AND REGULATORY ASPECTS  
18.1. Study -Specific Design Considerations  
Potential subjects will be fully informed of the risks and requirements of the study and, during the study, subjects will be given any new information that may affect their decision to continue participation.  Subjects will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given and without penalty or loss of benefits to which they would otherwise be entitled.  Only subjects who are fully able 
CR-6267, v2.0
 
Page 78 of 218
JJVC CONFIDENTIAL

 
  
 to understand the risks, benefits, and potential adverse events of the study, and provide their 
consent voluntarily will be enrolled. 
18.2. Investigator Responsibility 
The Principal Investigator is responsible for ensuring that the cl inical study is performed in 
accordance with the signed agreement, the investigational plan, Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP) ,2 and applicable regulatory requirements.  GCP 
is an international ethical and scientific quality standard for designing, conducting, recording, 
and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are protected, consistent with the principles of the Declaration of Helsinki 64
th WMA General 
Assembly 20133 and that the clinical study data are credible.  The Investigator must maintain 
clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical 
Practice (GCP) ,2 and applicable regulatory requirements. 
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IR B) 
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copies of the following documents (where applicable): 
• Final protocol and, if applicable, amendments 
• Sponsor-approved informed consent form (and any other written materials to be 
provided to the subjects) 
• Investigator’s Brochure (or equivalent information) and amendments 
• Sponsor-approved subject recruitment materials 
• Information on compensation for study -related injuries or payme nt to subjects for 
participation in the study  
• Investigator’s curriculum vitae, clinical licenses, or equivalent information (unless 
not required, as documented by IEC/IRB) 
• Information regarding funding, name of the Sponsor, institutional affiliations, othe r 
potential conflicts of interest, and incentives for subjects 
• Any other documents that the IEC/IRB requests to fulfill its obligation  
 
This study will be undertaken only after IEC/IRB has given full approval of the final protocol, amendments (if any), the  informed consent form, applicable recruiting materials, 
and subject compensation programs, and the Sponsor has received a copy of this approval. This approval letter must be dated and must clearly identify the documents being approved.  During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
• Protocol amendments 
• Revision(s) to informed consent form and any other written materials to be provided to subjects 
• If applicable, new or revised subject recruitment materials approved by the Sponsor 
• Revisions to compensation for study -related injuries or payment to subjects for 
participation in the study  
• Investigator’s Brochure amendments or new edition(s) 
CR-6267, v2.0
 
Page 79 of 218
JJVC CONFIDENTIAL

 
  
 • Summaries of the status of the study (at least annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
• Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB’s requirements  
• New information that may adversely affect the safety of the subjects or the conduct of the study 
• Major protocol deviations as required by the IEC/IRB 
• Report of deaths of subjects under the Investigator's care 
• Notification if a new Investigator is responsible for the study  at the clinical site  
• Any other requirements of the IEC/IRB 
 For protocol amendments that increase subject risk, the amendment and applicable informed consent form revisions must be submitted promptly to the IEC/IRB for review and approval before implement ation of the change(s). 
 At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing.  At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the  study completion.  Documentation of this notification must be retained at the 
clinical site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent  
Each subject must give written consent according to local requirements after the nature o f the 
study has been fully explained. The consent form must be signed before performance of any 
study-related activity. The consent form that is used must be approved by both the Sponsor 
and by the reviewing IEC/IRB. The informed consent is in accordance w ith principles that 
originated in the Declaration of Helsinki,
3 current ICH2 and ISO 141551 guidelines,  
applicable regul atory requirements, and Sponsor Policy. 
 Before entry into the study, the Investigator or an authorized member of the clinical site personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any discomfort it may entail. Subjects will be informed that their participation is voluntary and that they may withdraw consent to participate at any time.  
 The subject will be given sufficient time to read the informed consent form and the opportunity to ask questions. After this explanation and before entry into the study, consent should be appropriately recorded by means of the subject's dated signature. After having obtained the consent, a copy of the informed consent form must be given to the subject.  
 The collection, processing and disclosure of personal data and medical information related to the Study Subject, and personal data related to Principal Investigator and any clinical site personnel (e.g., name, clinic address and phone number , curriculum vitae) is subject to 
compliance with the Health Information Portability and Accountability Act (HIPAA) in the United States
5 and other applicable personal data protection and security laws and 
CR-6267, v2.0
 
Page 80 of 218
JJVC CONFIDENTIAL

 
  
 regulations.  Appropriate measures will be employed to safeguard these data, to maintain the 
confidentiality of the person’s related health and medical information, to properly inform the 
concerned persons about the collection and processing of their personal data, to grant them reasonable access to their personal data and to prevent access by unauthorized persons.  All information obtained during the course of the investigation will be regarded as confidential. All personal data gathered in this trial will be treated in strictest confidence by Investigators, monitors, Sponsor’s personnel and IEC/IRB.  No data will be disclosed to any third party without the express permission of the subject concerned, with the exception of Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their investigation related activities that, as part of the investigation will have access to the CRFs and subject records. 
18.5. Privacy of Personal Data 
The collection and processing of personal data from s ubjects enrolled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, quality, and utility 
of the investigational product(s) used in this study.  These data must be collected and processed with adequate precau tions to ensure 
confidentiality and compliance with applicable data privacy protection laws and regulations. The Sponsor ensures that the personal data will be: 
• processed fairly and lawfully 
• collected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes 
• adequate, relevant, and not excessive in relation to said purposes 
• accurate and, where necessary, kept current  
 Explicit consent for the processing of personal data will be obtained from the par ticipating 
subject before collection of data. Such consent should also address the transfer of the data to other entities and to other countries.  The subject has the right to request through the Investigator access to his personal data and the right to re quest rectification of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the request, the conditions of the study, and the applicable laws and regulations.  Appropriate technical and organizational measures to protect the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects confidential. 
19. STUDY RECORD RETENTI ON 
In compliance with the ICH/GCP guidelines ,
2 the Investigator/Institution will maintain all 
CRFs and a ll subject records that support the data collected from each subject, as well as all 
study documents as specified in ICH/GCP2 and all study documents as specified by the 
CR-6267, v2.0
 
Page 81 of 218
JJVC CONFIDENTIAL

 
  
 applicable regulatory requirement(s). The  Investigator/Institution will take measures to 
prevent accidental or premature destruction of these documents. 
 Essential documents must be retained until at least two (2) years after the last approval of a 
marketing application in an ICH region and until  there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical development of the investigational product. These documents will be retained for a longe r period if required by the applicable regulatory 
requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained.  If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping the study records, custody must be transferred to a person who will accept the responsibility. The Sponsor must be notified in writing of the name and address of the new custodian. Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.  If it becomes necessary for the Sponsor or the appropriate regulatory authority to review a ny 
documentation relating to this study, the Investigator must permit access to such reports. If the Investigator has a question regarding retention of study records, he/she should contact JJV. 
20. FINANCIAL CONSIDERATIONS  
Remuneration for study services and e xpenses will be set forth in detail in the Clinical 
Research Agreement.  The Research Agreement will be signed by the Principal Investigator and a JJV  management representative prior to study initiation.  
 JJV reserves the right to withhold remuneration for  costs associated with protocol violations 
such as: 
• Continuing an ineligible subject in the study 
• Scheduling a study visit outside the subject’s acceptable visit range  
JJV reserves the right to withhold final remuneration until all study related activitie s have 
been completed, such as:  
• Query resolution 
• Case Report Form signature  
• Completion of any follow- up action items  
21. PUBLICATION  
This study will be registered on ClinicalTrials.gov by the Sponsor . 
CR-6267, v2.0
 
Page 82 of 218
JJVC CONFIDENTIAL

 
  
 22. REFERENCES  
1. ISO 14155:2011: Clinical Investigation of Medic al Devices for Human Subjects — 
Good Clinical Practice. Available at: https://www.iso.org/standard/45557.html   
2. International Conference on Harmonization Good Clinical Practice E6 (ICH- GCP). 
Available at: http://www.ich.org/products/guidelines/efficacy/article/efficacy -
guidelines.html   
3. Declaration of Helsinki - Ethical principles for Medical Research Involving Human 
Subjects. Available at: https://www.wma.net/policies -post/wma -declaration -of-
helsinki-ethical-principles- for-medical-research-involving-human-subjects/   
4. United States (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR   
5. Health Information Portability  and Accountability Act (HIPAA).  Available at: 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html   
6. Keselman HJ , Algina J, Kowalchuk RK, Wolfinger RD. A Comparison of Two 
Approaches for Selecting Covariance Structures in the Analysis of Repeated Measures. Communications in Statistics—Simulation and Computation. 
1998;27:591-604. 
7. Kenward MG, Roger JH. Small Sample In ference for Fixed Effects from Restricted 
Maximum Likelihood . Biometrics . 1997;53:983–997. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CR-6267, v2.0
 
Page 83 of 218
JJVC CONFIDENTIAL

 
  
  
 
 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
 
 
CR-6267, v2.0
 
Page 84 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 1
CR-6267, v2.0
 
Page 85 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 2
CR-6267, v2.0
 
Page 86 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 3
CR-6267, v2.0
 
Page 87 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 4
CR-6267, v2.0
 
Page 88 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 5
CR-6267, v2.0
 
Page 89 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 6
CR-6267, v2.0
 
Page 90 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 7
CR-6267, v2.0
 
Page 91 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 8
CR-6267, v2.0
 
Page 92 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 9
CR-6267, v2.0
 
Page 93 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 10
CR-6267, v2.0
 
Page 94 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 11
CR-6267, v2.0
 
Page 95 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 12
CR-6267, v2.0
 
Page 96 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 13
CR-6267, v2.0
 
Page 97 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 14
CR-6267, v2.0
 
Page 98 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO n 1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 15
CR-6267, v2.0
) 
Page 99 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 16
CR-6267, v2.0
 
Page 100 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 17
CR-6267, v2.0
 
Page 101 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 18
CR-6267, v2.0
 
Page 102 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 19
CR-6267, v2.0
 
Page 103 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 20
CR-6267, v2.0
 
Page 104 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 21
CR-6267, v2.0
 
Page 105 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 22
CR-6267, v2.0
 
Page 106 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 23
CR-6267, v2.0
 
Page 107 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 24
CR-6267, v2.0
 
Page 108 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 25
CR-6267, v2.0
 
Page 109 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 26
CR-6267, v2.0
 
Page 110 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 27
CR-6267, v2.0
 
Page 111 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 28
CR-6267, v2.0
 
Page 112 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 29
CR-6267, v2.0
 
Page 113 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO  1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 30
CR-6267, v2.0
 
Page 114 of 218
JJVC CONFIDENTIAL

PRO SPECIFICATIO n 1 Final  2018-04-03Protocol 6267                 Johnson & Johnson Vision Care, Inc.                  Confidential 31
CR-6267, v2.0
) 
Page 115 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX B : PATIENT INSTRUCTION GUIDE   
Patient Instruction Guide will be provided separately. 
CR-6267, v2.0
 
Page 116 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
 
ACUVUE OASYS®  
1-DAY ACUVUE® MOIST MULTIFOCAL  
1-DAY ACUVUE® MOIST  
CR-6267, v2.0
 
Page 117 of 218
JJVC CONFIDENTIAL

 
CR-6267, v2.0
 
Page 118 of 218
JJVC CONFIDENTIAL

 
CR-6267, v2.0
 
Page 119 of 218
JJVC CONFIDENTIAL

T h e  l e n s e s  a r e  t i n t e d  b l u e  u s i n g  R e a c t i v e  B l u e  D y e  # 4  t o  m a k e  t h e  l e n s e s  m o r e  
v i s i b l e  f o r  h a n d l i n g .  A  b e n z o t r i a z o l e  U V  a b s o r b i n g  m o n om e r  i s  u s e d  t o  b l o c k  U V  
r a d i a t i o n .  
L e n s  P r o p e r t i e s : 
T h e  p h y s i c a l / o p t i c a l  p r o p e r t i e s  o f  t h e  l e n s  a r e : 
•  S p e c i ﬁ  c  G r a v i t y  ( c a l c u l a t e d ) :   0 . 9 8  –  1 . 1 2 
•  R e f r a c t i v e  I n d e x :  1 . 4 0 
•  L i g h t  T r a n sm i t t a n c e : 8 5%  m i n im um 
•  S u r f a c e  C h a r a c t e r : H y d r o p h i l i c 
•  W a t e r  C o n t e n t : 5 8% 
•  O x y g e n  P e rm e a b i l i t y  ( D / k ) : 
V A L U E M E T HO D 
2 1 . 4  x  1 0 1 1  ( c m 2/ s e c ) 
( m l  O 2/ m l  x  m m  H g )  @  3 5 ° C   F a t t  ( b o u n d a r y  c o r r e c t e d ,  e d g e  c o r r e c t e d ) 
2 8 . 0  x  1 0 1 1  ( c m 2/ s e c ) 
( m l  O 2/ m l  x  m m  H g )  @  3 5 ° C F a t t  ( b o u n d a r y  c o r r e c t e d ,  n o n - e d g e  c o r r e c t e d ) 
L e n s  P a r am e t e r s  R a n g e s : 
•  D i am e t e r  ( D I A ) : 1 2 . 0  mm  t o  1 5 . 0  mm 
•  C e n t e r  T h i c k n e s s : Va r i e s  w i t h  p o w e r 
•  B a s e  C u r v e  ( B C ) : 7 . 8 5  mm  t o  1 0 . 0 0  mm 
•  S p h e r i c a l  P o w e r  ( D ) : - 2 0 . 0 0 D  t o  + 2 0 . 0 0 D 
•  C y l i n d e r  P o w e r  ( C Y L ) :  - 0 . 2 5 D  t o  - 1 0 . 0 0 D 
•  A x i s  ( A X I S ) : 2 . 5 °  t o  1 8 0 ° 
•  A D D  P o w e r s : + 0 . 2 5 D  t o  + 4 . 0 0 D 
A V A I L A B L E  L E N S  P A R AM E T E R S 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  a r e  h em i s p h e r i c a l  s h e l l s  o f  t h e  
f o l l o w i n g  d im e n s i o n s : 
D i am e t e r  ( D I A ) : 1 4 . 2  mm 
C e n t e r  T h i c k n e s s : 0 . 0 8 4  mm  t o  0 . 2 3 0  mm  ( v a r i e s  w i t h  p o w e r ) 
C R - 6 2 6 7 ,  v 2 . 0 3
 
P a g e  1 2 2  o f  2 1 8 J J V C  CO N F I D E N T I A L 
B a s e  C u r v e  ( B C ) : 8 . 5  mm ,  9 . 0  mm 
P ow e r s  ( D ) : - 0 . 5 0 D  t o  - 6 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
- 6 . 5 0 D  t o  - 1 2 . 0 0 D  ( i n  0 . 5 0 D  i n c r em e n t s ) 
+ 0 . 5 0 D  t o  + 6 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  f o r  A S T I GM A T I SM  a r e  h em i t o r i c  
s h e l l s  o f  t h e  f o l l o w i n g  d im e n s i o n s : 
D i am e t e r  ( D I A ) : 1 4 . 5  mm 
C e n t e r  T h i c k n e s s : 0 . 0 9 0  mm  t o  0 . 1 8 9  mm  ( v a r i e s  w i t h  p o w e r ) 
B a s e  C u r v e  ( B C ) : 8 . 5  mm 
P ow e r s  ( D ) : + 0 . 0 0  t o  - 6 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
C y l i n d e r s  ( C Y L ) :  - 0 . 7 5 D ,  - 1 . 2 5 D ,  - 1 . 7 5 D ,  - 2 . 2 5 D * 
A x i s  ( A X I S ) :  1 0 °  t o  1 8 0 °  i n  1 0 °  i n c r em e n t s 
* - 2 . 2 5 D  c y l i n d e r  i s  a v a i l a b l e  i n  1 0 ° ,  2 0 ° ,  7 0 ° ,  8 0 ° ,  9 0 ° ,  
1 0 0 ° ,  1 1 0 ° ,  1 6 0 ° ,  1 7 0 ° ,  1 8 0 °  a x e s  o n l y 
- 6 . 5 0 D  t o  - 9 . 0 0 D  ( i n  0 . 5 0 D  i n c r em e n t s ) 
C y l i n d e r s  ( C Y L ) :  - 0 . 7 5 D ,  - 1 . 2 5 D ,  - 1 . 7 5 D ,  - 2 . 2 5 D * 
A x i s  ( A X I S ) :  1 0 ° ,  2 0 ° ,  6 0 ° ,  7 0 ° ,  8 0 ° ,  9 0 ° ,  1 0 0 ° ,  1 1 0 ° ,  
1 2 0 ° ,  1 6 0 ° ,  1 7 0 ° ,  1 8 0 ° 
* - 2 . 2 5 D  c y l i n d e r  i s  a v a i l a b l e  i n  2 0 ° ,  9 0 ° ,  1 6 0 ° ,  1 8 0 °  
a x e s  o n l y 
+ 0 . 2 5 D  t o  + 4 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
C y l i n d e r s  ( C Y L ) :  - 0 . 7 5 D ,  - 1 . 2 5 D ,  - 1 . 7 5 D 
A x i s  ( A X I S ) :  1 0 ° ,  2 0 ° ,  7 0 ° ,  8 0 ° ,  9 0 ° ,  1 0 0 ° ,  1 1 0 ° ,  1 6 0 ° ,  
1 7 0 ° ,  1 8 0 ° 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  M U L T I F O C A L  C o n t a c t  L e n s e s  a r e  h em i s p h e r i c a l  
s h e l l s  o f  t h e  f o l l o w i n g  d im e n s i o n s : 
D i am e t e r  ( D I A ) : 1 4 . 3  mm 
C e n t e r  T h i c k n e s s : 0 . 0 8 4  mm  t o  0 . 2 0 7  mm  ( v a r i e s  w i t h  p o w e r ) 
B a s e  C u r v e  ( B C ) : 8 . 4  mm 
P ow e r s  ( D ) : + 6 . 0 0 D  t o  - 9 . 0 0 D  ( i n  0 . 2 5 D  i n c r em e n t s ) 
N e a r  A D D  P ow e r s  
(M A X  A D D ) : L o w  N e a r  A D D  ( L OW ) :  + 1 . 2 5 D 
M e d i um  N e a r  A D D  (M I D ) :  + 1 . 7 5 D 
H i g h  N e a r  A D D  ( H G H ) :  + 2 . 5 0 D 
C R - 6 2 6 7 ,  v 2 . 0 4
 
P a g e  1 2 3  o f  2 1 8 J J V C  CO N F I D E N T I A L 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  ( e t a ﬁ  l c o n  A )  V i s i b i l i t y  T i n t e d  w i t h  
U V  B l o c k e r  v s .  2 4  y r .  o l d  h um a n  c o r n e a  a n d  2 5  y r .  o l d  h um a n  c r y s t a l l i n e  l e n s .  
* T h e  d a t a  a r e  r e p r e s e n t a t i v e  m e a s u r e m e n t s  t a k e n  t h r o u g h  t h e  c e n t r a l  3 - 5  m m  p o r t i o n  f o r  t h e  
t h i n n e s t  m a r k e t e d  l e n s  ( - 3 . 0 0 D  l e n s ,  0 . 0 8 4  m m  c e n t e r  t h i c k n e s s ) . 
1 L e rm a n ,  S . ,  R a d i a n t  E n e r g y  a n d  t h e  E y e ,  M a cM i l l a n ,  N e w  Y o r k ,  1 9 8 0 ,  p .  5 8 ,  ﬁ  g u r e  2 - 2 1 
2 W a x l e r ,  M . ,  H i t c h i n s ,  V .M . ,  O p t i c a l  R a d i a t i o n  a n d  V i s u a l  H e a  t h ,  C R C  P r e s s ,  B o c a  R a t o n ,  F l o r i d a ,  
1 9 8 6 ,  p .  1 9 ,  ﬁ  g u r e  5 
W A R N I N G :  U V  a b s o r b i n g  c o n t a c t  l e n s e s  a r e  NO T  s u b s t i t u t e s  f o r  
p r o t e c t i v e  U V  a b s o r b i n g  e y ew e a r ,  s u c h  a s  U V  a b s o r b i n g  g o g g l e s  
o r  s u n g l a s s e s  b e c a u s e  t h e y  d o  n o t  c om p l e t e l y  c o v e r  t h e  e y e  a n d  
s u r r o u n d i n g  a r e a .  T h e  p a t i e n t  s h o u l d  c o n t i n u e  t o  u s e  U V  a b s o r b i n g  
e y ew e a r  a s  d i r e c t e d . 
A C T IO N S 
I n  i t s  h y d r a t e d  s t a t e ,  t h e  c o n t a c t  l e n s ,  w h e n  p l a c e d  o n  t h e  c o r n e a ,  a c t s  a s  a  
r e f r a c t i n g  m e d i um  t o  f o c u s  l i g h t  r a y s  o n  t h e  r e t i n a . 
T h e  U V  B l o c k i n g  f o r  t h e s e  l e n s e s  a v e r a g e s  9 7%  i n  t h e  U V B  r a n g e  o f  2 8 0  nm  t o  
3 1 5  nm  a n d  8 2%  i n  t h e  U V A  r a n g e  o f  3 1 6  nm  t o  3 8 0  nm  f o r  t h e  e n t i r e  p o w e r  
r a n g e . T R A N SM I T T A N C E  C U R V E S 
1 - D A Y  A C U V U E ® M O I S T 
B r a n d  C o n t a c t  L e n s e s * 
2 4  Y R .  O L D  H U M A N  
C O R N E A 1
2 5  Y R .  O L D  H U M A N 
C R Y S T A L L I N E  L E N S 2
C R - 6 2 6 7 ,  v 2 . 0 5
 
P a g e  1 2 4  o f  2 1 8 J J V C  CO N F I D E N T I A L 
NO T E :  L o n g - t e rm  e x p o s u r e  t o  U V  r a d i a t i o n  i s  o n e  o f  t h e  r i s k  f a c t o r s  
a s s o c i a t e d  w i t h  c a t a r a c t s .  E x p o s u r e  i s  b a s e d  o n  a  n um b e r  o f  f a c t o r s  
s u c h  a s  e n v i r o nm e n t a l  c o n d i t i o n s  ( a l t i t u d e ,  g e o g r a p h y ,  c l o u d  c o v e r )  a n d  
p e r s o n a l  f a c t o r s  ( e x t e n t  a n d  n a t u r e  o f  o u t d o o r  a c t i v i t i e s ) .  U V - B l o c k i n g  
c o n t a c t  l e n s e s  h e l p  p r o v i d e  p r o t e c t i o n  a g a i n s t  h a rm f u l  U V  r a d i a t i o n .  
H ow e v e r ,  c l i n i c a l  s t u d i e s  h a v e  n o t  b e e n  d o n e  t o  d em o n s t r a t e  t h a t  
w e a r i n g  U V - B l o c k i n g  c o n t a c t  l e n s e s  r e d u c e s  t h e  r i s k  o f  d e v e l o p i n g  
c a t a r a c t s  o r  o t h e r  e y e  d i s o r d e r s .  T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  b e  
c o n s u l t e d  f o r  m o r e  i n f o rm a t i o n . 
I N D I C A T IO N S  ( U S E S ) 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  a r e  i n d i c a t e d  f o r  d a i l y  
d i s p o s a b l e  w e a r  f o r  t h e  o p t i c a l  c o r r e c t i o n  o f  r e f r a c t i v e  am e t r o p i a  (m y o p i a  a n d  
h y p e r o p i a )  i n  p h a k i c  o r  a p h a k i c  p e r s o n s  w i t h  n o n - d i s e a s e d  e y e s  w h o  m a y  h a v e  
1 . 0 0 D  o r  l e s s  o f  a s t i gm a t i sm . 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  C o n t a c t  L e n s e s  f o r  A S T I GM A T I SM  a r e  i n d i c a t e d  
f o r  d a i l y  d i s p o s a b l e  w e a r  f o r  t h e  o p t i c a l  c o r r e c t i o n  o f  r e f r a c t i v e  am e t r o p i a  (m y o p i a  
a n d  h y p e r o p i a )  i n  p h a k i c  o r  a p h a k i c  p e r s o n s  w i t h  n o n - d i s e a s e d  e y e s  w h o  m a y  
h a v e  0 . 5 0 D  t o  3 . 0 0 D  o f  a s t i gm a t i sm . 
1 - D A Y  A C U V U E ® M O I S T  B r a n d  M U L T I F O C A L  C o n t a c t  L e n s e s  a r e  i n d i c a t e d  
f o r  d a i l y  d i s p o s a b l e  w e a r  f o r  t h e  o p t i c a l  c o r r e c t i o n  o f  d i s t a n c e  a n d  n e a r  v i s i o n  i n  
p r e s b y o p i c  p h a k i c  o r  a p h a k i c  p e r s o n s  w i t h  n o n - d i s e a s e d  e y e s  w h o  m a y  h a v e  
4 . 0 0 D  o f  A D D  p o w e r  o r  l e s s  a n d  0 . 7 5 D  o r  l e s s  o f  a s t i gm a t i sm . 
T h e  l e n s e s  c o n t a i n  a  U V  B l o c k e r  t o  h e l p  p r o t e c t  a g a i n s t  t r a n sm i s s i o n  o f  h a rm f u l  
U V  r a d i a t i o n  t o  t h e  c o r n e a  a n d  i n t o  t h e  e y e . 
W h e n  p r e s c r i b e d  f o r  d a i l y  d i s p o s a b l e  u s e ,  n o  c l e a n i n g  o r  d i s i n f e c t i o n  i s  r e q u i r e d .  
L e n s e s  s h o u l d  b e  d i s c a r d e d  u p o n  r em o v a l . 
CO N T R A I N D I C A T IO N S  ( R E A SO N S  NO T  TO  U S E )  
D O  N O T  U S E  t h e s e  l e n s e s  w h e n  a n y  o f  t h e  f o l l ow i n g  c o n d i t i o n s  e x i s t : 
•   A c u t e  o r  s u b a c u t e  i n ﬂ  amm a t i o n  o r  i n f e c t i o n  o f  t h e  a n t e r i o r  c h am b e r  o f  
t h e  e y e . 
•   A n y  e y e  d i s e a s e ,  i n j u r y ,  o r  a b n o rm a l i t y  t h a t  a f f e c t s  t h e  c o r n e a ,  
c o n j u n c t i v a ,  o r  e y e l i d s . 
•   S e v e r e  i n s u f ﬁ  c i e n c y  o f  l a c r im a l  s e c r e t i o n  ( d r y  e y e ) . 
•   C o r n e a l  h y p o e s t h e s i a  ( r e d u c e d  c o r n e a l  s e n s i t i v i t y ) . 
C R - 6 2 6 7 ,  v 2 . 0 6
 
P a g e  1 2 5  o f  2 1 8 J J V C  CO N F I D E N T I A L 
•   A n y  s y s t em i c  d i s e a s e  t h a t  m a y  a f f e c t  t h e  e y e  o r  b e  e x a g g e r a t e d  b y  
w e a r i n g  c o n t a c t  l e n s e s . 
•   A l l e r g i c  r e a c t i o n s  o f  o c u l a r  s u r f a c e s  o r  a d n e x a  t h a t  m a y  b e  i n d u c e d  o r  
e x a g g e r a t e d  b y  w e a r i n g  c o n t a c t  l e n s e s  o r  u s e  o f  c o n t a c t  l e n s  s o l u t i o n s . 
•   O c u l a r  i r r i t a t i o n  d u e  t o  a l l e r g i c  r e a c t i o n s  w h i c h  m a y  b e  c a u s e d  b y  u s e  
o f  c o n t a c t  l e n s  s o l u t i o n s  ( i . e . ,  r e w e t t i n g  d r o p s )  t h a t  c o n t a i n  c h em i c a l s  o r  
p r e s e r v a t i v e s  ( s u c h  a s  m e r c u r y ,  T h im e r o s a l ,  e t c . )  t o  w h i c h  s om e  p e o p l e  
m a y  d e v e l o p  a n  a l l e r g i c  r e s p o n s e . 
•   A n y  a c t i v e  c o r n e a l  i n f e c t i o n  ( b a c t e r i a l ,  f u n g a l ,  p r o t o z o a l ,  o r  v i r a l ) . 
•   I f  e y e s  b e c om e  r e d  o r  i r r i t a t e d . 
W A R N I NG S 
P a t i e n t s  s h o u l d  b e  a d v i s e d  o f  t h e  f o l l ow i n g  w a r n i n g s  p e r t a i n i n g  t o  
c o n t a c t  l e n s  w e a r : 
E Y E  P RO B L EM S ,  I N C L U D I N G  CO R N E A L  U L C E R S ,  C A N  D E V E LO P  
R A P I D L Y  A N D  L E A D  TO  LO S S  O F  V I S IO N .  I F  T H E  P A T I E N T  
E X P E R I E N C E S : 
• E y e D i s c om f o r t , 
• E x c e s s i v e T e a r i n g , 
• V i s i o n C h a n g e s , 
•   L o s s  o f  V i s i o n , 
•   E y e  R e d n e s s ,  o r 
•   O t h e r  E y e  P r o b l em s , 
T H E  P A T I E N T  S HO U L D  B E  I N S T R U C T E D  TO  IMM E D I A T E L Y  
R EMO V E  T H E  L E N S E S  A N D  P ROM P T L Y  CO N T A C T  T H E  E Y E  C A R E  
P RO F E S S IO N A L . 
•   W h e n  p r e s c r i b e d  f o r  d a i l y  w e a r ,  p a t i e n t s  s h o u l d  b e  i n s t r u c t e d  n o t  t o  w e a r  
t h e i r  l e n s e s  w h i l e  s l e e p i n g .  C l i n i c a l  s t u d i e s  h a v e  s h o w n  t h a t  w h e n  l e n s e s  
a r e  w o r n  o v e r n i g h t ,  t h e  r i s k  o f  u l c e r a t i v e  k e r a t i t i s  i s  g r e a t e r  t h a n  am o n g  
t h o s e  w h o  d o  n o t  w e a r  t h em  o v e r n i g h t . 3
•   S t u d i e s  h a v e  s h o w n  t h a t  c o n t a c t  l e n s  w e a r e r s  w h o  a r e  sm o k e r s  h a v e  a  
h i g h e r  i n c i d e n c e  o f  a d v e r s e  r e a c t i o n s  t h a n  n o n sm o k e r s . 
•   P r o b l em s  w i t h  c o n t a c t  l e n s e s  o r  l e n s  c a r e  p r o d u c t s  c o u l d  r e s u l t  i n  
s e r i o u s  i n j u r y  t o  t h e  e y e .  P a t i e n t s  s h o u l d  b e  c a u t i o n e d  t h a t  p r o p e r  u s e  
a n d  c a r e  o f  c o n t a c t  l e n s e s  a n d  l e n s  c a r e  p r o d u c t s  a r e  e s s e n t i a l  f o r  t h e  
s a f e  u s e  o f  t h e s e  p r o d u c t s . 
C R - 6 2 6 7 ,  v 2 . 0 7
 
P a g e  1 2 6  o f  2 1 8 J J V C  CO N F I D E N T I A L 
•   T h e  o v e r a l l  r i s k  o f  u l c e r a t i v e  k e r a t i t i s  m a y  b e  r e d u c e d  b y  c a r e f u l l y  
f o l l o w i n g  d i r e c t i o n s  f o r  l e n s  c a r e . 
3  N e w  E n g l a n d  J o u r n a l  o f  M e d i c i n e ,  S e p t em b e r  2 1 ,  1 9 8 9 ;  3 2 1  ( 1 2 ) ,  p p .  7 7 3 - 7 8 3 
S p e c i ﬁ  c  I n s t r u c t i o n s  f o r  U s e  a n d  W a r n i n g s : 
• W a t e r A c t i v i t y 
I n s t r u c t i o n  f o r  U s e 
D o  n o t  e x p o s e  c o n t a c t  l e n s e s  t o  w a t e r  w h i l e  w e a r i n g  t h em . 
W A R N I N G : 
W a t e r  c a n  h a r b o r  m i c r o o r g a n i sm s  t h a t  c a n  l e a d  t o  s e v e r e  i n f e c t i o n ,  
v i s i o n  l o s s ,  o r  b l i n d n e s s .  I f  l e n s e s  h a v e  b e e n  s u bm e r s e d  i n  w a t e r  w h e n  
p a r t i c i p a t i n g  i n  w a t e r  s p o r t s  o r  s w imm i n g  i n  p o o l s ,  h o t  t u b s ,  l a k e s ,  o r  
o c e a n s ,  t h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  t o  d i s c a r d  t h em  a n d  r e p l a c e  
t h em  w i t h  a  n e w  p a i r .  T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  b e  c o n s u l t e d  f o r  
r e c omm e n d a t i o n s  r e g a r d i n g  w e a r i n g  l e n s e s  d u r i n g  a n y  a c t i v i t y  i n v o l v i n g  
w a t e r . 
P R E C A U T IO N S 
S p e c i a l  P r e c a u t i o n s  f o r  E y e  C a r e  P r o f e s s i o n a l s : 
•   D u e  t o  t h e  sm a l l  n um b e r  o f  p a t i e n t s  e n r o l l e d  i n  c l i n i c a l  i n v e s t i g a t i o n  o f  
l e n s e s ,  a l l  r e f r a c t i v e  p o w e r s ,  d e s i g n  c o n ﬁ  g u r a t i o n s ,  o r  l e n s  p a r am e t e r s  
a v a i l a b l e  i n  t h e  l e n s  m a t e r i a l  a r e  n o t  e v a l u a t e d  i n  s i g n i ﬁ  c a n t  n um b e r s .  
C o n s e q u e n t l y ,  w h e n  s e l e c t i n g  a n  a p p r o p r i a t e  l e n s  d e s i g n  a n d  
p a r am e t e r s ,  t h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  c o n s i d e r  a l l  c h a r a c t e r i s t i c s  
o f  t h e  l e n s  t h a t  c a n  a f f e c t  l e n s  p e r f o rm a n c e  a n d  o c u l a r  h e a l t h ,  i n c l u d i n g  
o x y g e n  p e rm e a b i l i t y ,  w e t t a b i l i t y ,  c e n t r a l  a n d  p e r i p h e r a l  t h i c k n e s s ,  a n d  
o p t i c  z o n e  d i am e t e r . 
T h e  p o t e n t i a l  im p a c t  o f  t h e s e  f a c t o r s  o n  t h e  p a t i e n t ’ s  o c u l a r  h e a l t h  
s h o u l d  b e  c a r e f u l l y  w e i g h e d  a g a i n s t  t h e  p a t i e n t ’ s  n e e d  f o r  r e f r a c t i v e  
c o r r e c t i o n ;  t h e r e f o r e ,  t h e  c o n t i n u i n g  o c u l a r  h e a l t h  o f  t h e  p a t i e n t  a n d  l e n s  
p e r f o rm a n c e  o n  t h e  e y e  s h o u l d  b e  c a r e f u l l y  m o n i t o r e d  b y  t h e  p r e s c r i b i n g  
E y e  C a r e  P r o f e s s i o n a l . 
•   P a t i e n t s  w h o  w e a r  t h e s e  l e n s e s  t o  c o r r e c t  p r e s b y o p i a  u s i n g  m o n o v i s i o n  
( o r  m o d i ﬁ  e d  m o n o v i s i o n  u s i n g  1 - D A Y  A C U V U E ® M O I S T  B r a n d  
M U L T I F O C A L )  m a y  n o t  a c h i e v e  t h e  b e s t  c o r r e c t e d  v i s u a l  a c u i t y  f o r  e i t h e r  
f a r  o r  n e a r  v i s i o n .  V i s u a l  r e q u i r em e n t s  v a r y  w i t h  t h e  i n d i v i d u a l  a n d  s h o u l d  
b e  c o n s i d e r e d  w h e n  s e l e c t i n g  t h e  m o s t  a p p r o p r i a t e  t y p e  o f  l e n s  f o r  e a c h  
p a t i e n t . 
C R - 6 2 6 7 ,  v 2 . 0 8
 
P a g e  1 2 7  o f  2 1 8 J J V C  CO N F I D E N T I A L 
•   F l u o r e s c e i n ,  a  y e l l o w  d y e ,  s h o u l d  n o t  b e  u s e d  w h i l e  t h e  l e n s e s  a r e  o n  
t h e  e y e s .  T h e  l e n s e s  a b s o r b  t h i s  d y e  a n d  b e c om e  d i s c o l o r e d .  W h e n e v e r  
ﬂ  u o r e s c e i n  i s  u s e d  i n  e y e s ,  t h e  e y e s  s h o u l d  b e  ﬂ  u s h e d  w i t h  a  s t e r i l e  
s a l i n e  s o l u t i o n  t h a t  i s  r e c omm e n d e d  f o r  i n - e y e  u s e . 
•   E y e  C a r e  P r o f e s s i o n a l s  s h o u l d  i n s t r u c t  t h e  p a t i e n t  t o  r em o v e  l e n s e s  
imm e d i a t e l y  i f  t h e  e y e s  b e c om e  r e d  o r  i r r i t a t e d .  
E y e  C a r e  P r o f e s s i o n a l s  s h o u l d  c a r e f u l l y  i n s t r u c t  p a t i e n t s  a b o u t  t h e  
f o l l ow i n g  c a r e  r e g im e n  a n d  s a f e t y  p r e c a u t i o n s . 
H a n d l i n g  P r e c a u t i o n s : 
•   B e f o r e  l e a v i n g  t h e  E y e  C a r e  P r o f e s s i o n a l ’ s  o f ﬁ  c e ,  t h e  p a t i e n t  s h o u l d  
b e  a b l e  t o  p r om p t l y  r em o v e  t h e  l e n s e s  o r  s h o u l d  h a v e  s om e o n e  e l s e  
a v a i l a b l e  w h o  c a n  r em o v e  t h e  l e n s e s  f o r  h im  o r  h e r . 
•   D O  N O T  u s e  i f  t h e  s t e r i l e  b l i s t e r  p a c k a g e  i s  o p e n e d  o r  d am a g e d . 
•   A l w a y s  w a s h  a n d  r i n s e  h a n d s  b e f o r e  h a n d l i n g  l e n s e s .  D o  n o t  g e t  
c o sm e t i c s ,  l o t i o n s ,  s o a p s ,  c r e am s ,  d e o d o r a n t s ,  o r  s p r a y s  i n  t h e  e y e s  o r  
o n  t h e  l e n s e s .  I t  i s  b e s t  t o  p u t  o n  l e n s e s  b e f o r e  p u t t i n g  o n  m a k e u p . 
•   D O  N O T  t o u c h  c o n t a c t  l e n s e s  w i t h  t h e  ﬁ  n g e r s  o r  h a n d s  i f  t h e  h a n d s  a r e  
n o t  f r e e  o f  f o r e i g n  m a t e r i a l s ,  a s  m i c r o s c o p i c  s c r a t c h e s  o f  t h e  l e n s e s  m a y  
o c c u r ,  c a u s i n g  d i s t o r t e d  v i s i o n  a n d / o r  i n j u r y  t o  t h e  e y e . 
•   C a r e f u l l y  f o l l o w  t h e  h a n d l i n g ,  i n s e r t i o n ,  r em o v a l ,  a n d  w e a r i n g  i n s t r u c t i o n s  
i n  t h e  P a t i e n t  I n s t r u c t i o n  G u i d e  f o r  t h e s e  l e n s e s  a n d  t h o s e  p r e s c r i b e d  b y  
t h e  E y e  C a r e  P r o f e s s i o n a l . 
•   A l w a y s  h a n d l e  l e n s e s  c a r e f u l l y  a n d  a v o i d  d r o p p i n g  t h em . 
•   N e v e r  u s e  t w e e z e r s  o r  o t h e r  t o o l s  t o  r em o v e  l e n s e s  f r om  t h e  l e n s  
c o n t a i n e r .  S l i d e  t h e  l e n s  u p  t h e  s i d e  o f  t h e  b o w l  u n t i l  i t  i s  f r e e  o f  t h e  
c o n t a i n e r . 
•   D o  n o t  t o u c h  t h e  l e n s  w i t h  ﬁ  n g e r n a i l s . 
L e n s  W e a r i n g  P r e c a u t i o n s : 
•   I f  t h e  l e n s  s t i c k s  ( s t o p s  m o v i n g )  o n  t h e  e y e ,  f o l l o w  t h e  r e c omm e n d e d  
d i r e c t i o n s  i n  “ C a r e  f o r  S t i c k i n g  ( N o n -M o v i n g )  L e n s e s . ”  T h e  l e n s  s h o u l d  
m o v e  f r e e l y  o n  t h e  e y e  f o r  t h e  c o n t i n u e d  h e a l t h  o f  t h e  e y e .  I f  n o n - 
m o v em e n t  o f  t h e  l e n s  c o n t i n u e s ,  t h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  t o  
imm e d i a t e l y  c o n s u l t  h i s  o r  h e r  E y e  C a r e  P r o f e s s i o n a l . 
•   N e v e r  w e a r  l e n s e s  b e y o n d  t h e  p e r i o d  r e c omm e n d e d  b y  t h e  E y e  C a r e  
P r o f e s s i o n a l . 
C R - 6 2 6 7 ,  v 2 . 0 9
 
P a g e  1 2 8  o f  2 1 8 J J V C  CO N F I D E N T I A L 
•   T h e  p a t i e n t  s h o u l d  b e  a d v i s e d  t o  n e v e r  a l l o w  a n y o n e  e l s e  t o  w e a r  t h e i r  
l e n s e s .  T h e y  h a v e  b e e n  p r e s c r i b e d  t o  ﬁ  t  t h e i r  e y e s  a n d  t o  c o r r e c t  t h e i r  
v i s i o n  t o  t h e  d e g r e e  n e c e s s a r y .  S h a r i n g  l e n s e s  g r e a t l y  i n c r e a s e s  t h e  
c h a n c e  o f  e y e  i n f e c t i o n s . 
•   I f  a e r o s o l  p r o d u c t s ,  s u c h  a s  h a i r s p r a y ,  a r e  u s e d  w h i l e  w e a r i n g  l e n s e s ,  
e x e r c i s e  c a u t i o n  a n d  k e e p  e y e s  c l o s e d  u n t i l  t h e  s p r a y  h a s  s e t t l e d . 
•   A v o i d  a l l  h a rm f u l  o r  i r r i t a t i n g  v a p o r s  a n d  f um e s  w h i l e  w e a r i n g  l e n s e s . 
L e n s  C a r e  P r e c a u t i o n s : 
•   T h e  p a t i e n t  s h o u l d  b e  i n f o rm e d  t h a t  n o  c l e a n i n g  o r  d i s i n f e c t i o n  i s  n e e d e d  
w h e n  l e n s e s  a r e  w o r n  f o r  d a i l y  d i s p o s a b l e  w e a r .  P a t i e n t s  s h o u l d  a l w a y s  
d i s p o s e  o f  l e n s e s  w h e n  r em o v e d  a n d  h a v e  s p a r e  l e n s e s  o r  s p e c t a c l e s  
a v a i l a b l e . 
O t h e r  T o p i c s  t o  D i s c u s s  w i t h  P a t i e n t s : 
•   A l w a y s  c o n t a c t  t h e  E y e  C a r e  P r o f e s s i o n a l  b e f o r e  u s i n g  a n y  m e d i c i n e  i n  
t h e  e y e s . 
•   C e r t a i n  m e d i c a t i o n s ,  s u c h  a s  a n t i h i s t am i n e s ,  d e c o n g e s t a n t s ,  d i u r e t i c s ,  
m u s c l e  r e l a x a n t s ,  t r a n q u i l i z e r s ,  a n d  t h o s e  f o r  m o t i o n  s i c k n e s s  m a y  c a u s e  
d r y n e s s  o f  t h e  e y e ,  i n c r e a s e d  l e n s  a w a r e n e s s ,  o r  b l u r r e d  v i s i o n .  S h o u l d  
s u c h  c o n d i t i o n s  e x i s t ,  p r o p e r  r em e d i a l  m e a s u r e s  s h o u l d  b e  p r e s c r i b e d .  
•   O r a l  c o n t r a c e p t i v e  u s e r s  c o u l d  d e v e l o p  v i s u a l  c h a n g e s  o r  c h a n g e s  i n  
l e n s  t o l e r a n c e  w h e n  u s i n g  c o n t a c t  l e n s e s .  P a t i e n t s  s h o u l d  b e  c a u t i o n e d  
a c c o r d i n g l y . 
•   A s  w i t h  a n y  c o n t a c t  l e n s ,  f o l l o w - u p  v i s i t s  a r e  n e c e s s a r y  t o  a s s u r e  t h e  
c o n t i n u i n g  h e a l t h  o f  t h e  p a t i e n t ’ s  e y e s .  T h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  
a s  t o  a  r e c omm e n d e d  f o l l o w - u p  s c h e d u l e . 
W h o  S h o u l d  K n ow  T h a t  t h e  P a t i e n t  i s  W e a r i n g  C o n t a c t  L e n s e s ? 
•   P a t i e n t s  s h o u l d  i n f o rm  a l l  d o c t o r s  ( H e a l t h  C a r e  P r o f e s s i o n a l s )  a b o u t  
b e i n g  a  c o n t a c t  l e n s  w e a r e r . 
•   P a t i e n t s  s h o u l d  a l w a y s  i n f o rm  t h e i r  em p l o y e r  o f  b e i n g  a  c o n t a c t  l e n s  
w e a r e r .  S om e  j o b s  m a y  r e q u i r e  u s e  o f  e y e  p r o t e c t i o n  e q u i pm e n t  o r  m a y  
r e q u i r e  t h a t  t h e  p a t i e n t  n o t  w e a r  c o n t a c t  l e n s e s . 
C R - 6 2 6 7 ,  v 2 . 0 1 0 
 
P a g e  1 2 9  o f  2 1 8 J J V C  CO N F I D E N T I A L 
A D V E R S E  R E A C T IO N S 
T h e  p a t i e n t  s h o u l d  b e  i n f o rm e d  t h a t  t h e  f o l l ow i n g  p r o b l em s  m a y  o c c u r  
w h e n  w e a r i n g  c o n t a c t  l e n s e s : 
•   T h e  e y e  m a y  b u r n ,  s t i n g ,  a n d / o r  i t c h . 
•   T h e r e  m a y  b e  l e s s  c om f o r t  t h a n  w h e n  t h e  l e n s  w a s  ﬁ  r s t  p l a c e d  o n  t h e  
e y e . 
•   T h e r e  m a y  b e  a  f e e l i n g  o f  s om e t h i n g  i n  t h e  e y e  ( f o r e i g n  b o d y ,  s c r a t c h e d  
a r e a ) . 
•   T h e r e  m a y  b e  t h e  p o t e n t i a l  f o r  s om e  t em p o r a r y  im p a i rm e n t  d u e  t o  
p e r i p h e r a l  i n ﬁ  l t r a t e s ,  p e r i p h e r a l  c o r n e a l  u l c e r s ,  o r  c o r n e a l  e r o s i o n .  T h e r e  
m a y  b e  t h e  p o t e n t i a l  f o r  o t h e r  p h y s i o l o g i c a l  o b s e r v a t i o n s ,  s u c h  a s  l o c a l  
o r  g e n e r a l i z e d  e d em a ,  c o r n e a l  n e o v a s c u l a r i z a t i o n ,  c o r n e a l  s t a i n i n g ,  
i n j e c t i o n ,  t a r s a l  a b n o rm a l i t i e s ,  i r i t i s ,  a n d  c o n j u n c t i v i t i s ,  s om e  o f  w h i c h  a r e  
c l i n i c a l l y  a c c e p t a b l e  i n  l o w  am o u n t s . 
•   T h e r e  m a y  b e  e x c e s s i v e  w a t e r i n g ,  u n u s u a l  e y e  s e c r e t i o n s ,  o r  r e d n e s s  
o f  t h e  e y e . 
•   P o o r  v i s u a l  a c u i t y ,  b l u r r e d  v i s i o n ,  r a i n b o w s  o r  h a l o s  a r o u n d  o b j e c t s ,  
p h o t o p h o b i a ,  o r  d r y  e y e s  m a y  a l s o  o c c u r  i f  t h e  l e n s e s  a r e  w o r n  
c o n t i n u o u s l y  o r  f o r  t o o  l o n g  a  t im e . 
T h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  t o  c o n d u c t  a  s im p l e  3 - p a r t  s e l f - e x am i n a t i o n  a t  
l e a s t  o n c e  a  d a y .  T h e y  s h o u l d  a s k  t h em s e l v e s : 
•   H o w  d o  t h e  l e n s e s  f e e l  o n  m y  e y e s ? 
•   H o w  d o  m y  e y e s  l o o k ? 
•   H a v e  I  n o t i c e d  a  c h a n g e  i n  m y  v i s i o n ?  
I f  t h e  p a t i e n t  r e p o r t s  a n y  p r o b l em s ,  h e  o r  s h e  s h o u l d  b e  i n s t r u c t e d  t o  
IMM E D I A T E L Y  R EM O V E  T H E  L E N S .  I f  t h e  p r o b l em  o r  d i s c om f o r t  s t o p s ,  t h e  
p a t i e n t  s h o u l d  d i s c a r d  t h e  l e n s  a n d  p l a c e  a  n e w  f r e s h  l e n s  o n  t h e  e y e . 
I f  a f t e r  i n s e r t i n g  t h e  n e w  l e n s ,  t h e  p r o b l em  c o n t i n u e s ,  t h e  p a t i e n t  s h o u l d  b e  
d i r e c t e d  t o  IMM E D I A T E L Y  R EM O V E  T H E  L E N S  A N D  C O N T A C T  H I S  O R  H E R  
E Y E  C A R E  P R O F E S S I O N A L . 
T h e  p a t i e n t  s h o u l d  b e  a d v i s e d  t h a t  w h e n  a n y  o f  t h e  a b o v e  s ym p t om s  o c c u r ,  
a  s e r i o u s  c o n d i t i o n  s u c h  a s  i n f e c t i o n ,  c o r n e a l  u l c e r ,  n e o v a s c u l a r i z a t i o n ,  o r  i r i t i s  
m a y  b e  p r e s e n t .  H e  o r  s h e  s h o u l d  b e  i n s t r u c t e d  t o  s e e k  imm e d i a t e  p r o f e s s i o n a l  
i d e n t i ﬁ  c a t i o n  o f  t h e  p r o b l em  a n d  p r om p t  t r e a tm e n t  t o  a v o i d  s e r i o u s  e y e  d am a g e . 
C R - 6 2 6 7 ,  v 2 . 0 1 1 
 
P a g e  1 3 0  o f  2 1 8 J J V C  CO N F I D E N T I A L 
G E N E R A L  F I T T I NG  G U I D E L I N E S 
A .  P a t i e n t  S e l e c t i o n 
P a t i e n t s  s e l e c t e d  t o  w e a r  t h e s e  l e n s e s  s h o u l d  b e  c h o s e n  b a s e d  o n :  
•  M o t i v a t i o n  t o  w e a r  l e n s e s  
•  A b i l i t y  t o  f o l l o w  i n s t r u c t i o n s  r e g a r d i n g  l e n s  w e a r 
•  G e n e r a l  h e a l t h  
•  A b i l i t y  t o  a d e q u a t e l y  h a n d l e  a n d  c a r e  f o r  t h e  l e n s e s  
•  A b i l i t y  t o  u n d e r s t a n d  t h e  r i s k s  a n d  b e n e ﬁ  t s  o f  l e n s  w e a r 
P a t i e n t s  w h o  d o  n o t  m e e t  t h e  a b o v e  c r i t e r i a  s h o u l d  n o t  b e  p r o v i d e d  w i t h  c o n t a c t  
l e n s e s .  
B .  P r e - ﬁ  t t i n g  E x am i n a t i o n 
I n i t i a l  e v a l u a t i o n  o f  t h e  p a t i e n t  s h o u l d  b e g i n  w i t h  a  t h o r o u g h  c a s e  h i s t o r y  
t o  d e t e rm i n e  i f  t h e r e  a r e  a n y  c o n t r a i n d i c a t i o n s  t o  c o n t a c t  l e n s  w e a r .  D u r i n g  
t h e  c a s e  h i s t o r y ,  t h e  p a t i e n t ’ s  v i s u a l  n e e d s  a n d  e x p e c t a t i o n s  s h o u l d  b e  
d e t e rm i n e d  a s  w e l l  a s  a n  a s s e s sm e n t  o f  t h e i r  o v e r a l l  o c u l a r ,  p h y s i c a l ,  a n d  
m e n t a l  h e a l t h .  
P r e c e d i n g  t h e  i n i t i a l  s e l e c t i o n  o f  t r i a l  c o n t a c t  l e n s e s ,  a  c om p r e h e n s i v e  o c u l a r  
e v a l u a t i o n  s h o u l d  b e  p e r f o rm e d  t h a t  i n c l u d e s ,  b u t  i s  n o t  l im i t e d  t o ,  t h e  
m e a s u r em e n t  o f  d i s t a n c e  a n d  n e a r  v i s u a l  a c u i t y ,  d i s t a n c e  a n d  n e a r  r e f r a c t i v e  
p r e s c r i p t i o n  ( i n c l u d i n g  d e t e rm i n i n g  t h e  p r e f e r r e d  r e a d i n g  d i s t a n c e  f o r  
p r e s b y o p e s ) ,  k e r a t om e t r y ,  a n d  b i om i c r o s c o p i c  e v a l u a t i o n .  
B a s e d  o n  t h i s  e v a l u a t i o n ,  i f  i t  i s  d e t e rm i n e d  t h a t  t h e  p a t i e n t  i s  e l i g i b l e  t o  w e a r  
t h e s e  l e n s e s ,  t h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  p r o c e e d  t o  t h e  l e n s  ﬁ  t t i n g  
i n s t r u c t i o n s  a s  o u t l i n e d  b e l o w .  
C .   I n i t i a l  P ow e r  D e t e rm i n a t i o n 
A  s p e c t a c l e  r e f r a c t i o n  s h o u l d  b e  p e r f o rm e d  t o  e s t a b l i s h  t h e  p a t i e n t ’ s  b a s e l i n e  
r e f r a c t i v e  s t a t u s  a n d  t o  g u i d e  i n  t h e  s e l e c t i o n  o f  t h e  a p p r o p r i a t e  l e n s  p o w e r .  
R em em b e r  t o  c om p e n s a t e  f o r  v e r t e x  d i s t a n c e  i f  t h e  r e f r a c t i o n  i s  g r e a t e r  t h a n  
± 4 . 0 0 D . 
D .   B a s e  C u r v e  S e l e c t i o n  ( T r i a l  L e n s  F i t t i n g ) 
T h e  f o l l o w i n g  t r i a l  l e n s e s  s h o u l d  b e  s e l e c t e d  f o r  p a t i e n t s  r e g a r d l e s s  o f  
k e r a t om e t r y  r e a d i n g s .  H o w e v e r ,  c o r n e a l  c u r v a t u r e  m e a s u r em e n t s  s h o u l d  b e  
p e r f o rm e d  t o  e s t a b l i s h  t h e  p a t i e n t ’ s  b a s e l i n e  o c u l a r  s t a t u s .  
C R - 6 2 6 7 ,  v 2 . 0 1 2 
 
P a g e  1 3 1  o f  2 1 8 J J V C  CO N F I D E N T I A L 
•  1 - D A Y  A C U V U E ® M O I S T :  8 . 5  mm / 1 4 . 2  mm 
•  1 - D A Y  A C U V U E ® M O I S T  f o r  A S T I GM A T I SM :  8 . 5  mm / 1 4 . 5  mm 
•  1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L :  8 . 4  mm / 1 4 . 3  mm 
T h e  t r i a l  l e n s  s h o u l d  b e  p l a c e d  o n  e a c h  o f  t h e  p a t i e n t ’ s  e y e s  a n d  e v a l u a t e d  
a f t e r  t h e  p a t i e n t  h a s  a d j u s t e d  t o  t h e  l e n s e s . 
1 .   C r i t e r i a  o f  a  P r o p e r l y  F i t  L e n s 
A  p r o p e r l y  ﬁ  t  l e n s  w i l l  c e n t e r  a n d  c om p l e t e l y  c o v e r  t h e  c o r n e a  ( i . e . ,  n o  
l im b a l  e x p o s u r e ) ,  h a v e  s u f ﬁ  c i e n t  m o v em e n t  t o  p r o v i d e  t e a r  e x c h a n g e  
u n d e r  t h e  c o n t a c t  l e n s  w i t h  t h e  b l i n k ,  a n d  b e  c om f o r t a b l e .  T h e  l e n s  
s h o u l d  m o v e  f r e e l y  w h e n  m a n i p u l a t e d  d i g i t a l l y  w i t h  t h e  l o w e r  l i d ,  a n d  t h e n  
r e t u r n  t o  i t s  p r o p e r l y  c e n t e r e d  p o s i t i o n  w h e n  r e l e a s e d . 
2 .   C r i t e r i a  o f  a  F l a t  F i t t i n g  L e n s 
A  ﬂ  a t  ﬁ  t t i n g  l e n s  m a y  e x h i b i t  o n e  o r  m o r e  o f  t h e  f o l l o w i n g  c h a r a c t e r i s t i c s :  
d e c e n t r a t i o n ,  i n c om p l e t e  c o r n e a l  c o v e r a g e  ( i . e . ,  l im b a l  e x p o s u r e ) ,  
e x c e s s i v e  m o v em e n t  w i t h  t h e  b l i n k  a n d / o r  e d g e  s t a n d o f f .  I f  t h e  l e n s  i s  
j u d g e d  t o  b e  ﬂ  a t  ﬁ  t t i n g ,  i t  s h o u l d  n o t  b e  d i s p e n s e d  t o  t h e  p a t i e n t . 
3 .   C r i t e r i a  o f  a  S t e e p  F i t t i n g  L e n s 
A  s t e e p  ﬁ  t t i n g  l e n s  m a y  e x h i b i t  o n e  o r  m o r e  o f  t h e  f o l l o w i n g  
c h a r a c t e r i s t i c s :  i n s u f ﬁ  c i e n t  m o v em e n t  w i t h  t h e  b l i n k ,  c o n j u n c t i v a l  
i n d e n t a t i o n ,  a n d  r e s i s t a n c e  w h e n  p u s h i n g  t h e  l e n s  u p  d i g i t a l l y  w i t h  
t h e  l o w e r  l i d .  I f  t h e  l e n s  i s  j u d g e d  t o  b e  s t e e p  ﬁ  t t i n g ,  i t  s h o u l d  n o t  b e  
d i s p e n s e d  t o  t h e  p a t i e n t . 
I f  t h e  i n i t i a l  t r i a l  b a s e  c u r v e  i s  j u d g e d  t o  b e  ﬂ  a t  o r  s t e e p  ﬁ  t t i n g ,  t h e  a l t e r n a t e  
b a s e  c u r v e ,  i f  a v a i l a b l e ,  s h o u l d  b e  t r i a l  ﬁ  t  a n d  e v a l u a t e d  a f t e r  t h e  p a t i e n t  h a s  
a d j u s t e d  t o  t h e  l e n s .  T h e  l e n s  s h o u l d  m o v e  f r e e l y  w h e n  m a n i p u l a t e d  d i g i t a l l y  
w i t h  t h e  l o w e r  l i d ,  a n d  t h e n  r e t u r n  t o  a  p r o p e r l y  c e n t e r e d  p o s i t i o n  w h e n  
r e l e a s e d .  I f  r e s i s t a n c e  i s  e n c o u n t e r e d  w h e n  p u s h i n g  t h e  l e n s  u p ,  t h e  l e n s  i s  
ﬁ  t t i n g  t i g h t l y  a n d  s h o u l d  n o t  b e  d i s p e n s e d  t o  t h e  p a t i e n t . 
E .   F i n a l  L e n s  P ow e r  ( S p h e r i c a l ) 
A  s p h e r i c a l  o v e r - r e f r a c t i o n  s h o u l d  b e  p e r f o rm e d  t o  d e t e rm i n e  t h e  ﬁ  n a l  l e n s  
p o w e r  a f t e r  t h e  l e n s  ﬁ  t  i s  j u d g e d  a c c e p t a b l e .  T h e  s p h e r i c a l  o v e r - r e f r a c t i o n  
s h o u l d  b e  c om b i n e d  w i t h  t h e  t r i a l  l e n s  p o w e r  t o  d e t e rm i n e  t h e  ﬁ  n a l  l e n s  
p r e s c r i p t i o n .  T h e  p a t i e n t  s h o u l d  e x p e r i e n c e  g o o d  v i s u a l  a c u i t y  w i t h  t h e  
c o r r e c t  l e n s  p o w e r  u n l e s s  t h e r e  i s  e x c e s s i v e  r e s i d u a l  a s t i gm a t i sm . 
C R - 6 2 6 7 ,  v 2 . 0 1 3 
 
P a g e  1 3 2  o f  2 1 8 J J V C  CO N F I D E N T I A L 
E x am p l e  1 
D i a g n o s t i c  l e n s : - 2 . 0 0 D 
S p h e r i c a l  o v e r - r e f r a c t i o n :   - 0 . 2 5 D 
F i n a l  l e n s  p o w e r :   - 2 . 2 5 D 
E x am p l e  2 
D i a g n o s t i c  l e n s : - 2 . 0 0 D 
S p h e r i c a l  o v e r - r e f r a c t i o n :  + 0 . 2 5 D 
F i n a l  l e n s  p o w e r :  - 1 . 7 5 D 
I f  v i s i o n  i s  a c c e p t a b l e ,  p e r f o rm  a  s l i t  l am p  e x am i n a t i o n  t o  a s s e s s  a d e q u a t e  ﬁ  t  
( c e n t r a t i o n  a n d  m o v em e n t ) .  I f  t h e  ﬁ  t  i s  a c c e p t a b l e ,  d i s p e n s e  t h e  l e n s e s  a n d  
i n s t r u c t  t h e  p a t i e n t  t o  r e t u r n  i n  o n e  w e e k  f o r  r e a s s e s sm e n t  ( s e e  P A T I E N T  
M A N A G EM E N T  s e c t i o n ) . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
A l t h o u g h  m o s t  a s p e c t s  o f  t h e  ﬁ  t t i n g  p r o c e d u r e  a r e  i d e n t i c a l  f o r  a l l  t y p e s  o f  s o f t  
c o n t a c t  l e n s e s ,  i n c l u d i n g  t o r i c  l e n s e s ,  t h e r e  a r e  s om e  a d d i t i o n a l  s t e p s  a n d / o r  
r u l e s  t o  f o l l o w  t o  a s s u r e  t h e  p r o p e r  ﬁ  t  o f  t o r i c  l e n s e s .  
T h e  o n l y  n e w  s t e p s  y o u  m u s t  f o l l o w  i n  p r e s c r i b i n g  1 - D A Y  A C U V U E ® M O I S T  
f o r  A S T I GM A T I SM  a r e  t h a t  y o u  m u s t  d e t e rm i n e  t h e  s t a b i l i t y ,  r e p e a t a b i l i t y ,  a n d  
d r i f t  a n g l e  o f  t h e  l e n s  a x i s  s o  t h a t  y o u  c a n  p r e s c r i b e  t h e  c o r r e c t  l e n s  a x i s  f o r  t h e  
p a t i e n t .  
A .  H ow  t o  D e t e rm i n e  L e n s  C y l i n d e r  a n d  A x i s  O r i e n t a t i o n 
1 .    L o c a t e  t h e  O r i e n t a t i o n  M a r k s  
T o  h e l p  d e t e rm i n e  t h e  p r o p e r  o r i e n t a t i o n  o f  t h e  t o r i c  l e n s ,  y o u ’ l l  ﬁ  n d  t w o  
p r im a r y  m a r k s  a p p r o x im a t e l y  1  mm  f r om  t h e  l e n s  e d g e  r e p r e s e n t i n g  t h e  
v e r t i c a l  p o s i t i o n  o n  o p p o s i t e  e n d s  o f  t h e  l e n s  a t  6  a n d  1 2  o ’ c l o c k  ( F i g .  1 ) .  
B e c a u s e  o f  t h e  l e n s ’  b a l l a s t i n g  s y s t em ,  e i t h e r  m a r k  c a n  r e p r e s e n t  t h e  v e r - 
t i c a l  p o s i t i o n  –  t h e r e  i s  n o  “ t o p ”  a n d  “ b o t t om ”  a s  i n  a  p r i sm - b a l l a s t e d  l e n s .  
Y o u  d o n ’ t  n e e d  t o  v i e w  b o t h  m a r k s  t o  a s s e s s  o r i e n t a t i o n ;  s im p l y  l o o k  f o r  t h e  
6  o ’ c l o c k  m a r k  a s  y o u  w o u l d  w i t h  a  p r i sm - b a l l a s t e d  l e n s . TO R I C  F I T T I NG  G U I D E L I N E S 
C R - 6 2 6 7 ,  v 2 . 0 1 4 
 
P a g e  1 3 3  o f  2 1 8 J J V C  CO N F I D E N T I A L 
     F i g u r e  1 
Y o u ’ l l  n e e d  a  s l i t  l am p  b i om i c r o s c o p e  w i t h  a  1  t o  2  mm  p a r a l l e l e p i p e d  
b e am  t o  h i g h l i g h t  t h e  m a r k s  w h e n  t h e  l e n s  i s  ﬁ  t t e d  t o  t h e  e y e .  T h e r e  a r e  a  
n um b e r  o f  t e c h n i q u e s  y o u  c a n  u s e  t o  im p r o v e  t h e  v i s i b i l i t y  o f  t h e  6  o ’ c l o c k  
m a r k .  U s i n g  a  p a r a l l e l e p i p e d  b e am  a n d  m e d i um  m a g n i ﬁ  c a t i o n  ( 1 0 x  o r  1 5 x ) ,  
s l o w l y  p a n  d o w n  t h e  l e n s ,  l o o k i n g  j u s t  b e l o w  t h e  d i r e c t  i l l um i n a t i o n  a t  t h e  
r e t r o i l l um i n a t e d  a r e a .  B a c k l i g h t i n g  t h e  m a r k  t h i s  w a y  s h o u l d  m a k e  i t  m o r e  
v i s i b l e .  S om e t im e s  m a n i p u l a t i n g  t h e  l o w e r  l i d  m a y  b e  n e c e s s a r y  t o  u n c o v e r  
t h e  m a r k . 
2 .    O b s e r v e  L e n s  R o t a t i o n  a n d  S t a b i l i t y  
O b s e r v e  t h e  p o s i t i o n  a n d  s t a b i l i t y  o f  t h e  “ b o t t om ”  m a r k .  I t  u s u a l l y  s t a b i l i z e s  
a t  t h e  6  o ’ c l o c k  p o s i t i o n .  I f  i t  d o e s ,  c a l c u l a t i o n  o f  t h e  l e n s  p o w e r  w i l l  b e  
s t r a i g h t f o r w a r d .  T h e  6  o ’ c l o c k  p o s i t i o n  i s  n o t  a  “m u s t ” ;  h o w e v e r ,  t h e  
a b s o l u t e  r e q u i r em e n t  i s  t h a t  t h e  a x i s  p o s i t i o n  b e  s t a b l e  a n d  r e p e a t a b l e .  
T h e  m a r k  m a y  s t a b i l i z e  s om e w h a t  l e f t  o r  r i g h t  ( d r i f t )  o f  t h e  v e r t i c a l  m e r i d i a n  
a n d  s t i l l  e n a b l e  y o u  t o  ﬁ  t  a  t o r i c  l e n s  f o r  t h a t  e y e ,  a s  l o n g  a s  t h e  l e n s  a l w a y s  
r e t u r n s  t o  t h e  s am e  “ d r i f t  a x i s ”  p o s i t i o n  a f t e r  s e t t l i n g .  T h e  d e v i a t i o n  c a n  
b e  c om p e n s a t e d  f o r  i n  t h e  ﬁ  n a l  p r e s c r i p t i o n .  Y o u r  o b j e c t i v e  i s  t o  e n s u r e  
t h a t  w h a t e v e r  p o s i t i o n  t h e  i n i t i a l  l e n s  a s s um e s  n e a r  6  o ’ c l o c k ,  t h i s  p o s i t i o n  
m u s t  b e  s t a b l e  a n d  r e p e a t a b l e .  W i t h  f u l l  e y e  m o v em e n t  o r  h e a v y  b l i n k ,  y o u  
m a y  s e e  t h e  m a r k s  s w i n g  a w a y ,  b u t  t h e y  m u s t  r e t u r n  q u i c k l y  t o  t h e  o r i g i n a l  
s t a b l e  p o s i t i o n .  I f  t h e  l e n s  d o e s  n o t  r e t u r n  q u i c k l y ,  y o u  m a y  n e e d  t o  s e l e c t  
a  d i f f e r e n t  l e n s .  
3 .   A s s e s s i n g  R o t a t i o n  
Im a g i n e  t h e  e y e  a s  a  c l o c k  d i a l  a n d  e v e r y  h o u r  r e p r e s e n t s  a  3 0 °  i n t e r v a l .  I f  
t h e  o r i e n t a t i o n  m a r k  o f  t h e  i n i t i a l  l e n s  s t a b i l i z e s  s om e w h a t  l e f t  o r  r i g h t  o f  t h e  
v e r t i c a l  p o s i t i o n ,  t h e  ﬁ  n a l  l e n s  w i l l  o r i e n t  o n  t h e  e y e  w i t h  t h e  s am e  d e v i a t i o n .  
Y o u  c a n  u s e  a n  a x i s  r e t i c u l e  i n  t h e  s l i t  l am p  o r  u s e  a  l i n e - s c r i b e d  l e n s  i n  a  
s p e c t a c l e  t r i a l  f r am e  t o  m e a s u r e  o r  e s t im a t e  t h e  “ d r i f t  a n g l e ”  o f  t h e  c y l i n d e r  
a x i s .  
T o  c om p e n s a t e  f o r  t h i s  “ d r i f t , ”  m e a s u r e  o r  e s t im a t e  t h e  “ d r i f t , ”  t h e n  a d d  
o r  s u b t r a c t  i t  f r om  t h e  r e f r a c t i v e  a x i s  t o  d e t e rm i n e  t h e  c o r r e c t  c y l i n d e r  
a x i s .  U s e  t h e  L A R S  ( L e f t  A d d ,  R i g h t  S u b t r a c t )  m e t h o d  t o  d e t e rm i n e  w h i c h  
d i r e c t i o n  t o  c om p e n s a t e .   
C R - 6 2 6 7 ,  v 2 . 0 1 5 
 
P a g e  1 3 4  o f  2 1 8 J J V C  CO N F I D E N T I A L 
B .  F i n a l  L e n s  P ow e r 
W h e n  t h e  d i a g n o s t i c  l e n s  h a s  i t s  a x i s  a l i g n e d  i n  t h e  s am e  m e r i d i a n  a s  t h e  
p a t i e n t ’ s  r e f r a c t i v e  a x i s ,  a  s p h e r o c y l i n d r i c a l  o v e r - r e f r a c t i o n  m a y  b e  p e r f o rm e d  
a n d  v i s u a l  a c u i t y  d e t e rm i n e d .  H o w e v e r ,  i n  t h e  c a s e  o f  c r o s s e d  a x e s ,  s u c h  a s  
w h e n  t h e  d i a g n o s t i c  l e n s  a x i s  i s  d i f f e r e n t  f r om  t h e  s p e c t a c l e  c y l i n d e r  a x i s ,  i t  i s  
n o t  a d v i s a b l e  t o  p e r f o rm  a  f u l l  s p h e r o c y l i n d r i c a l  o v e r - r e f r a c t i o n  b e c a u s e  o f  t h e  
d i f ﬁ  c u l t y  i n  c om p u t i n g  t h e  r e s u l t a n t  p o w e r .  A  s p h e r i c a l  o v e r - r e f r a c t i o n  w i t h o u t  
c y l i n d e r  r e f r a c t i o n  m a y  b e  p e r f o rm e d . 
I f  t h e  r e q u i r e d  c y l i n d e r  c o r r e c t i o n  f a l l s  b e t w e e n  t w o  a v a i l a b l e  c y l i n d e r  p o w e r s ,  
i t  i s  r e c omm e n d e d  t o  p r e s c r i b e  t h e  l o w e r  c y l i n d e r  p o w e r  l e n s .  S e e  b e l o w  f o r  
i n s t r u c t i o n s  o n  h o w  t o  d e t e rm i n e  t h e  ﬁ  n a l  l e n s  p o w e r . 
1 .   F o r  t h e  S p h e r e  
I f  s p h e r e  a l o n e  o r  c om b i n e d  s p h e r e  a n d  c y l i n d e r  R x  >  4 . 0 0 D ,  c om p e n s a t e  
f o r  v e r t e x  d i s t a n c e .  I f  s p h e r e  a l o n e  o r  c om b i n e d  s p h e r e  a n d  c y l i n d e r  
R x  <  ± 4 . 0 0 D ,  v e r t e x  c om p e n s a t i o n  i s  n o t  n e c e s s a r y . 
2 .   F o r  t h e  C y l i n d e r 
A d j u s t  t h e  a x i s  b y  t h e  d r i f t  a n g l e  u s i n g  t h e  L A R S  m e t h o d .  C h o o s e  a  c y l i n d e r  
t h a t  i s  ≤  0 . 5 0 D  f r om  t h e  r e f r a c t i v e  c y l i n d e r . 
3 .   C a s e  E x am p l e s 
E x am p l e  1 
M a n i f e s t  ( s p e c t a c l e )  r e f r a c t i o n : 
O . D .  - 2 . 5 0 D  /  - 1 . 2 5 D  x  1 8 0 °  2 0 / 2 0 
O . S .  - 2 . 0 0 D  /  - 1 . 0 0 D  x  1 8 0 °  2 0 / 2 0 
C h o o s e  a  d i a g n o s t i c  l e n s  f o r  e a c h  e y e  w i t h  a x i s  1 8 0 ° .  P l a c e  t h e  l e n s  o n  
e a c h  e y e  a n d  a l l o w  a  m i n im um  o f  3  m i n u t e s  f o r  i t  t o  e q u i l i b r a t e ,  b a s e d  o n  
t h e  p a t i e n t ’ s  i n i t i a l  r e s p o n s e  t o  t h e  l e n s .  I f  t h e  l e n s  h a s  n o t  y e t  s t a b i l i z e d ,  
r e c h e c k  u n t i l  s t a b l e . 
C h e c k  t h e  o r i e n t a t i o n  o f  t h e  a x i s  m a r k .  I f  t h e  b o t t om  a x i s  m a r k  i s  i n  t h e  6  
o ’ c l o c k  p o s i t i o n  o n  b o t h  e y e s ,  c h o o s e  t h e  a p p r o p r i a t e  c y l i n d e r  a s  l i s t e d  
p r e v i o u s l y .  I f  t h e  l e n s  h a s  n o t  y e t  s t a b i l i z e d ,  r e c h e c k  u n t i l  s t a b l e . 
H e r e  i s  t h e  R x  p r e s c r i b e d : 
O . D .  - 2 . 5 0 D  /  - 1 . 2 5 D  x  1 8 0 ° 
O . S .  - 2 . 0 0 D  /  - 0 . 7 5 D  x  1 8 0 ° 
C R - 6 2 6 7 ,  v 2 . 0 1 6 
 
P a g e  1 3 5  o f  2 1 8 J J V C  CO N F I D E N T I A L 
E x am p l e  2 
M a n i f e s t  ( s p e c t a c l e )  r e f r a c t i o n : 
O . D .  - 3 . 0 0 D  /  - 1 . 0 0 D  x  9 0 °  2 0 / 2 0 
O . S .  - 4 . 7 5 D  /  - 2 . 0 0 D  x  9 0 °  2 0 / 2 0 
C h o o s e  d i a g n o s t i c  l e n s e s  o f  - 3 . 0 0 D  /  - 0 . 7 5 D  x  9 0 °  f o r  t h e  r i g h t  e y e  a n d  
- 4 . 5 0 D  /  - 1 . 7 5 D  x  9 0 °  f o r  t h e  l e f t  e y e ,  t h e  n e a r e s t  l e n s e s  a v a i l a b l e  t o  t h e  
s p h e r i c a l  p o w e r  a n d  a x i s  n e e d e d .  F o r  t h e  l e f t  e y e ,  s i n c e  t h e  m a n i f e s t  
r e f r a c t i o n  c a l l e d  f o r  - 4 . 7 5 D ,  c om p e n s a t i n g  f o r  v e r t e x  d i s t a n c e  t h e  s p h e r e  
i s  r e d u c e d  b y  0 . 2 5 D  t o  - 4 . 5 0 D .  T h e  c y l i n d e r  p o w e r  w i l l  b e  - 1 . 7 5 D .  P l a c e  
t h e  l e n s  o n  e a c h  e y e  a n d  a l l o w  a  m i n im um  o f  3  m i n u t e s  f o r  i t  t o  e q u i l i b r a t e ,  
b a s e d  o n  t h e  p a t i e n t ' s  i n i t i a l  r e s p o n s e  t o  t h e  l e n s .  I f  t h e  l e n s  h a s  n o t  y e t  
s t a b i l i z e d ,  r e c h e c k  u n t i l  s t a b l e . 
R i g h t  E y e 
T h e  o r i e n t a t i o n  m a r k  o n  t h e  r i g h t  l e n s  r o t a t e s  l e f t  f r om  t h e  6  o ’ c l o c k  p o s i t i o n  
b y  1 0 °  a n d  r em a i n s  s t a b l e  i n  t h i s  p o s i t i o n .  C om p e n s a t i o n  f o r  t h i s  r o t a t i o n  
s h o u l d  b e  d o n e  a s  f o l l o w s : 
C om p e n s a t e  t h e  1 0 °  a x i s  d r i f t  b y  a d d i n g  i t  t o  t h e  m a n i f e s t  r e f r a c t i o n  a x i s . 
H e r e  i s  t h e  R x  p r e s c r i b e d : 
O . D .  - 3 . 0 0 D  /  - 0 . 7 5 D  x  1 0 0 ° 
L e f t  E y e 
T h e  o r i e n t a t i o n  m a r k  o n  t h e  l e f t  l e n s  r o t a t e s  r i g h t  f r om  t h e  6  o ’ c l o c k  p o s i t i o n  
b y  1 0 °  a n d  r em a i n s  s t a b l e  i n  t h i s  p o s i t i o n .  C om p e n s a t i o n  f o r  t h i s  r o t a t i o n  
s h o u l d  b e  d o n e  a s  f o l l o w s : 
C om p e n s a t e  f o r  t h e  1 0 °  a x i s  d r i f t  b y  s u b t r a c t i n g  i t  f r om  t h e  m a n i f e s t  
r e f r a c t i o n  a x i s .  
H e r e  i s  t h e  R x  p r e s c r i b e d : 
O . S .  - 4 . 5 0 D  /  - 1 . 7 5 D  x  8 0 °  
I f  v i s i o n  i s  a c c e p t a b l e ,  p e r f o rm  a  s l i t  l am p  e x am i n a t i o n  t o  a s s e s s  a d e q u a t e  
ﬁ  t  ( c e n t r a t i o n  a n d  m o v em e n t ) .  I f  ﬁ  t  i s  a c c e p t a b l e ,  d i s p e n s e  t h e  l e n s e s  
i n s t r u c t i n g  t h e  p a t i e n t  t o  r e t u r n  i n  o n e  w e e k  f o r  r e a s s e s sm e n t  ( s e e  
P A T I E N T  M A N A G EM E N T  s e c t i o n ) . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
C R - 6 2 6 7 ,  v 2 . 0 1 7 
 
P a g e  1 3 6  o f  2 1 8 J J V C  CO N F I D E N T I A L 
A .   P r e s b y o p i c  N e e d s  A s s e s sm e n t  &  P a t i e n t  E d u c a t i o n 
M u l t i f o c a l  c o n t a c t  l e n s e s  m a y  p r o d u c e  c om p r om i s e  t o  v i s i o n  u n d e r  c e r t a i n  
c i r c um s t a n c e s  a n d  t h e  p a t i e n t  s h o u l d  u n d e r s t a n d  t h a t  t h e y  m i g h t  n o t  ﬁ  n d  
t h e i r  v i s i o n  a c c e p t a b l e  i n  s p e c i ﬁ  c  s i t u a t i o n s  ( i . e . ,  r e a d i n g  a  m e n u  i n  a  d im  
r e s t a u r a n t ,  d r i v i n g  a t  n i g h t  i n  r a i n y / f o g g y  c o n d i t i o n s ,  e t c . ) .  T h e r e f o r e ,  c a u t i o n  
s h o u l d  b e  e x e r c i s e d  w h e n  t h e  p a t i e n t  i s  w e a r i n g  t h e  c o r r e c t i o n  f o r  t h e  ﬁ  r s t  
t im e  u n t i l  t h e y  a r e  f am i l i a r  w i t h  t h e  v i s i o n  p r o v i d e d  i n  v i s u a l l y  c h a l l e n g i n g  
e n v i r o nm e n t s .  O c c u p a t i o n a l  a n d  e n v i r o nm e n t a l  v i s u a l  d em a n d s  s h o u l d  
b e  c o n s i d e r e d .  I f  t h e  p a t i e n t  r e q u i r e s  c r i t i c a l  v i s u a l  a c u i t y  a n d  s t e r e o p s i s ,  i t  
s h o u l d  b e  d e t e rm i n e d  b y  t r i a l  w h e t h e r  t h i s  p a t i e n t  c a n  f u n c t i o n  a d e q u a t e l y  
w i t h  1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L .  W e a r i n g  t h e s e  l e n s e s  m a y  n o t  
b e  o p t im a l  f o r  a c t i v i t i e s  s u c h  a s : 
•  V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s u c h  a s  o p e r a t i n g  p o t e n t i a l l y  d a n g e r o u s  
m a c h i n e r y  o r  p e r f o rm i n g  o t h e r  p o t e n t i a l l y  h a z a r d o u s  a c t i v i t i e s ;  a n d 
•  D r i v i n g  a u t om o b i l e s  ( e . g . ,  d r i v i n g  a t  n i g h t ) .  P a t i e n t s  w h o  c a n n o t  m e e t  
t h e i r  s t a t e  d r i v e r ’ s  l i c e n s e  r e q u i r em e n t s  w i t h  t h e  1 - D A Y  A C U V U E ® M O I S T  
M U L T I F O C A L  s h o u l d  b e  a d v i s e d  t o  n o t  d r i v e  w i t h  t h i s  c o r r e c t i o n ,  O R  m a y  
r e q u i r e  t h a t  a d d i t i o n a l  o v e r - c o r r e c t i o n  b e  p r e s c r i b e d . 
1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L  i s  n o t  r e c omm e n d e d  f o r  p a t i e n t s  
w h o  h a v e  - 1 . 0 0 D  o r  g r e a t e r  o f  r e f r a c t i v e  c y l i n d e r  a s  t h i s  l e v e l  o f  u n c o r r e c t e d  
c y l i n d e r  m a y  l e a d  t o  a d d i t i o n a l  v i s u a l  c om p r om i s e .  T h e s e  l e n s e s  a r e  a v a i l a b l e  
i n  t h e  f o l l o w i n g  A D D  p o w e r s :  
•  L e n s  “ L OW ”  =  l o w  n e a r  A D D  l e n s  (M a x  A D D  + 1 . 2 5 )  
•  L e n s  “M I D ”  =  m e d i um  n e a r  A D D  l e n s  (M a x  A D D  + 1 . 7 5 )  
•  L e n s  “ H G H ”  =  h i g h  n e a r  A D D  l e n s  (M a x  A D D  + 2 . 5 0 ) 
B .   I n i t i a l  P ow e r  D e t e rm i n a t i o n 
A  s p e c t a c l e  r e f r a c t i o n  s h o u l d  b e  p e r f o rm e d  t o  e s t a b l i s h  t h e  p a t i e n t ’ s  b a s e l i n e  
r e f r a c t i v e  s t a t u s  a n d  t o  g u i d e  i n  t h e  s e l e c t i o n  o f  t h e  a p p r o p r i a t e  l e n s  p o w e r .  
R em em b e r  t o  c om p e n s a t e  f o r  v e r t e x  d i s t a n c e  i f  t h e  r e f r a c t i o n  i s  g r e a t e r  
t h a n  ± 4 . 0 0 D .  D e t e rm i n e  t h e  s p h e r i c a l  e q u i v a l e n t  d i s t a n c e  p r e s c r i p t i o n  f o r  a  
m u l t i f o c a l  p a t i e n t .  D e t e rm i n e  t h e  e y e  d om i n a n c e  u s i n g  o n e  o f  t h e  m e t h o d s  
b e l o w : M U L T I FO C A L  F I T T I NG  G U I D E L I N E S 
C R - 6 2 6 7 ,  v 2 . 0 1 8 
 
P a g e  1 3 7  o f  2 1 8 J J V C  CO N F I D E N T I A L 
M e t h o d  1     D e t e rm i n e  w h i c h  e y e  i s  t h e  “ s i g h t i n g  e y e . ”  H a v e  t h e  p a t i e n t  p o i n t  
t o  a n  o b j e c t  a t  t h e  f a r  e n d  o f  t h e  r o om .  C o v e r  o n e  e y e .  I f  t h e  
p a t i e n t  i s  s t i l l  p o i n t i n g  d i r e c t l y  a t  t h e  o b j e c t ,  t h e  e y e  b e i n g  u s e d  i s  
t h e  d om i n a n t  ( s i g h t i n g )  e y e . 
M e t h o d  2     D e t e rm i n e  w h i c h  e y e  d o e s  n o t  a c c e p t  a d d e d  p l u s  p o w e r .  P l a c e  a  
+ 1 . 0 0 D  h a n d - h e l d  t r i a l  l e n s  i n  f r o n t  o f  o n e  e y e  a n d  t h e n  t h e  o t h e r  
w h i l e  t h e  d i s t a n c e  r e f r a c t i v e  e r r o r  c o r r e c t i o n  i s  i n  p l a c e  f o r  b o t h  
e y e s  w h i l e  t h e  p a t i e n t  i s  v i e w i n g  t h e  d i s t a n c e  v i s u a l  a c u i t y  c h a r t .  
T h e  e y e  w i t h  t h e  p l u s  o v e r  i t  t h a t  t h e  p a t i e n t  n o t i c e s  t h e  g r e a t e s t  
r e d u c t i o n  i n  v i s i o n  i s  d e t e rm i n e d  t o  b e  t h e  d om i n a n t  e y e . 
C .  S e l e c t  t h e  I n i t i a l  T r i a l  L e n s  
1 .   F o r  e a c h  e y e ,  s e l e c t  t h e  t r i a l  l e n s  d i s t a n c e  p o w e r  t h a t  i s  c l o s e s t  t o  t h e  
p a t i e n t ’ s  d i s t a n c e  s p h e r i c a l  e q u i v a l e n t .  R em em b e r  t o  c om p e n s a t e  f o r  
v e r t e x  d i s t a n c e  i f  t h e  r e f r a c t i o n  i s  g r e a t e r  t h a n  ± 4 . 0 0 D . 
2 .   S e l e c t  t h e  n e a r  p o w e r  o f  t h e  l e n s  b a s e d  o n  t h e  p a t i e n t s  A D D  r a n g e  a s  
f o l l o w s :  
•  A D D :  + 0 . 7 5 D  t o  + 1 . 2 5 D  u s e  a  l o w  n e a r  A D D  ( L OW )  l e n s  o n  e a c h  e y e  
•  A D D :  + 1 . 5 0 D  t o  + 1 . 7 5 D  u s e  a  m e d i um  n e a r  A D D  (M I D )  l e n s  o n  e a c h  
e y e  
•  A D D :  + 2 . 0 0 D  t o  + 2 . 5 0 D  u s e  a  m e d i um  n e a r  A D D  (M I D )  o n  t h e  
d om i n a n t  e y e  a n d  a  h i g h  n e a r  A D D  ( H G H )  l e n s  o n  t h e  n o n - d om i n a n t  
e y e 
3 .   A l l o w  t h e  l e n s e s  t o  s e t t l e  f o r  a  m i n im um  o f  1 0  m i n u t e s .  
4 .   A s s e s s  d i s t a n c e  a n d  n e a r  v i s i o n  b i n o c u l a r l y  a n d  m o n o c u l a r l y .  
5 .   D em o n s t r a t e  t h e  v i s i o n  u n d e r  v a r i o u s  l i g h t i n g  c o n d i t i o n s  ( n o rm a l  a n d  
d e c r e a s e d  i l l um i n a t i o n )  a n d  a t  d i s t a n c e ,  i n t e rm e d i a t e ,  a n d  n e a r .  
6 .   M a k e  a d j u s tm e n t s  i n  p o w e r  a s  n e c e s s a r y  b a s e d  o n  t h e  d i s t a n c e  o v e r - 
r e f r a c t i o n .  T h e  u s e  o f  h a n d - h e l d  t r i a l  l e n s e s  i s  r e c omm e n d e d .  C h e c k  t h e  
im p a c t  o n  d i s t a n c e  a n d  n e a r  v i s i o n . 
7 .  I f  v i s i o n  i s  s t i l l  u n a c c e p t a b l e ,  m a k e  a d j u s tm e n t s  i n  p o w e r  a s  n e c e s s a r y  
( s e e  "M u l t i f o c a l  T r o u b l e s h o o t i n g "  b e l o w ) .  I f  d i s t a n c e  a n d  n e a r  v i s i o n  
a r e  a c c e p t a b l e ,  p e r f o rm  a  s l i t  l am p  e x am i n a t i o n  t o  a s s e s s  a d e q u a t e  
ﬁ  t  ( c e n t r a t i o n  a n d  m o v em e n t ) .  I f  ﬁ  t  i s  a c c e p t a b l e ,  d i s p e n s e  t h e  l e n s e s  
i n s t r u c t i n g  t h e  p a t i e n t  t o  r e t u r n  i n  o n e  w e e k  f o r  r e a s s e s sm e n t  ( s e e  
P A T I E N T  M A N A G EM E N T  s e c t i o n ) . 
C R - 6 2 6 7 ,  v 2 . 0 1 9 
 
P a g e  1 3 8  o f  2 1 8 J J V C  CO N F I D E N T I A L 
D .  M u l t i f o c a l  T r o u b l e s h o o t i n g 
U n a c c e p t a b l e  N e a r  V i s i o n 
I f  i t  h a s  b e e n  d e t e rm i n e d  t h a t  n o  c h a n g e  i s  r e q u i r e d  b a s e d  o n  t h e  o v e r - 
r e f r a c t i o n ,  t h e n  a d d  + 0 . 2 5 D  t o  t h e  s p h e r i c a l  p o w e r  o f  t h e  n o n - d om i n a n t  e y e . 
U n a c c e p t a b l e  D i s t a n c e  V i s i o n 
I f  i t  h a s  b e e n  d e t e rm i n e d  t h a t  n o  c h a n g e  i s  r e q u i r e d  b a s e d  o n  t h e  o v e r - 
r e f r a c t i o n ,  t h e n  m a k e  t h e  c h a n g e s  a s  l i s t e d  b e l o w : 
•  I f  t h e  p a t i e n t  i s  w e a r i n g  t w o  " L OW "  A D D  l e n s e s ,  c h a n g e  t h e  d om i n a n t  
e y e  t o  a  1 - D A Y  A C U V U E ® M O I S T  s p h e r e  l e n s  w i t h  a  p o w e r  e q u a l  t o  t h e  
s p h e r i c a l  e q u i v a l e n t  d i s t a n c e  p r e s c r i p t i o n . 
•  I f  t h e  p a t i e n t  i s  w e a r i n g  t w o  "M I D "  A D D  l e n s e s ,  c h a n g e  t h e  A D D  p o w e r  i n  
t h e  d om i n a n t  e y e  t o  t h e  " L OW "  A D D  p o w e r . 
•  I f  t h e  p a t i e n t  i s  w e a r i n g  a  "M I D "  A D D  l e n s  i n  t h e  d om i n a n t  e y e  a n d  a  
" H G H "  A D D  l e n s  i n  t h e  n o n - d om i n a n t  e y e ,  c h a n g e  t h e  n o n - d om i n a n t  e y e  
t o  a  "M I D "  A D D  l e n s  a n d  a d d  + 0 . 2 5 D  t o  t h e  d i s t a n c e  p o w e r . 
E .  A d a p t a t i o n 
V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s h o u l d  b e  a v o i d e d  d u r i n g  t h e  i n i t i a l  w e a r i n g  
p e r i o d .  A  p a t i e n t  m a y  a t  ﬁ  r s t  e x p e r i e n c e  s om e  m i l d  b l u r r e d  v i s i o n ,  d i z z i n e s s ,  
h e a d a c h e s  a n d  a  f e e l i n g  o f  s l i g h t  im b a l a n c e .  Y o u  s h o u l d  e x p l a i n  t h e  
a d a p t a t i o n a l  s ym p t om s  t o  t h e  p a t i e n t .  T h e s e  s ym p t om s  m a y  l a s t  f o r  a  b r i e f  
m i n u t e  o r  f o r  s e v e r a l  w e e k s .  T h e  l o n g e r  t h e s e  s ym p t om s  p e r s i s t ,  t h e  p o o r e r  
t h e  p r o g n o s i s  f o r  s u c c e s s f u l  a d a p t a t i o n . 
T o  h e l p  i n  t h e  a d a p t a t i o n  p r o c e s s ,  t h e  p a t i e n t  c a n  b e  a d v i s e d  t o  ﬁ  r s t  u s e  t h e  
l e n s e s  i n  a  c om f o r t a b l e ,  f am i l i a r  e n v i r o nm e n t  s u c h  a s  i n  t h e  h om e . 
S om e  p a t i e n t s  f e e l  t h a t  a u t om o b i l e  d r i v i n g  p e r f o rm a n c e  m a y  n o t  b e  o p t im a l  
d u r i n g  t h e  a d a p t a t i o n  p r o c e s s .  T h i s  i s  p a r t i c u l a r l y  t r u e  w h e n  d r i v i n g  a t  n i g h t .  
B e f o r e  d r i v i n g  a  m o t o r  v e h i c l e ,  i t  m a y  b e  r e c omm e n d e d  t h a t  t h e  p a t i e n t  b e  
a  p a s s e n g e r  ﬁ  r s t  t o  m a k e  s u r e  t h a t  t h e i r  v i s i o n  i s  s a t i s f a c t o r y  f o r  o p e r a t i n g  
a n  a u t om o b i l e .  D u r i n g  t h e  ﬁ  r s t  s e v e r a l  w e e k s  o f  w e a r  ( w h e n  a d a p t a t i o n  i s  
o c c u r r i n g ) ,  i t  m a y  b e  a d v i s a b l e  f o r  t h e  p a t i e n t  t o  o n l y  d r i v e  d u r i n g  o p t im a l  
d r i v i n g  c o n d i t i o n s .  A f t e r  a d a p t a t i o n  a n d  s u c c e s s  w i t h  t h e s e  a c t i v i t i e s ,  t h e  
p a t i e n t  s h o u l d  b e  a b l e  t o  d r i v e  u n d e r  o t h e r  c o n d i t i o n s  w i t h  c a u t i o n . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
C R - 6 2 6 7 ,  v 2 . 0 2 0 
 
P a g e  1 3 9  o f  2 1 8 J J V C  CO N F I D E N T I A L 
A .  P a t i e n t  S e l e c t i o n 
1 .  M o n o v i s i o n  N e e d s  A s s e s sm e n t 
F o r  a  g o o d  p r o g n o s i s ,  t h e  p a t i e n t  s h o u l d  h a v e  a d e q u a t e l y  c o r r e c t e d  
d i s t a n c e  a n d  n e a r  v i s u a l  a c u i t y  i n  e a c h  e y e .  T h e  am b l y o p i c  p a t i e n t  o r  t h e  
p a t i e n t  w i t h  s i g n i ﬁ  c a n t  a s t i gm a t i sm  ( g r e a t e r  t h a n  1 . 0 0 D )  i n  o n e  e y e  m a y  n o t  
b e  a  g o o d  c a n d i d a t e  f o r  m o n o v i s i o n  c o r r e c t i o n  w i t h  t h e s e  l e n s e s . 
O c c u p a t i o n a l  a n d  e n v i r o nm e n t a l  v i s u a l  d em a n d s  s h o u l d  b e  c o n s i d e r e d .  
I f  t h e  p a t i e n t  r e q u i r e s  c r i t i c a l  v i s i o n  ( v i s u a l  a c u i t y  a n d  s t e r e o p s i s ) ,  i t  s h o u l d  
b e  d e t e rm i n e d  b y  t r i a l  w h e t h e r  t h i s  p a t i e n t  c a n  f u n c t i o n  a d e q u a t e l y  w i t h  
m o n o v i s i o n  c o r r e c t i o n .  M o n o v i s i o n  c o n t a c t  l e n s  w e a r  m a y  n o t  b e  o p t im a l  
f o r  a c t i v i t i e s  s u c h  a s : 
•  V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s u c h  a s  o p e r a t i n g  p o t e n t i a l l y  d a n g e r o u s  
m a c h i n e r y  o r  p e r f o rm i n g  o t h e r  p o t e n t i a l l y  h a z a r d o u s  a c t i v i t i e s ;  a n d 
•  D r i v i n g  a u t om o b i l e s  ( e . g . ,  d r i v i n g  a t  n i g h t ) .  P a t i e n t s  w h o  c a n n o t  m e e t  
t h e i r  s t a t e  d r i v e r ’ s  l i c e n s e  r e q u i r em e n t s  w i t h  m o n o v i s i o n  c o r r e c t i o n  
s h o u l d  b e  a d v i s e d  t o  n o t  d r i v e  w i t h  t h i s  c o r r e c t i o n ,  O R  m a y  r e q u i r e  t h a t  
a d d i t i o n a l  o v e r - c o r r e c t i o n  b e  p r e s c r i b e d . 
2 .  P a t i e n t  E d u c a t i o n 
A l l  p a t i e n t s  d o  n o t  f u n c t i o n  e q u a l l y  w e l l  w i t h  m o n o v i s i o n  c o r r e c t i o n .  P a t i e n t s  
m a y  n o t  p e r f o rm  a s  w e l l  f o r  c e r t a i n  t a s k s  w i t h  t h i s  c o r r e c t i o n  a s  t h e y  h a v e  
w i t h  s p e c t a c l e s  (m u l t i f o c a l ,  b i f o c a l ,  t r i f o c a l ,  r e a d e r s ,  p r o g r e s s i v e s ) .  E a c h  
p a t i e n t  s h o u l d  u n d e r s t a n d  t h a t  m o n o v i s i o n ,  a s  w e l l  a s  o t h e r  p r e s b y o p i c  
a l t e r n a t i v e s ,  c a n  c r e a t e  a  v i s i o n  c om p r om i s e  t h a t  m a y  r e d u c e  v i s u a l  a c u i t y  
a n d  d e p t h  p e r c e p t i o n  f o r  d i s t a n c e  a n d  n e a r  t a s k s .  T h e r e f o r e ,  c a u t i o n  
s h o u l d  b e  e x e r c i s e d  w h e n  t h e  p a t i e n t  i s  w e a r i n g  t h e  c o r r e c t i o n  f o r  t h e  ﬁ  r s t  
t im e  u n t i l  t h e y  a r e  f am i l i a r  w i t h  t h e  v i s i o n  p r o v i d e d  i n  v i s u a l l y  c h a l l e n g i n g  
e n v i r o nm e n t s  ( e . g . ,  r e a d i n g  a  m e n u  i n  a  d im l y  l i t  r e s t a u r a n t ,  d r i v i n g  a t  n i g h t  
i n  r a i n y / f o g g y  c o n d i t i o n s ,  e t c . ) .  D u r i n g  t h e  ﬁ  t t i n g  p r o c e s s ,  i t  i s  n e c e s s a r y  f o r  
t h e  p a t i e n t  t o  r e a l i z e  t h e  d i s a d v a n t a g e s  a s  w e l l  a s  t h e  a d v a n t a g e s  o f  c l e a r  
n e a r  v i s i o n ,  a n d  s t r a i g h t  a h e a d  a n d  u p w a r d  g a z e  t h a t  m o n o v i s i o n  c o n t a c t  
l e n s e s  p r o v i d e . MO NO V I S IO N  F I T T I NG  G U I D E L I N E S 
C R - 6 2 6 7 ,  v 2 . 0 2 1 
 
P a g e  1 4 0  o f  2 1 8 J J V C  CO N F I D E N T I A L 
B .  E y e  S e l e c t i o n 
1 .   O c u l a r  P r e f e r e n c e  D e t e rm i n a t i o n  M e t h o d s 
G e n e r a l l y ,  t h e  n o n - d om i n a n t  e y e  i s  c o r r e c t e d  f o r  n e a r  v i s i o n .  T h e  f o l l o w i n g  
t w o  m e t h o d s  f o r  e y e  d om i n a n c e  c a n  b e  u s e d . 
M e t h o d  1     D e t e rm i n e  w h i c h  e y e  i s  t h e  “ s i g h t i n g  e y e . ”  H a v e  t h e  p a t i e n t  
p o i n t  t o  a n  o b j e c t  a t  t h e  f a r  e n d  o f  t h e  r o om .  C o v e r  o n e  e y e .  
I f  t h e  p a t i e n t  i s  s t i l l  p o i n t i n g  d i r e c t l y  a t  t h e  o b j e c t ,  t h e  e y e  
b e i n g  u s e d  i s  t h e  d om i n a n t  ( s i g h t i n g )  e y e . 
M e t h o d  2     D e t e rm i n e  w h i c h  e y e  w i l l  a c c e p t  t h e  a d d e d  p o w e r  w i t h  t h e  
l e a s t  r e d u c t i o n  i n  v i s i o n .  P l a c e  a  h a n d - h e l d  t r i a l  l e n s  e q u a l  t o  
t h e  s p e c t a c l e  n e a r  A D D  i n  f r o n t  o f  o n e  e y e  a n d  t h e n  t h e  o t h e r  
w h i l e  t h e  d i s t a n c e  r e f r a c t i v e  e r r o r  c o r r e c t i o n  i s  i n  p l a c e  f o r  
b o t h  e y e s .  D e t e rm i n e  w h e t h e r  t h e  p a t i e n t  f u n c t i o n s  b e s t  w i t h  
t h e  n e a r  A D D  l e n s  o v e r  t h e  r i g h t  o r  l e f t  e y e . 
2 .   O t h e r  E y e  S e l e c t i o n  M e t h o d s 
O t h e r  m e t h o d s  i n c l u d e  t h e  “ R e f r a c t i v e  E r r o r  M e t h o d ”  a n d  t h e  “ V i s u a l  
D em a n d s  M e t h o d . ” 
R e f r a c t i v e  E r r o r  M e t h o d 
F o r  a n i s om e t r o p i c  c o r r e c t i o n ,  i t  i s  g e n e r a l l y  b e s t  t o  ﬁ  t  t h e  m o r e  h y p e r o p i c  
( l e s s  m y o p i c )  e y e  f o r  d i s t a n c e  a n d  t h e  m o r e  m y o p i c  ( l e s s  h y p e r o p i c )  e y e  
f o r  n e a r . 
V i s u a l  D em a n d s  M e t h o d 
C o n s i d e r  t h e  p a t i e n t ’ s  o c c u p a t i o n  d u r i n g  t h e  e y e  s e l e c t i o n  p r o c e s s  t o  
d e t e rm i n e  t h e  c r i t i c a l  v i s i o n  r e q u i r em e n t s .  I f  a  p a t i e n t ’ s  g a z e  f o r  n e a r  t a s k s  
i s  u s u a l l y  i n  o n e  d i r e c t i o n ,  c o r r e c t  t h e  e y e  o n  t h a t  s i d e  f o r  n e a r . 
E x am p l e :  A  s e c r e t a r y  w h o  p l a c e s  c o p y  t o  t h e  l e f t  s i d e  o f  t h e  d e s k  w i l l  
f u n c t i o n  b e s t  w i t h  t h e  n e a r  l e n s  o n  t h e  l e f t  e y e . 
C .   S p e c i a l  F i t t i n g  C h a r a c t e r i s t i c s 
1 .   U n i l a t e r a l  V i s i o n  C o r r e c t i o n 
T h e r e  a r e  c i r c um s t a n c e s  w h e r e  o n l y  o n e  c o n t a c t  l e n s  i s  r e q u i r e d .  A s  a n  
e x am p l e ,  a n  emm e t r o p i c  p a t i e n t  w o u l d  o n l y  r e q u i r e  a  n e a r  l e n s ,  w h e r e a s  
a  b i l a t e r a l  m y o p e  w o u l d  r e q u i r e  c o r r e c t i v e  l e n s e s  o n  b o t h  e y e s .  
C R - 6 2 6 7 ,  v 2 . 0 2 2 
 
P a g e  1 4 1  o f  2 1 8 J J V C  CO N F I D E N T I A L 
E x am p l e s : 
A  p r e s b y o p i c  emm e t r o p i c  p a t i e n t  w h o  r e q u i r e s  a  + 1 . 7 5 D  A D D  w o u l d  
h a v e  a  + 1 . 7 5 D  l e n s  o n  t h e  n e a r  e y e  a n d  t h e  o t h e r  e y e  l e f t  w i t h o u t  
c o r r e c t i o n . 
A  p r e s b y o p i c  p a t i e n t  r e q u i r i n g  a  + 1 . 5 0 D  A D D  w h o  i s  - 2 . 5 0 D  m y o p i c  i n  
t h e  r i g h t  e y e  a n d  - 1 . 5 0 D  m y o p i c  i n  t h e  l e f t  e y e  m a y  h a v e  t h e  r i g h t  e y e  
c o r r e c t e d  f o r  d i s t a n c e  a n d  t h e  l e f t  e y e  u n c o r r e c t e d  f o r  n e a r . 
2 .   N e a r  A D D  D e t e rm i n a t i o n 
A l w a y s  p r e s c r i b e  t h e  l e n s  p o w e r  f o r  t h e  n e a r  e y e  t h a t  p r o v i d e s  o p t im a l  
n e a r  a c u i t y  a t  t h e  m i d p o i n t  o f  t h e  p a t i e n t ’ s  h a b i t u a l  r e a d i n g  d i s t a n c e .  
H o w e v e r ,  w h e n  m o r e  t h a n  o n e  p o w e r  p r o v i d e s  o p t im a l  r e a d i n g  
p e r f o rm a n c e ,  p r e s c r i b e  t h e  l e a s t  p l u s  (m o s t  m i n u s )  o f  t h e  p o w e r s . 
3 .   T r i a l  L e n s  F i t t i n g 
A  t r i a l  ﬁ  t t i n g  i s  p e r f o rm e d  i n  t h e  o f ﬁ  c e  t o  a l l o w  t h e  p a t i e n t  t o  e x p e r i e n c e  
m o n o v i s i o n  c o r r e c t i o n .  L e n s e s  a r e  ﬁ  t  a c c o r d i n g  t o  t h e  G E N E R A L  
F I T T I N G  G U I D E L I N E S  f o r  b a s e  c u r v e  s e l e c t i o n  d e s c r i b e d  i n  t h i s  
P a c k a g e  I n s e r t . 
C a s e  h i s t o r y  a n d  a  s t a n d a r d  c l i n i c a l  e v a l u a t i o n  p r o c e d u r e  s h o u l d  b e  u s e d  
t o  d e t e rm i n e  t h e  p r o g n o s i s .  D e t e rm i n e  t h e  d i s t a n c e  c o r r e c t i o n  a n d  t h e  
n e a r  c o r r e c t i o n .  N e x t ,  d e t e rm i n e  t h e  n e a r  A D D .  W i t h  t r i a l  l e n s e s  o f  t h e  
p r o p e r  p o w e r  i n  p l a c e ,  o b s e r v e  t h e  r e a c t i o n  t o  t h i s  m o d e  o f  c o r r e c t i o n . 
A l l o w  t h e  l e n s e s  t o  s e t t l e  f o r  a b o u t  2 0  m i n u t e s  w i t h  t h e  c o r r e c t  p o w e r  
l e n s e s  i n  p l a c e .  W a l k  a c r o s s  t h e  r o om  a n d  h a v e  t h e  p a t i e n t  l o o k  a t  
y o u .  A s s e s s  t h e  p a t i e n t ’ s  r e a c t i o n  t o  d i s t a n c e  v i s i o n  u n d e r  t h e s e  
c i r c um s t a n c e s .  T h e n  h a v e  t h e  p a t i e n t  l o o k  a t  f am i l i a r  n e a r  o b j e c t s  s u c h  
a s  a  w a t c h  f a c e  o r  ﬁ  n g e r n a i l s .  A g a i n  a s s e s s  t h e  r e a c t i o n .  A s  t h e  p a t i e n t  
c o n t i n u e s  t o  l o o k  a r o u n d  t h e  r o om  a t  b o t h  n e a r  a n d  d i s t a n c e  o b j e c t s ,  
o b s e r v e  t h e  r e a c t i o n s .  O n l y  a f t e r  t h e s e  v i s i o n  t e s t s  a r e  c om p l e t e d ,  s h o u l d  
t h e  p a t i e n t  b e  a s k e d  t o  r e a d  p r i n t .  E v a l u a t e  t h e  p a t i e n t ’ s  r e a c t i o n  t o  l a r g e  
p r i n t  ( e . g . ,  t y p e w r i t t e n  c o p y )  a t  ﬁ  r s t  a n d  t h e n  g r a d u a t e  t o  n e w s p r i n t  a n d  
ﬁ  n a l l y  sm a l l e r  t y p e  s i z e s . 
A f t e r  t h e  p a t i e n t ’ s  p e r f o rm a n c e  u n d e r  t h e  a b o v e  c o n d i t i o n s  i s  c om p l e t e d ,  
t e s t s  o f  v i s u a l  a c u i t y  a n d  r e a d i n g  a b i l i t y  u n d e r  c o n d i t i o n s  o f  m o d e r a t e l y  
d im  i l l um i n a t i o n  s h o u l d  b e  a t t em p t e d . 
C R - 6 2 6 7 ,  v 2 . 0 2 3 
 
P a g e  1 4 2  o f  2 1 8 J J V C  CO N F I D E N T I A L 
A n  i n i t i a l  u n f a v o r a b l e  r e s p o n s e  i n  t h e  o f ﬁ  c e ,  w h i l e  i n d i c a t i v e  o f  a  g u a r d e d  
p r o g n o s i s ,  s h o u l d  n o t  imm e d i a t e l y  r u l e  o u t  a  m o r e  e x t e n s i v e  t r i a l  u n d e r  
t h e  u s u a l  c o n d i t i o n s  i n  w h i c h  a  p a t i e n t  f u n c t i o n s . 
4 .  A d a p t a t i o n 
V i s u a l l y  d em a n d i n g  s i t u a t i o n s  s h o u l d  b e  a v o i d e d  d u r i n g  t h e  i n i t i a l  w e a r i n g  
p e r i o d .  A  p a t i e n t  m a y  a t  ﬁ  r s t  e x p e r i e n c e  s om e  m i l d  b l u r r e d  v i s i o n ,  
d i z z i n e s s ,  h e a d a c h e s ,  a n d  a  f e e l i n g  o f  s l i g h t  im b a l a n c e .  Y o u  s h o u l d  
e x p l a i n  t h e  a d a p t a t i o n a l  s ym p t om s  t o  t h e  p a t i e n t .  T h e s e  s ym p t om s  m a y  
l a s t  f o r  a  b r i e f  m i n u t e  o r  f o r  s e v e r a l  w e e k s .  T h e  l o n g e r  t h e s e  s ym p t om s  
p e r s i s t ,  t h e  p o o r e r  t h e  p r o g n o s i s  f o r  s u c c e s s f u l  a d a p t a t i o n .  
T o  h e l p  i n  t h e  a d a p t a t i o n  p r o c e s s ,  t h e  p a t i e n t  c a n  b e  a d v i s e d  t o  ﬁ  r s t  u s e  
t h e  l e n s e s  i n  a  c om f o r t a b l e ,  f am i l i a r  e n v i r o nm e n t  s u c h  a s  i n  t h e  h om e . 
S om e  p a t i e n t s  f e e l  t h a t  a u t om o b i l e  d r i v i n g  p e r f o rm a n c e  m a y  n o t  b e  
o p t im a l  d u r i n g  t h e  a d a p t a t i o n  p r o c e s s .  T h i s  i s  p a r t i c u l a r l y  t r u e  w h e n  
d r i v i n g  a t  n i g h t .  B e f o r e  d r i v i n g  a  m o t o r  v e h i c l e ,  i t  m a y  b e  r e c omm e n d e d  
t h a t  t h e  p a t i e n t  b e  a  p a s s e n g e r  ﬁ  r s t  t o  m a k e  s u r e  t h a t  t h e i r  v i s i o n  i s  
s a t i s f a c t o r y  f o r  o p e r a t i n g  a n  a u t om o b i l e .  D u r i n g  t h e  ﬁ  r s t  s e v e r a l  w e e k s  o f  
w e a r  ( w h e n  a d a p t a t i o n  i s  o c c u r r i n g ) ,  i t  m a y  b e  a d v i s a b l e  f o r  t h e  p a t i e n t  t o  
o n l y  d r i v e  d u r i n g  o p t im a l  d r i v i n g  c o n d i t i o n s .  A f t e r  a d a p t a t i o n  a n d  s u c c e s s  
w i t h  t h e s e  a c t i v i t i e s ,  t h e  p a t i e n t  s h o u l d  b e  a b l e  t o  d r i v e  u n d e r  o t h e r  
c o n d i t i o n s  w i t h  c a u t i o n . 
D .  O t h e r  S u g g e s t i o n s 
T h e  s u c c e s s  o f  t h e  m o n o v i s i o n  t e c h n i q u e  m a y  b e  f u r t h e r  im p r o v e d  b y  h a v i n g  
y o u r  p a t i e n t  f o l l o w  t h e  s u g g e s t i o n s  b e l o w : 
•  H a v e  a  t h i r d  c o n t a c t  l e n s  ( d i s t a n c e  p o w e r )  t o  u s e  w h e n  c r i t i c a l  
d i s t a n c e  v i e w i n g  i s  n e e d e d . 
•  H a v e  a  t h i r d  c o n t a c t  l e n s  ( n e a r  p o w e r )  t o  u s e  w h e n  c r i t i c a l  n e a r  
v i e w i n g  i s  n e e d e d . 
•  H a v e  s u p p l em e n t a l  s p e c t a c l e s  t o  w e a r  o v e r  t h e  m o n o v i s i o n  
c o n t a c t  l e n s e s  f o r  s p e c i ﬁ  c  v i s u a l  t a s k s  m a y  im p r o v e  t h e  s u c c e s s  o f  
m o n o v i s i o n  c o r r e c t i o n .  T h i s  i s  p a r t i c u l a r l y  a p p l i c a b l e  f o r  t h o s e  p a t i e n t s  
w h o  c a n n o t  m e e t  s t a t e  d r i v e r ’ s  l i c e n s i n g  r e q u i r em e n t s  w i t h  m o n o v i s i o n  
c o r r e c t i o n . 
•  M a k e  u s e  o f  p r o p e r  i l l um i n a t i o n  w h e n  c a r r y i n g  o u t  v i s u a l  t a s k s . 
C R - 6 2 6 7 ,  v 2 . 0 2 4 
 
P a g e  1 4 3  o f  2 1 8 J J V C  CO N F I D E N T I A L 
M o n o v i s i o n  ﬁ  t t i n g  s u c c e s s  c a n  b e  im p r o v e d  b y  t h e  f o l l o w i n g  s u g g e s t i o n s : 
•  R e v e r s e  t h e  d i s t a n c e  a n d  n e a r  e y e s  i f  a  p a t i e n t  i s  h a v i n g  t r o u b l e  
a d a p t i n g . 
•  R e ﬁ  n e  t h e  l e n s  p o w e r s  i f  t h e r e  i s  t r o u b l e  w i t h  a d a p t a t i o n .  A c c u r a t e  
l e n s  p o w e r  i s  c r i t i c a l  f o r  p r e s b y o p i c  p a t i e n t s . 
•  Em p h a s i z e  t h e  b e n e ﬁ  t s  o f  c l e a r  n e a r  v i s i o n ,  a n d  s t r a i g h t  a h e a d  a n d  
u p w a r d  g a z e  w i t h  m o n o v i s i o n . 
T h e  d e c i s i o n  t o  ﬁ  t  a  p a t i e n t  w i t h  m o n o v i s i o n  c o r r e c t i o n  i s  m o s t  a p p r o p r i a t e l y  
l e f t  t o  t h e  E y e  C a r e  P r o f e s s i o n a l  i n  c o n j u n c t i o n  w i t h  t h e  p a t i e n t  a f t e r  c a r e f u l l y  
c o n s i d e r i n g  t h e  p a t i e n t ’ s  n e e d s . 
A l l  p a t i e n t s  s h o u l d  b e  s u p p l i e d  w i t h  a  c o p y  o f  t h e  P A T I E N T  
I N S T R U C T IO N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d ow n l o a d  a t  www . a c u v u e . c om . 
P A T I E N T  M A N AG EM E N T 
•  F o l l o w  t h e  a c c e p t e d  s t a n d a r d  o f  c a r e  i n  ﬁ  t t i n g  a n d  f o l l o w i n g  u p  w i t h  y o u r  
p a t i e n t ,  e . g . ,  Am e r i c a n  O p t om e t r i c  A s s o c i a t i o n  s t a n d a r d  o f  c a r e .  
•  S c h e d u l e  t h e  a p p r o p r i a t e  f o l l o w - u p  e x am i n a t i o n .  
•  P r e f e r a b l y ,  a t  t h e  f o l l o w - u p  v i s i t s ,  l e n s e s  s h o u l d  h a v e  b e e n  w o r n  f o r  a t  
l e a s t  s i x  h o u r s .  
•  P r o v i d e  t h e  p a t i e n t  w i t h  a  c o p y  o f  t h e  P A T I E N T  I N S T R U C T I O N  G U I D E  f o r  
t h e s e  l e n s e s ,  w h i c h  c a n  b e  f o u n d  a t  w w w . a c u v u e . c om .  R E V I EW  T H E S E  
I N S T R U C T I O N S  W I T H  T H E  P A T I E N T  S O  T H A T  H E  O R  S H E  C L E A R L Y  
U N D E R S T A N D S  T H E  P R E S C R I B E D  W E A R I N G  A N D  R E P L A C EM E N T  
S C H E D U L E S . 
T h e  w e a r i n g  s c h e d u l e  s h o u l d  b e  d e t e rm i n e d  b y  t h e  E y e  C a r e  P r o f e s s i o n a l .  
R e g u l a r  c h e c k u p s ,  a s  d e t e rm i n e d  b y  t h e  E y e  C a r e  P r o f e s s i o n a l ,  a r e  a l s o  
e x t r em e l y  im p o r t a n t . 
P a t i e n t s  t e n d  t o  o v e r  w e a r  t h e  l e n s e s  i n i t i a l l y .  T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  
em p h a s i z e  t h e  im p o r t a n c e  o f  a d h e r i n g  t o  t h e  i n i t i a l  m a x im um  w e a r i n g  s c h e d u l e .  
M a x im um  w e a r i n g  t im e  s h o u l d  b e  d e t e rm i n e d  b y  t h e  E y e  C a r e  P r o f e s s i o n a l  
b a s e d  u p o n  t h e  p a t i e n t ’ s  p h y s i o l o g i c a l  e y e  c o n d i t i o n ,  b e c a u s e  i n d i v i d u a l  
r e s p o n s e  t o  c o n t a c t  l e n s e s  v a r i e s .  W E A R I NG  S C H E D U L E 
C R - 6 2 6 7 ,  v 2 . 0 2 5 
 
P a g e  1 4 4  o f  2 1 8 J J V C  CO N F I D E N T I A L 
T h e  m a x im um  s u g g e s t e d  w e a r i n g  t im e  f o r  t h e s e  l e n s e s  i s : 
D A Y H O U R S 
1 6 - 8 
2 8 - 1 0 
3 1 0 - 1 2 
4 1 2 - 1 4 
5  a n d  a f t e r a l l  w a k i n g  h o u r s 
T h e s e  l e n s e s  a r e  i n d i c a t e d  f o r  d a i l y  d i s p o s a b l e  w e a r  a n d  s h o u l d  b e  d i s c a r d e d  
u p o n  r em o v a l . 
W h e n  d i s p o s e d  o f  a f t e r  a  s i n g l e  d a i l y  u s e ,  t h e s e  l e n s e s  m a y  r e d u c e  t h e  r i s k  o f  
d e v e l o p i n g  g i a n t  p a p i l l a r y  c o n j u n c t i v i t i s . 4
W h e n  w o r n  a s  a  d a i l y  d i s p o s a b l e  l e n s ,  t h e s e  l e n s e s  m a y  p r o v i d e  im p r o v e d  
c om f o r t  f o r  m a n y  p a t i e n t s  w h o  e x p e r i e n c e  m i l d  d i s c om f o r t  a n d  i t c h i n g  
a s s o c i a t e d  w i t h  a l l e r g i e s  d u r i n g  c o n t a c t  l e n s  w e a r ,  c om p a r e d  t o  l e n s e s  r e p l a c e d  
a t  i n t e r v a l s  o f  g r e a t e r  t h a n  2  w e e k s . 
C l i n i c a l  r e s e a r c h  h a s  s h o w n  t h a t  w h e n  w o r n  o n  a  d a i l y  d i s p o s a b l e  b a s i s ,  t h e s e  
l e n s e s  m a y  p r o v i d e  im p r o v e d  c om f o r t  f o r  2  o u t  o f  3  p a t i e n t s  w h o  r e p o r t e d  
s u f f e r i n g  f r om  d i s c om f o r t  a s s o c i a t e d  w i t h  a l l e r g i e s  d u r i n g  c o n t a c t  l e n s  w e a r . 
4  Th e  C L A O  J o u r n a l ,  J u l y  1 9 9 9 ,  V o l um e  2 5 ,  N um b e r  3 
T h e  E y e  C a r e  P r o f e s s i o n a l  s h o u l d  r e v i e w  w i t h  p a t i e n t s  t h a t  n o  c l e a n i n g  o r  
d i s i n f e c t i o n  i s  n e e d e d  w i t h  d a i l y  d i s p o s a b l e  l e n s e s .  P a t i e n t s  s h o u l d  a l w a y s  
d i s p o s e  o f  l e n s e s  w h e n  t h e y  a r e  r em o v e d  a n d  h a v e  r e p l a c em e n t  l e n s e s  o r  
s p e c t a c l e s  a v a i l a b l e . 
F o r  c om p l e t e  i n f o rm a t i o n  c o n c e r n i n g  c o n t a c t  l e n s  h a n d l i n g  a n d  c a r e ,  r e f e r  t o  
t h e  P A T I E N T  I N S T R U C T I O N  G U I D E  f o r  t h e s e  l e n s e s .  C o p i e s  a r e  a v a i l a b l e  f o r  
d o w n l o a d  a t  w w w . a c u v u e . c om .  
C a r e  f o r  S t i c k i n g  ( N o n -M o v i n g )  L e n s e s 
D u r i n g  r em o v a l ,  i f  t h e  l e n s  s t i c k s  t o  t h e  e y e ,  t h e  p a t i e n t  s h o u l d  b e  i n s t r u c t e d  
t o  a p p l y  a  f e w  d r o p s  o f  t h e  r e c omm e n d e d  l u b r i c a t i n g  o r  r e w e t t i n g  s o l u t i o n  R E P L A C EM E N T  S C H E D U L E 
L E N S  C A R E  D I R E C T IO N S 
C R - 6 2 6 7 ,  v 2 . 0 2 6 
 
P a g e  1 4 5  o f  2 1 8 J J V C  CO N F I D E N T I A L 
d i r e c t l y  t o  t h e  e y e  a n d  w a i t  u n t i l  t h e  l e n s  b e g i n s  t o  m o v e  f r e e l y  o n  t h e  e y e  b e f o r e  
r em o v i n g  i t .  I f  n o n -m o v em e n t  o f  t h e  l e n s  c o n t i n u e s  a f t e r  a  f e w  m i n u t e s ,  t h e  
p a t i e n t  s h o u l d  imm e d i a t e l y  c o n s u l t  t h e  E y e  C a r e  P r o f e s s i o n a l . 
T h e  p a t i e n t  s h o u l d  b e  i n f o rm e d  t h a t  i f  c h em i c a l s  o f  a n y  k i n d  ( h o u s e h o l d  
p r o d u c t s ,  g a r d e n i n g  s o l u t i o n s ,  l a b o r a t o r y  c h em i c a l s ,  e t c . )  a r e  s p l a s h e d  i n t o  
t h e  e y e s ,  t h e  p a t i e n t  s h o u l d :   F L U S H  E Y E S  IMM E D I A T E L Y  W I T H  T A P  W A T E R  
A N D  IMM E D I A T E L Y  C O N T A C T  T H E  E Y E  C A R E  P R O F E S S I O N A L  O R  V I S I T  A  
H O S P I T A L  EM E R G E N C Y  R O OM  W I T H O U T  D E L A Y . 
E a c h  U V - a b s o r b i n g  s t e r i l e  l e n s  i s  s u p p l i e d  i n  a  f o i l - s e a l e d  p l a s t i c  p a c k a g e  
c o n t a i n i n g  b u f f e r e d  s a l i n e  s o l u t i o n  w i t h  p o v i d o n e .  T h e  p l a s t i c  p a c k a g e  i s  m a r k e d  
w i t h  t h e  f o l l o w i n g :  
•  1 - D A Y  A C U V U E ® M O I S T :  b a s e  c u r v e ,  p o w e r ,  d i am e t e r ,  l o t  n um b e r ,  a n d  
e x p i r a t i o n  d a t e 
•  1 - D A Y  A C U V U E ® M O I S T  f o r  A S T I GM A T I SM :  b a s e  c u r v e ,  p o w e r ,  
d i am e t e r ,  c y l i n d e r ,  a x i s ,  l o t  n um b e r ,  a n d  e x p i r a t i o n  d a t e 
•  1 - D A Y  A C U V U E ® M O I S T  M U L T I F O C A L :  b a s e  c u r v e ,  p o w e r ,  d i am e t e r ,  
A D D  p o w e r ,  l o t  n um b e r ,  a n d  e x p i r a t i o n  d a t e 
A l l  s e r i o u s  a d v e r s e  e x p e r i e n c e s  a n d  a d v e r s e  r e a c t i o n s  o b s e r v e d  i n  p a t i e n t s  
w e a r i n g  t h e s e  l e n s e s  o r  e x p e r i e n c e d  w i t h  t h e s e  l e n s e s  s h o u l d  b e  r e p o r t e d  t o : 
J o h n s o n  &  J o h n s o n  V i s i o n  C a r e ,  I n c . 
7 5 0 0  C e n t u r i o n  P a r k w a y 
J a c k s o n v i l l e ,  F L  3 2 2 5 6 
U S A 
T e l :  1 - 8 0 0 - 8 4 3 - 2 0 2 0 
w w w . a c u v u e . c om EM E RG E N C I E S 
HOW  S U P P L I E D 
R E PO R T I NG  O F  A D V E R S E  R E A C T IO N S 
C R - 6 2 6 7 ,  v 2 . 0 2 7 
 
P a g e  1 4 6  o f  2 1 8 J J V C  CO N F I D E N T I A L 
 
  
  
APPENDIX D: BINOCULAR OVER REF RACTION  
 
Binocular Over -refraction Technique  
 
1. Place trial frame on subject  
2. Add +1.00 D sphere to OS  
3. Add + 0.50DS OD and check VA  
       - if VA remained unchanged or improved, repeat step 3  
- if VA decreased, add minus until best VA firs t achieved *note: add minus for 0.5 
seconds to avoid reflex accommodation.  
4. Record VA  
5. Change +1.00 D sphere to OD  
6. Repeat steps 3 and 4  
 
  
 
   
 
CR-6267, v2.0
 
Page 148 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX E: PRESBYOPIC SYMPTOMS QUESTIONNAIRE  
 
Presbyopic Symptoms Questionnaire  
 
1. Do you notice that you often have to hold things farther away so that you c an read 
them? 
2. Do you notice that you often have difficulty focusing on near objects (i.e., 
experiencing blurry vision when looking at things close-up)? 
3. Do you often have headaches or eyestrain, or feel fatigued,  when read ing or 
conducting other near activities?  
4. Do you often have difficulty reading small or fine prints, such as phone books, 
medicine bottles or package labels, etc.?  
5. Do you often have difficulty reading under dim or low light? 
 
 
 
 
  
 
 
 
 
 
  
 
CR-6267, v2.0
 
Page 149 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX G: TEST  LENS FITTING GUIDE  
Step 1.  
Choose the first lens based on the best spherical equivalent refraction and ADD power for 
both eyes.   Select the first lens per table 1 below.   
 Table 1.  Initial Lens Selection   
 ADD        
 +0.75 +1.00 +1.25 +1.50 +1.75 +2.00 +2.25 +2.50 
Dominant Eye   
LOW  
LOW  
LOW  
MID  
MID  
MID  
MID  
MID 
 
Non-
Dominant  Eye  
LOW  
LOW  
LOW  
MID  
MID  
HGH  
HGH  
HGH 
 Assess the subject’s vision at distance and near after the lens has settled (10 minutes).  If the vision is acceptable continue with the fit assessment and dispensing as per the protocol.    If the vision is not acceptable, e nsure that the proper initial lens power was selected by 
performing a distance over -refraction with +/ - 0.25D trial lenses (or flippers) to determine if 
a change in the initial lens power is required (note:  the over-refraction should be performed outside of the phoropter in normal room illumination).  Recheck both distance and near vision with the over-refraction in place.  If a change in the initial lens power is not required refer to the fitting steps listed below in step 2 (table 2).    
Step 2.  
   Table 2.  Lens change if required. * 
Distance 
Complaint          
ADD +0.75 +1.00 +1.25 +1.50 +1.75 +2.00 +2.25 +2.50 
Dominant 
Eye ACUVUE® 
OASYS®           
2-WEEK 
Sphere  ACUVUE®
OASYS®           
2-WEEK 
Sphere  ACUVUE® 
OASYS®           
2-WEEK 
Sphere   
LOW  
LOW  
MID  
MID  
MID 
Non-
Dominant 
Eye  
LOW  
LOW  
LOW  
MID  
MID  
MID
+  
MID
+  
MID
+ 
       
CR-6267, v2.0
 
Page 151 of 218
JJVC CONFIDENTIAL

 
  
 Near  
Complaint          
ADD +0.75 +1.00 +1.25 +1.50 +1.75 +2.00 +2.25 +2.50 
Dominant 
Eye  
LOW  
LOW  
LOW  
MID  
MID  
MID  
MID  
MID 
Non-
Dominant 
Eye  
LOW+  
LOW+  
LOW+  
MID+  
MID+  
HGH+  
HGH+  
HGH+ 
 
*Note:  a + following the contact lens design indicates to add +0.25 D to the distance contact 
lens power on the non-dominant eye (see example below).   
 
Example:  The subject is a +1.75 ADD and has a near complaint and it is dete rmined a 
change in lens pairs is needed.  Referring to table 2 near complaint section, under the +1.75 ADD it states to keep the dominant eye the same (i.e. MID) and add +0.25D to the non-dominant eye (i.e. MID+).        
 Subjects spherical equivalent dist ance refraction   
OD: +2.50 
OS:  +3.00 (OS non-dominant eye) 
 
The new lens chosen should be as follows:  
OD: +2.50 MID ADD (i.e. no change)  
OS:  +3.25 MID ADD  
 
Step 3.  
If after the above lens modifications have been attempted and the subject’s vision is s till not 
satisfactory, and additional optimization s are allowed by the protocol, lens changes may be 
attempted , based on the Investigator’s clinical experience, to determine if acceptable vision 
can be achieved.    
    
  
 
   
CR-6267, v2.0
 
Page 152 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX H: CONTROL LENS FITTING  GUIDE  
Step 1.  
Choose the first lens based on the best spherical equivalent refraction and ADD power for 
both eyes.   Select the first lens per table 1 below.    Table 1.  Initial Lens Selection   
 ADD        
 +0.75 +1.00 +1.25 +1.50 +1.75 +2.00 +2.25 +2.50 
Dominant Eye   
LOW  
LOW  
LOW  
MID  
MID  
MID  
MID  
MID 
 
Non-
Dominant Eye   
LOW  
LOW  
LOW  
MID  
MID  
HGH  
HGH  
HGH 
 Assess the subject’s vision at distance and near after the lens has settled (10 minutes).  If the vision is acceptable continue with the fit assessment and dispensing as per the protocol.    If the vision is not acceptable, ensure that the proper initial lens power was selected by performing a distance over -refraction with +/ - 0.25D trial lenses (or flippers) to determine if 
a change in the initial lens power is required (note:  the over-refraction should be performed 
outside of the phoropter in normal room illumination).  Recheck both distance and near vision with the over-refraction in place.  If a change in the initial lens power is not required refer to the fitting steps listed below in step 2 (table 2).    
Step 2.  
   Table 2.  Lens change if required. *  
Distance 
Complaint          
ADD +0.75 +1.00 +1.25 +1.50 +1.75 +2.00 +2.25 +2.50 
Dominant 
Eye  
1-Day 
ACUVUE® 
Moist 
  
1-Day 
ACUVUE® 
Moist 
  
1-Day 
ACUVUE® 
Moist 
  
LOW  
LOW  
MID  
MID  
MID 
Non-
Dominant 
Eye  
LOW  
LOW  
LOW  
MID  
MID  
MID
+  
MID
+  
MID
+ 
      
CR-6267, v2.0
 
Page 153 of 218
JJVC CONFIDENTIAL

 
  
 Near  
Complaint          
ADD +0.75 +1.00 +1.25 +1.50 +1.75 +2.00 +2.25 +2.50 
Dominant 
Eye  
LOW  
LOW  
LOW  
MID  
MID  
MID  
MID  
MID 
Non-
Dominant 
Eye  
LOW+  
LOW+  
LOW+  
MID+  
MID+  
HGH+  
HGH+  
HGH+ 
 
*Note:  a + following the contact lens design indicates to add +0.25 D to the distance contact 
lens power on the non-dominant eye (see example below).   
 
Example:  The subject is a +1.75 ADD and ha s a near complaint and it is determined a 
change in lens pairs is needed.  Referring to table 2 near complaint section, under the +1.75 ADD it states to keep the dominant eye the same (i.e. MID) and add +0.25D to the non-dominant eye (i.e. MID+).        
 Subjects spherical equivalent distance refraction   
OD: -2.50 
OS:  -3.00 (OS non-dominant eye) 
 
The new lens chosen should be as follows:  
OD: -2.50 MID ADD (i.e. no change)  
OS:  -2.75 MID ADD 
 
Step 3 .  
If after the above lens modifications have been attemp ted and the subject’s vision is still not 
satisfactory, and additional optimizations are allowed by the protocol, lens changes may be attempted based on the Investigator’s clinical experience, to determine if acceptable vision 
can be achieved.   
 
  
 
 
      
CR-6267, v2.0
 
Page 154 of 218
JJVC CONFIDENTIAL

 
  
 APPENDIX I:   
 
•  LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS  
•  EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING 
•  DETERMINATION OF NEAR ADD  
•  NEAR logMAR VISUAL ACUITY MEASUREMENT PROCEDURE  
•  LENS FITTING CHARACTERISTICS  
•  SUBJECT REPORTED OCULAR SYMPTOMS  
•  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
•  BIOMICROSCOPY SCALE  
•   KERATOMETRY  
•  DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
•  ETDRS DISTA NCE VISUAL ACUITY MEASURMENT PROCEDURE  
•  VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING  
 
                  
CR-6267, v2.0
 
Page 155 of 218
JJVC CONFIDENTIAL

 
  
  LIMBAL AND CONJUNCTIVAL (BULBAR) REDNESS  
 
 
CR-6267, v2.0
 
Page 156 of 218
JJVC CONFIDENTIAL

   
 
 
 
Page 3 of 7 
 
CR-6267, v2.0
 
Page 159 of 218
JJVC CONFIDENTIAL

  
 
 
                          
Page 4 of 7 
 
CR-6267, v2.0
 
Page 160 of 218
JJVC CONFIDENTIAL

   
 
 
 
 
Page 5 of 7 
 
CR-6267, v2.0
 
Page 161 of 218
JJVC CONFIDENTIAL

  
 
 
                            
Page 6 of 7 
 
CR-6267, v2.0
 
Page 162 of 218
JJVC CONFIDENTIAL

 
  
  EXPANDED S ODIUM FLUORESCEIN CORNEAL STAINING   
 
CR-6267, v2.0
 
Page 164 of 218
JJVC CONFIDENTIAL

 
  
 
  
 
Page 4 of 4 
 
CR-6267, v2.0
 
Page 168 of 218
JJVC CONFIDENTIAL

 
  
  DETERMINATION OF NEAR ADDITION 
 
CR-6267, v2.0
 
Page 169 of 218
JJVC CONFIDENTIAL

Page 4 of 7 
   
  
 
  
 
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
    
 
  
  
 
  
 
  
 
  
 
  
  
 
 
 
 
 
  
 
     
  
 
 
   
 
  
  
 
  
 
  
 
  
 
  
CR-6267, v2.0
 
Page 173 of 218
JJVC CONFIDENTIAL

Page 5 of 7 
  
 
    
 
 
 
  
 
 
                          
 
 
    
                          
 
 
   
 
 
 
  
  
 
 
 
 
  
 
 
 
 
  
 
 
CR-6267, v2.0
 
Page 174 of 218
JJVC CONFIDENTIAL

Page 7 of 7 
  
 
 
 
 
 
 
CR-6267, v2.0
 
Page 176 of 218
JJVC CONFIDENTIAL

 
  
  NEAR LOGMAR VISUAL ACUITY MEASUREMENT PROCEDURE  
 
CR-6267, v2.0
 
Page 177 of 218
JJVC CONFIDENTIAL

 
  
  LENS FITTI NG CHARACTERISTICS   
 
CR-6267, v2.0
 
Page 180 of 218
JJVC CONFIDENTIAL

Page 4 of 6 
   
 
 
 
 
  
 
 
 
CR-6267, v2.0
 
Page 184 of 218
JJVC CONFIDENTIAL

Page 5 of 6 
   
 
CR-6267, v2.0
 
Page 185 of 218
JJVC CONFIDENTIAL

Page 6 of 6 
  
 
 
CR-6267, v2.0
 
Page 186 of 218
JJVC CONFIDENTIAL

 
  
  SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS  
 
CR-6267, v2.0
 
Page 187 of 218
JJVC CONFIDENTIAL

 
  
  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
 
CR-6267, v2.0
 
Page 189 of 218
JJVC CONFIDENTIAL

 
  
  BIOMICROSC OPY SCALE  
 
CR-6267, v2.0
 
Page 196 of 218
JJVC CONFIDENTIAL

 
  
  KERATOMETRY PROCEDURE 
 
CR-6267, v2.0
 
Page 202 of 218
JJVC CONFIDENTIAL

 
  
  DISTANCE A ND NEAR VISUAL ACUITY EVALUATION 
 
CR-6267, v2.0
 
Page 204 of 218
JJVC CONFIDENTIAL

 
  
  DISTANCE LOGMAR VISUAL ACUITY MEASUREMENT 
PROCEDURE  
 
CR-6267, v2.0
 
Page 209 of 218
JJVC CONFIDENTIAL

 
  
  
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING  
 
         
CR-6267, v2.0
 
Page 213 of 218
JJVC CONFIDENTIAL

  
 
   
Page 3 of 4 
 
CR-6267, v2.0
 
Page 216 of 218
JJVC CONFIDENTIAL

  
 
   
 
 
 
  
 
      
      
      
      
      
      
      
      
      
      
      
      
 
 
 
  
 
 
 
      
      
      
      
      
      
      
      
      
      
      
 
 
Page 4 of 4 
 
CR-6267, v2.0
 
Page 217 of 218
JJVC CONFIDENTIAL

 
  
 PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE  
 
CR-6267 Clinical Evaluation of a Reusable Multifocal  Optical Design in a Presbyopic 
Population  Version and Date:  2.0 Amendment 1 22 June 2018 
 I have read and understand the protocol specified above and agree on its content.    I agree to conduct this study according to ISO 14155,
1 GCP and ICH guidelines ,2 the 
Declaration of Helsinki ,3 United States (US) Code of Federal Regulations (CFR) ,4 and the 
pertinent individual country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. The Principal Investigator is responsible for ensuring that all clinical site personnel, including Sub -Investigators adhere to all ICH
2 regulations and 
GCP guidelines regarding clinical trials during and after study completion.  
 I will assure that no deviation from, or changes to the protocol will take place without pri or 
agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.  
 I am responsible for ensuring that all clinical site personnel including  Sub-Investigators 
adhere to all ICH
2 regulations and GCP guidelines regarding clinical trials during and after 
study completion.  All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training.   I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about their obligations in meeting the above commitments.  
 I shall not disclose the information contained in this protocol or any results obtained from this study without written authorization.  
 
Principal 
Investigator:   
   
 Signature  
 
  Date 
 Name and Professional Position (Printed)    
 
Institution/Site:     
 Institution/Site Name  
 
   
 Institution/Site Address    
 
CR-6267, v2.0
 
Page 218 of 218
JJVC CONFIDENTIAL
